HIV/AIDS Cure Research
Introduction, Glossary & Resource Guide 2017
Cover Design

Upper left: Young woman looking through microscope
Upper right: Cutaway design of an HIV virion (single virus particle)
Lower left: Pipette dropping liquid into test tube
Lower right: HIV virion surface photomicrograph

Table of Contents

| Notes to the Reader                      | 1 |
| Introduction to HIV/AIDS Cure Research   | 2 |
| Perspectives on HIV/AIDS Cure Research   | 13|
| Glossary of HIV/AIDS Research Terms & Phrases | 15|
| Resource Guide                          | 51|

This document is designed for the media and laypersons interested in understanding the issues involved in research related to curing HIV infection. It is essential to understanding most of the material to know what HIV, DNA, and a virus are, and it is quite helpful to have taken at least an introductory high school biology course.

**Notes to the Reader:**

1. **STRUCTURE & COLOR OF HEADERS:** This document is divided into four sections titled “Introduction to HIV/AIDS Cure Research,” “Perspectives on HIV/AIDS Cure Research,” “Glossary of HIV/AIDS Cure Research Terms & Phrases,” and “Resource Guide” in that order. Introduction and Glossary entries have headers that are color coded to indicate what scientific areas they belong to, as follows:
   - Basic science and biology entries have headers that are green.
   - HIV background, that is, entries that aren’t specifically related to cure research, and those that span categories have headers that are blue.
   - Gene-editing- and transplant-related entries have headers that are violet.
   - Entries related to HIV reservoirs, latency reversal, shock and kill, and latency silencing have headers that are red.
   - Entries related to individuals and groups of individuals have headers that are orange.
   - Entries related to social issues and practical considerations have headers that are brown.
   - All other entries have headers that are black.

Items are arranged in each of the four parts alphabetically by the first nontrivial word; thus, for example, the Resource Guide entry THE BODY is under “B”, not “T”.

2. **Introduction to HIV/AIDS Cure Research and the Glossary of HIV Cure Terms and Phrases:** Most of the entries that occur in the Introduction are also in the Glossary, nearly always with the same header, but occasionally, as for the first Introduction entry, with similar headers—in this case Alleles and Mutations and Allele. The difference between the two is that the Introduction entries are designed to provide introductions to their topics, while those in the Glossary provide the details.

3. **CROSSREFERENCES:** Terms that are underlined are defined elsewhere in this document. To reduce clutter, for cross-referenced terms that occur more than once in an entry, only the first occurrence is hyperlinked. Note that entries in the Introduction may refer to entries there or in the Glossary. There are also URLs for external resources.

4. **HIV, HIV-1 & HIV-2:** References to HIV are to what is more specifically named HIV-1, which is responsible for the pandemic. There is also a variety named HIV-2 that is confined to parts of West Africa and a few small pockets in Europe of immigrants from West Africa. See the HIV-2 Glossary entry for an explanation of why there is so little attention to it here.

5. **RESPONSIBILITY:** This document is a project of the Delaney AIDS Research Enterprise (DARE) to Find a Cure Community Advisory Board (CAB)—which is responsible for its content—with some input from members of some of the other Martin Delaney Collaboratories for HIV Cure Research CABs and several DARE researchers.

6. **FORMS AND AVAILABILITY OF THIS DOCUMENT:** This document is available online on this website as a PDF and a webpage, both of which are accessible from the page http://www.daretocure.org/CAB/cureglossary.html.

7. **SPANISH INTRODUCTION:** The Introduction section has been transformed to a self-contained version that has been translated to Spanish and is available as a PDF on this website from the web page http://www.daretocure.org/CAB/introduccion.html.

8. **CONTACTING THE AUTHOR:** You are welcome to send suggestions for edits and additions to this document's author at hivcureglossary@gmail.com. You may also send questions to the author about items in this document. However, please note that, while an attempt will be made to answer all relevant questions, not all of them will be answered quickly because of time limitations.
Introduction to HIV/AIDS Cure Research

Overview

While effective treatment is available that turns living with HIV from an almost certain death sentence to a relatively normal lifespan on treatment, there are several reasons why curing it is essential, as follows:

1. Despite treatment that reduces HIV viral load to an undetectable level in almost everyone who can stand that treatment and stick to taking it daily, everyone—including almost all elite controllers, who achieve un-detectability without treatment—suffers from the effects of chronic systemic inflammation that is a factor in the development of diabetes, cancer, and other diseases that shorten lifespan. Long-term HIV infection makes older people effectively about ten years older biologically than they are chronologically.

2. Despite having undetectable viral load, one still has a tiny possibility of passing HIV on to a sexual partner.

Note that these reasons make it essential to cure HIV as soon as possible after one becomes infected.

There are two types of cures that are the subject of research. The more ambitious is sterilizing, which removes all HIV from the body, or at least all HIV that can replicate. This is the kind of cure that is achieved for most diseases. It is increasingly being realized that sterilizing cure is likely not to be achievable for HIV, or at least not in the foreseeable future. The more realistic is functional cure, also known as remission, whose goal is to make the body able to control the disease without needing antiretroviral treatment (ART) for some period of time, preferably measured in years, and to have remission be repeatable.

There are five approaches to curing HIV infection being explored in research, namely:

- **Hematopoietic stem cell transplant:** Transplantation of hematopoietic (that is, blood-cell-producing) stem cells that lack a factor essential to most HIV infections is the approach used to cure the one person who has been cured so far, namely, the Berlin patient (Timothy Ray Brown). However, this approach is very impractical. It requires conditioning of the body—wiping out its immune system—so the transplant is not rejected, which makes one open to a wide range of infections until the transplant repopulates the immune system. In fact, Timothy nearly died in the process of his cure. The conditioning and the series of other medical interventions make this approach very time consuming, expensive, and risky. As a result, despite its being effective, this approach is simply not anywhere near generalizable to everyone living with HIV either now or in the near future, though there are researchers working on “transplant in a box.”

- **Gene editing:** One reason HIV is so difficult to cure is that, unlike almost all other viruses, it integrates many copies of its genetic material into the DNA of the human cells it infects. Gene editing is a strategy for modifying the HIV DNA in the host’s cells, such as removing it entirely or altering one or more of the factors that make those cells susceptible to HIV infection. There are numerous experimental gene editing techniques being investigated. However, the most precise and effective one is named CRISPR or CRISPR/Cas9. A recent mathematical modeling study of gene editing strategies for HIV cure has shown that achieving positive results requires major improvement of some key components of the strategy.

- **Shock and kill:** Shock and kill is focused on a type of immune-system cells called helper T cells or CD4+ T cells, which are the cells that are the primary focus of HIV infection. In fact, one would not be far wrong to say that HIV is a disease of helper T cells because it preferentially infects them and in the process of reproducing HIV virions (single virus particles) it destroys them. After becoming infected, CD4+ T cells go into a state called latency in some bodily organs, particularly lymph nodes. In that state they are not producing new virions, are out of the blood, and are inaccessible to anti-HIV drugs.

Shock and kill’s goal is to reactivate latent infected helper T cells and kill them. It is—obviously—a two-step process. The shock step uses drugs called latency-reversal agents (mostly ones developed for treating cancers) to reactivate the latent infected T cells. The second step uses other drugs to kill them.
There are currently two very significant problems with shock and kill: (1) there is no solid way to measure the number of latent infected cells in the body; there are several methods, but they provide vastly different numbers; and (2) despite the variation in measurements, it is clear that all the approaches to reactivation come nowhere near reactivating all the latently infected helper T cells, and there are several cases of people who were thought to be cured turning out to have viral rebound either quickly or eventually.

Shock and kill is also known as kick and kill.

- **Latency Silencing**: Latency silencing is the opposite of shock and kill. Instead of reactivating latent cells to kill them, its goal is to keep latent infected helper T cells and other infected cells from ever being activated. It is particularly important in the central nervous system (the brain and spinal cord) where reactivation could cause a storm of disastrous effects. Several approaches are being explored including using gene editing to make the HIV neither dangerous nor infective, using drugs to inhibit important HIV proteins, and using a protein to block integration of HIV into cellular DNA.

- **Immune-Based Therapies**: Immune-based therapies use drugs to alter some part of HIV’s replication process or enhance the effects of other approaches. An example is the use of drugs called TLR7 agonists (drugs that cause another substance to perform an action) to suppress HIV replication. Other immune-based therapies include therapeutic vaccines that boost immune system responses to HIV in infected persons, natural killer (NK) cells, and immune-system-related drugs that enhance shock and kill.

### AIDS (Acquired Immune Deficiency Syndrome)

AIDS (Acquired Immune Deficiency Syndrome) is the final stage of HIV infection. While AIDS and death for most HIV-positive people before 1996, with the advent of highly active antiretroviral therapy (HAART) that year it slowly retreated into the background in the developed world, though it remains a serious problem in some areas.

### Alleles and Mutations

An allele is a variant of a gene at a particular position on a chromosome. Humans and all other living organisms have two mirror images of each gene linked together on the two strands making up the double helix of DNA. The linkage of the genes across the strands provides a checking mechanism that greatly decreases the occurrence of errors (called mutations) that may cause diseases and particularly the runaway replication that characterizes cancer.

HIV has two strands of RNA as its genetic material, but the strands are not linked together unlike in the DNA double helix. The two occurrences of a gene are one on each strand. Because the strands are not connected there is no error checking, which makes the occurrence of mutations very much more common than in living things. This can result in virions (single virus particles) that are not infective, but it can also lead to so-called escape variants of HIV that are not susceptible to one’s current antiretroviral therapy (ART).

### Allogeneic Transplant

An allogeneic transplant, in the context of curing HIV infection, involves transplanting hematopoietic stem cells from a donor other than the transplant recipient.

As described above, this is being studied as a possible way to perform a sterilizing cure of HIV infection. See autologous transplant below for an alternative.

Allogeneic transplants, so far (and this is shared with autologous transplants), are very expensive and require intensive medical monitoring, making this approach simply technologically infeasible. What is needed has been called “transplant in a box” technology, analogous to what has been achieved by home HIV testing, and there are researchers working on this, though achieving the goal is still far in the future.

### Analytical Treatment Interruption (ATI)

An analytical treatment interruption (ATI) is a medically monitored interruption of antiretroviral therapy (ART) as part of a research study. The monitoring is almost always done by the researchers performing the study or by clinicians working with them. The purpose of the interruption is to determine the effect of the intervention used in the study on one or more measures of, for example, latent reservoir reactivation or the CD4+ T cell population. Analytical treatment interruptions pose important ethical issues, such as the possibility that the participant’s viral load becomes high enough that he or she infects one or more other persons or that her or his virus population becomes resistant to all available antiretrovirals (ARV); for a
Animal Models

Animal models, such as macaque monkeys, are particularly useful in HIV cure research because:

- They make it possible for the researcher to do what he or she wants;
- The ethical issues concerning them are simpler than those for people;
- They may be quite faithful models of what occurs in humans; and
- They may be “sacrificed” as the final step in the research and their tissues analyzed in ways that are obviously not possible in human clinical trials.

Numerous studies have been done in monkeys using simian immunodeficiency virus (SIV), a variety of which is the virus HIV developed from, or simian-human immunodeficiency virus (SHIV), a genetic combination of SIV and HIV created in a laboratory, before they were tried in human clinical trials. Unfortunately, neither of these models is as faithful to HIV and humans as would be preferred.

Another quite useful animal model is bone marrow-liver-thymus mice with HIV.

Antigens and Antibodies

An antigen is an invading bacterium, virus, or foreign substance that induces an immune response in the body, particularly the production of an antibody. An antibody is a mechanism the body has for fighting infections and other foreign substances. It is a specific protein produced by a B cell in the blood in response to and to counteract an antigen. It forms a chemical combination with the foreign substance that makes it inert.

Antiretroviral Therapy (ART)

Antiretroviral therapy (ART) involves the use of several (usually three) anti-HIV drugs to halt or greatly decrease viral replication. ART drugs may target any of several viral enzymes, such as reverse transcriptase, protease, or integrase, or entry of HIV into cells. Some drugs may instead target essential parts of the infected cell, as the CCR5-blocking drugs do. Some researchers believe that ART will be needed in shock and kill cure strategies to halt HIV reproduction as part of killing them in cells that have been reactivated by latency reversal.

Autologous Transplant

An autologous transplant is, specifically for curing HIV, a transplant of hematopoietic stem cells that have been provided by the transplant recipient and been modified to remove the DNA that encodes HIV, or, for example, the gene that encodes the CCR5 co-receptor for HIV. This is being studied as a possible way of performing a sterilizing cure of HIV infection. It has been argued that autologous transplantation is much more likely to be easily scalable to larger patient populations than allogeneic transplant for at least two reasons, namely, (1) it avoids the issue of having to find a very well-matched donor, since the recipient is the donor; and (2) it greatly reduces the risk of graft-versus-host disease (GVHD), again because the donor is the recipient.

However, autologous transplants have issues of their own, the most important of which are:

1. The cells to be transplanted (presumably hematopoietic stem cells) must be modified by some method to make them resistant to HIV infection (rather than being selected to be resistant, for example, by having the CCR5Δ32/Δ32 mutation—see the Zinc-Finger Nuclease (ZFN) item under the Gene Editing Glossary header for an example of a clinical trial with this goal);
2. There is not yet a safe and effective method for selecting the gene-modified cells, though several have been tried;
3. There must be sufficient numbers of transplanted cells to swamp the already infected blood stem cells.

Autologous transplants, so far (and this is shared with allogeneic transplants), are very expensive and require intensive medical monitoring, making this approach simply technologically infeasible. What is needed has been called “transplant in a box” technology, analogous to what has been achieved by home HIV testing; there are researchers working on this, though the goal is still far in the future.

B Cell

A B cell is a variety of immune-system cell that originates in the bone marrow (hence the “B”). It produces antibodies in response to an antigen presented by an antigen-presenting cell, such as a dendritic cell.

Berlin Patient (Timothy Ray Brown)

The Berlin Patient (Timothy Ray Brown) is the only person to have achieved a sterilizing cure of his HIV infection so far. His cure occurred after he had been diagnosed with an acute leukemia that affects a type of white blood cells essential for fighting infections. The leukemia would almost certainly have been fatal, so he...
had nothing to lose by trying a CCR5Δ32/Δ32 allogeneic transplant of hematopoietic stem cells in his bone marrow that would make him insusceptible to infection by most types of HIV. He actually required two transplants (in 2006 and 2007) for the cure to be successful. A very serious infection after the second transplant nearly killed him, but he bounced back from it, and he remains HIV free by the most sensitive tests available. Replicating such a cure remains a very high priority of cure research, preferably without requiring the chemotherapy (called conditioning) that Timothy required to wipe out his leukemia and prepare his bone marrow for the transplants.

Figure 1. This sequence shows HIV binding to the CD4 receptor, then to the CCR5 co-receptor, and finally having released its genetic material into a CD4+ T cell in four steps: (1) the CD4 receptor and CCR5 co-receptor on the cell surface; (2) HIV glycoprotein gp120 binds to CD4; (3) gp120 binds to CCR5 and releases gp41, which pierces the cell surface releasing the infective part of the virion into the cell; (4) the capsid (see HIV Structure and Function in the Glossary) enters the CD4+ T cell through the pore in the cell wall created in (3).

**CCR5**

CCR5 is a co-receptor on the surface of CD4+ T cells and some other cells that, during most of the course of HIV infection, is essential to entry of HIV into these cells. HIV attaches to both CD4 and CCR5 to achieve entry. (Some variants of HIV use a co-receptor called CXCR4 rather than CCR5; these variants almost always occur only late in untreated HIV infection; HIV transmitted from one person to another almost always uses the CCR5 co-receptor. However, some rare strains of HIV use both the CCR5 and the CXCR4 co-receptors.) Figure 1 (adapted from https://en.wikipedia.org/wiki/CCR5) shows (1) the CD4 receptor and the CCR5 co-receptor on the surface of a cell, (2) HIV binding to CD4, (3) then to CCR5, and finally (4) having released its genetic material into a CD4+ T cell through the pore in the cell wall created in (3). CCR5-tropic HIV is also called M-tropic because it can also infect macrophages and monocytes.

**CCR5Δ32/Δ32**

CCR5Δ32/Δ32 indicates a mutation that deletes 32 nucleic acid base pairs from both parents' copies of the gene that encodes the cellular co-receptor CCR5. The absence of these base pairs eliminates the ability of CCR5 to function on CD4+ T cells; the CCR5 co-receptor is needed by almost all strains of HIV to enter and infect these cells. Notably, the allogeneic immune-system transplants that resulted in a sterilizing cure of HIV infection in the Berlin Patient (Timothy Ray Brown) had this mutation in both strands of the DNA included in the transplant. Unfortunately, only about 10 - 15% of Caucasians have this mutation and almost no one else does, which makes this approach nearly useless for curing HIV infection in all infected persons, unless gene editing can make more instances of the mutation,
which is one of the focuses of HIV cure research. Note that "Δ" is the upper-case Greek letter “delta” and stands for the deletion. Further, CCR5Δ32/Δ32 is associated with increased susceptibility to West Nile virus infection and a variety of encephalitis.

**CD4**

CD4 is a receptor that is necessary, along with a co-receptor (CCR5 or CXCR4), to the attachment of HIV virions to CD4+ T cells. CD4 is one of hundreds of receptors known as clusters of differentiation that are found on the surfaces of various cell types and facilitate attachment of virions, chemicals, and other cells. CD8 is another. Note that, in addition to HIV-specific CD4+ T cells, CD4 is also found on other types of immune-system cells.

**CD4+ T Cell**

A CD4+ T cell is a primary white blood cell of the immune system; it is also known as a helper T cell. CD4+ T cells act, for the most part, as the “directors” of the immune system; they signal to other immune-system cells how and when to fight infections. CD4+ T cells are preferentially infected by HIV, which causes its own genetic material to be converted from RNA to the corresponding DNA and to be integrated into the cells’ DNA. HIV-infected CD4+ T cells, when activated, produce copies of HIV instead of reproducing or conducting immune functions.

CD4+ T cells can develop that specifically target parts of an infectious agent and such cells become activated in response to infection by that pathogen. After the infection is cleared or controlled, they can then become resting memory CD4+ T cells that lie in wait for future occurrences of the pathogen to which they then respond. Such resting memory CD4+ T cells are thought to constitute most of the latent reservoir of HIV. CD4+ T cells all have the CD4 receptor on their surfaces.

**CD8**

CD8 is a receptor that is necessary to the attachment of virions chemicals, and other cells to CD8+ T cells. CD8 is one of hundreds of receptors known as clusters of differentiation that are found on the surfaces of various cell types and facilitate attachment of virions, chemicals, and other cells. CD4 is another example. Note that, in addition to responding to HIV-specific CD4+ T cells, CD8+ T cells also respond to other CD4+ T cells and CD8 is found on other types of immune system cells.

**CD8+ T Cell**

A CD8+ T cell is a primary white blood cell of the immune system that kills infected or disabled cells as directed by CD4+ T cells. CD8+ T cells can be created that are specific to HIV. CD8+ T cells all have the CD8 receptor on their surfaces. These cells are also known as cytotoxic T lymphocytes (CTLs).

Recent research suggests that harnessing the killing power of CD8+ T cells may be essential to both functional and sterilizing HIV cures (see the HIV Cure (Functional) and HIV Cure (Sterilizing) Glossary entries).

**Central Nervous System (CNS)**

The central nervous system (CNS) consists of the brain and spinal cord. It is important for curing HIV for at least four reasons:

1. it is a latent reservoir for HIV that is affected by chronic inflammation that begins very early in HIV infection;
2. it can only be reached by a small minority of HIV antiretroviral therapy (ART);
3. HIV’s gp120 glycoprotein impacts the function of neurons; and
4. since the brain is so very essential, there is concern among cure researchers that approaches other than shock and kill, such as latency silencing of reactivation entirely, will be necessary to achieve a cure in the CNS because of the seriously toxic effect reactivation is likely to have on CNS functioning.

Also, several free-floating HIV proteins have been shown to enter neurons and have pathogenic effects.

**Clinical Trials**

Clinical trials are the standard process for testing new medications, medical devices, and medical procedures in humans. They are typically preceded by studies done in nonhuman animals (sometimes called “Phase 0”) to weed out those that are not worth the effort and expense of clinical trials. Clinical trials have three phases, as follows (we use medication to represent all three categories below):

1. **Phase I**: A Phase I clinical trial involves a small number (usually not more than about 20) of healthy volunteers to test the safety of the medication and any side effects it may have. If the procedure is determined to be safe and to have only acceptable side effects, it may proceed to Phase II.
2. **Phase II**: A Phase II clinical trial will usually involve several hundred volunteers. It continues to test for safety and side effects and also adds on determination of its effectiveness.
3. **Phase III**: A Phase III clinical trial involves several thousand volunteers and is intended to confirm the
effectiveness of the medication, monitor its side effects, compare it to commonly used drugs if there are any already, and continue to collect information to determine whether the drug is safe. Only after a successful Phase III study does a medication go before a panel of the U.S. Food and Drug Administration (FDA) or similar agency elsewhere in the world for approval for distribution.

There is also what is sometimes called “Phase IV”: a post-marketing phase, in which the medication or procedure is used in diverse populations and continues to be monitored for side effects.

In some case, clinical trials have phases that are numbered with a Roman numeral followed by the letter “A” or “B” to indicate whether it is an early or late part of the phase, respectively. These letters are usually used in combinations of phase numbers to indicate that the clinical trial straddles two consecutive phases; an example of this might be a Phase IB/IIA trial.

Every clinical trial done in the United States is required to have a written trial protocol that describes at the least:

- a detailed plan of what is to be done,
- why it is being done,
- justification for it based on prior research,
- known and hypothetical risks and benefits,
- criteria for inclusion and exclusion of potential participants, and
- a schedule of what will be done (for example, physical exams, blood draws, and monitoring side effects).

It also must have an informed consent form (ICF) that explains the trial to the volunteers, informs them of the above facts in lay language, tells them they may withdraw from participation at any point without giving a reason for doing so, and requires their signed and witnessed consent to participation before they begin the trial’s procedures. Every clinical trial protocol and ICF is reviewed and approved by an independent Institutional Review Board and one or more of several government agencies (which one(s) depend on the nature of the trial) before it can begin recruiting volunteers.

Clinical trials done outside the United States are required to follow the same or a very similar rigorous plan and process.

**Clonal Expansion**

Clonal expansion is the production of numerous daughter cells with identical genomes resulting from a parent cell. Clonal expansion of HIV-infected CD4+ T cells in circulating blood is thought by some researchers to be a significant contributor to the latent reservoir and so a barrier to HIV remission.

**Co-Receptor**

A co-receptor, in the context of HIV medicine (including cure research), is a chemical, such as CCR5 or CXCR4, attached to the surface of a cell such as a CD4+ T cell that facilitates attachment and entry along with a receptor, such as CD4, of an HIV virion into the cell.

**CXCR4**

CXCR4 is a co-receptor on the surface of CD4+ T cells that, during late stages of untreated HIV infection, is essential to entry of HIV into these cells. (Some variants of HIV use a co-receptor named CCR5 rather than CXCR4; these variants almost always occur in all but the last part of the course of HIV infection; HIV transmitted from one person to another almost always uses the CCR5 co-receptor, though rare cases with the CXCR4 co-receptor do occur.) Further, some rare strains of HIV use both the CCR5 and the CXCR4 co-receptors. Also, unlike CCR5, CXCR4 is not a good candidate for gene editing because it occurs on several cell types other than CD4+ T cells and is essential to their function. CXCR4-tropic HIV is also called T-tropic because unlike CCR5-tropic virus it can infect CD4+ T cells but not macrophages and monocytes.

**Defective Virion**

A defective HIV virion is one containing an RNA genome that makes it incapable of viral replication. This results from the single-stranded nature of HIV's RNA. All living organisms have linked double-stranded DNA making up the well-known double helix; the cross links in the helix provide a self-checking mechanism to prevent frequent mutations. Of course, some mutations do occur in living organisms, and they are one of the mechanisms that cause cancers and numerous other diseases, such as sickle-cell anemia and Huntington’s disease. However, the unlinked single strands of HIV’s RNA have no such self-checking mechanism, and mutations occur in them very frequently, as we shall see.

Let’s calculate how often a typical nucleic acid base is mutated each day in a person who is not on antiretroviral therapy (ART). Note that, despite the extremely high frequency of mutations, this has no chance at all of eliminating HIV from a human in a lifetime!

1. The current best estimate for the overall mutation rate is one per 34 viral replication cycles.
2. Given that roughly 10 billion new virions are created each day, roughly 300 million of the new virions will have at least one mutation.

3. With about 9,750 nucleic acid bases in each strand or 19,500 across both strands, that's an average of one mutation in each base position about 16,000 times a day!

Compared to a living organism’s mutation rate, this is absolutely staggering! It doesn’t require very many mutations in genes encoding critical proteins, such as reverse transcriptase or integrase (see the HIV Structure and Function Glossary entry), to render a virion incapable of infectivity, that is, make it defective. Even in persons on suppressive antiretroviral therapy (ART), the accumulation of mutations that make new virions defective is staggeringly common.

Dendritic Cell
A dendritic cell is one variety of antigen-presenting cell whose main function is presenting antigens found on external surfaces in the body to B cells or CD4+ T cells. They are found in the skin and other areas that are on the outside of the body, such as the nose, lungs, mouth, stomach, and intestines, and so in contact with the environment.

Diversity and Inclusiveness in Cure Research
It is no secret that HIV/AIDS is a pandemic disease, yet HIV-related research and cure research in particular tend very strongly to be concentrated in the developed world (particularly the United States, Canada, Western Europe, and Australia) plus a few relatively isolated outposts in Thailand and South Africa. There are issues of sex, gender, sexuality, age, race, economics, convenience, and researcher bias at the least that are responsible for this. Following are a few of the relevant facts and resources that make clear some of the issues and possible approaches to dealing with some of them; all of them are discussed in the Perspectives entry with the same header (in black).

- It is clear from numerous studies that the immune system’s effectiveness decreases with increasing age. This has effects on how well the body can deal with HIV infection among many other types of assaults and it also probably impacts the effectiveness of approaches to HIV cure, though this is currently unknown.
- Similarly, the hormonal and other developmental changes that occur during adolescence and the legal issues involved in obtaining informed consent for research very often exclude adolescents from HIV research studies. A notable positive development in this area is in South Africa, the country with the highest prevalence of HIV+ youths and young adults.
- There are barriers to including women in cure research, at the least because current approaches to cure have unknown interactions with pregnancy, both on the mother and the fetus.
- Transgender health is a developing field, but, so far, virtually nothing is known about the impact of hormonal treatment and cure strategies.

Droplet Digital Polymerase Chain Reaction (ddPCR)
Droplet digital polymerase chain reaction (ddPCR) is a type of polymerase chain reaction that is characterized by the creation under digital control of tiny droplets of highly amplified DNA resulting from an initial single molecule that are digitally measured. This technique has greatly automated the PCR technology and markedly decreased its expense.

Dual Antibody Use to Reduce the Latent Reservoir
Three studies published in late 2015 examine the use of so-called dual antibodies to achieve various aspects of reduction of the latent reservoir of HIV-infected CD4+ T cells, as follows:

1. One study discusses the use of dual-affinity re-targeting (DART) molecules to bind to both the HIV Env protein and the CD3 receptor on infected cells and “recruit” CD8+ T cells to kill the bound cells.
2. Another study used DARTs to bind to the same protein and receptor as in item 1 above to direct CD8+ T cells to kill infected CD4+ T cells.
3. The third study used what it calls bispecific antibodies that bind to the Env epitope recognized by the broadly neutralizing antibody VRC07 and the CD3 receptor to reduce HIV DNA in most of the laboratory isolates of infected cells tested. A broadly neutralizing antibody is one that is effective against a large class of antigens. “VRC” abbreviates the Vaccine Research Center at NIH that was responsible for discovering and characterizing the antibody.

One potential concern about all three of these studies is the possibility that their targeting CD3 might cause general activation of T cells, since it is the receptor that occurs on all of them, which could be disastrous. Apparently the dual nature of the targeting caused only minor, transient effects of this sort.

Elite Controllers
Elite controllers are rare individuals living with HIV who maintain undetectable viral loads in the absence of—in most cases—any antiretroviral therapy. In about 2/3 of
known cases, they possess immune-system mutations that appear to enhance immune-system recognition and removal of HIV. In some elite controllers, undetectable viral loads are found in the absence of protective genes, indicating that specific genes are neither necessary nor sufficient for elite control of HIV. However, there is evidence that many elite controllers suffer from chronic systemic inflammation like other people living with HIV, so they are likely to suffer from its long-term effects.

**Enzyme**

An enzyme is an organic molecule, in most cases a protein or peptide but in a few cases an RNA (such as a ribozyme), that acts as a catalyst: It facilitates a biochemical process without itself being modified, so it can be used again. Almost all proteins that are enzymes have names ending in "ase".

**Gene Editing**

Gene editing is a cure strategy for modifying genetic information in cells, such as removing HIV proviral DNA from a person's DNA or altering the CD4 receptor, CCR5 co-receptor, or anti-HIV restriction factors to make CD4+ T cells resistant to HIV infection. There are numerous experimental gene-editing techniques being investigated (many targeting the gene that encodes CCR5). We describe below only the most important one, namely, CRISPR. A recent mathematical modeling study of gene editing for HIV cure has shown that achieving positive results is possible only under a narrow range of conditions and that further improvements are likely necessary to improve outcomes.

CRISPR-based gene editing is a combination of two drugs, CRISPR (a DNA sequence originally derived from bacteria) and, usually, a Cas protein (CRISPR associated protein—most often Cas9), that is currently the most efficient, effective, and easy-to-use method for gene editing. A recent report discussed laboratory comparisons between older methods and uses of CRISPR/Cas9 to perform the same tasks and showed that there were erroneous results in a significant number of cases using the older methods.

In fact, Science, the most prominent U.S. scientific journal, declared CRISPR to be the “Breakthrough of the Year” for 2015 because of its very wide applicability and ease of use, and Nature, the most prominent British scientific journal, chose it as No. 1 among its ten most important breakthroughs of 2015. Further, in early 2016, it was reported by two research teams that CRISPR technology, one using Cas9 and another using a different protein, had been used to remove entire HIV proviral DNA from latently infected CD4+ T cells in vitro and this has more recently been reported in vivo. Problems remain, however, for generally translating this technology to use in vivo—in fact another recent study about it reported that CRISPR/Cas9 resulted in an immune response to the Cas9 protein as a substance foreign to the body (a pathogen).

See also the CRISPR Perspectives entry and the first item under the Gene Editing header in the Glossary.

**Genome**

A genome is the collection of all the genes in a living organism or virion.

**Graft-versus-Host Disease (GVHD)**

Graft-versus-host disease (GVHD), also called rejection, is a natural reaction by the body's immune system to a graft or transplant that typically results in elimination of the graft or transplant unless immunosuppressive drugs, such as cyclosporine, are administered. The reaction is predominantly carried out by CD8+ T cells. Nevertheless, in the case of the Berlin Patient (Timothy Ray Brown), graft-versus-host disease may have played a significant essential role in destroying his original HIV-infected CD4+ T cells.

**Gut-Associated Lymphoid Tissue (GALT)**

Gut-associated lymphoid tissue (GALT) consists of immune cells lining the gut that are a critical component of the immune response to pathogens. It is usually severely depleted very early in the course of HIV infection. It is believed that the depletion is mostly irreversible.

**HIV Cure (Functional)**

This type of cure allows some infected cells to persist in the body of a person living with HIV but means that antiretroviral therapy is no longer necessary, at least for a long time. With this approach, the immune system should be able to handle the virus that is still in the body. Because such individuals would typically have very low levels of HIV, they would much be less likely to transmit HIV to others than most infected people but might themselves be vulnerable to reinfection with other strains of HIV than the one with which they are already infected. This type of cure is also commonly called HIV remission.

**HIV Cure (Sterilizing)**

This type of cure completely eliminates HIV from an infected person's body, which would likely require activation and killing of all infected CD4+ T cells (and probably infected macrophages), plus eliminating or silencing other cells contained in latent reservoirs. Depending on the strategy used, such individuals might or might not be resistant to reinfection with HIV. This
approach results in there being no HIV capable of viral replication left in the body, so the person would not be able to transmit HIV to others. However, proving that all HIV has been eliminated from a person’s body is impossible with current approaches, including in the case of the Berlin Patient (Timothy Ray Brown), though he has been HIV– for ten years.

HIV Genome
The nucleus of HIV (see the HIV Structure & Function Glossary entry) contains the two separate single strands of RNA that make up HIV’s genetic material or genome. It comprises nine genes and the two long terminal repeats (LTR), the right-hand one of which is crucial for beginning the production of proteins from the resulting proviral DNA. The overlapping of segments in the diagram corresponds to what are known as open reading frames. (Note that the open reading frames in the HIV genome are never directly transcribed and translated to proteins: The HIV genome must first be integrated into a host cell’s DNA as proviral DNA that is, in turn, transcribed and translated to proteins.) In all, each strand has roughly 9,750 bases (nucleic acids), though this varies somewhat with the faulty replication of HIV RNA (see the Defective Virion Introduction and Glossary entries).

HIV Structure & Function
The cutaway diagram in Figure 5 in the Glossary shows schematically the structure and components of an HIV virion. Note that Figure 1 here shows the capsid about to be inserted into an about-to-be infected cell. The capsid contains everything necessary to insert the HIV genome (transcribed from RNA to DNA) into the cell’s DNA and to produce new virions. The components are described in detail in the Glossary entry with the same name.

The virion also includes a transfer RNA (tRNA) from the cell that produced the virion that serves to prime insertion of the resulting proviral DNA into the infected cell.

HIV’s Uniqueness
HIV is unique among human pathogens in several respects, as follows (adapted in part from a slide created and provided for use by Nobel Prize winner Prof. David Baltimore, PhD, of CalTech):

- It preferentially attacks CD4+ T cells, the “directors” of the adaptive immune system.
- It eludes control by antibodies.
- Sugars cover almost its entire accessible surface. The only notable exception is the CD4 binding site, but that site is deep inside the protein coat, where it can’t be reached by most antibodies.
- It employs a remarkable two-part attachment mechanism, using CCR5 or CXCR4 in addition to CD4. Entry only takes place after viral gp120 protein has bound to the CD4 site (see the CCR5 Glossary entry). As a result, very few antiviral antibodies can neutralize HIV, and fewer still are broad and potent.
- It destroys the gut-associated lymphoid tissue (GALT) very early in infection altering the gut’s bacterial community.
- It also attacks the central nervous system (CNS) very early in infection.

All of these aspects of HIV’s uniqueness make it a much more difficult target for cure research than for almost all other pathogens.

Immune System
The immune system is the body’s system that protects against disease. It consists of two major parts, the innate immune system and the adaptive immune system.

The innate immune system comprises three parts: biological barriers, natural killer (NK) cells, and killer-cell immunoglobulin-like receptors on the surfaces of natural killer cells, which are generally known by their abbreviation “KIR”. Biological barriers at the surface of the body may be effective in keeping out pathogens, such as foreign substances, bacteria, and viruses that the barriers recognize as different from the body. Pathogens that make it through the biological barriers may be recognized by KIR components that are specific to them. If a KIR component recognizes a pathogen, it activates natural killer cells.

The adaptive immune system comprises B cells, T cells, antibodies produced by B cells, and the human leukocyte antigen (HLA) complex, which consists of genes that code for body surface proteins that distinguish between self and non-self and cell-surface proteins, such as CD4 and CD8, that regulate the adaptive immune system in humans. T cells, in turn, are a large family of varieties, including at least CD4+ T cells, CD8+ T cells, and at least a half dozen other types. See the entries for the underlined cell types for descriptions of their roles in immunity.

Inflammation
Inflamed immune-system cells can signal other immune-system cells to reproduce or respond to a pathogen. The key white blood cell in inflammation is the macrophage. Macrophages can assemble within themselves specialized platforms named inflammasomes that produce the substances that promote inflammation. These platforms are assembled
when needed and destroyed when they are no longer needed. This is usually helpful.

However, HIV infection, even in those whose virus is either suppressed naturally (elite controllers) or by antiretroviral therapy (ART), is known to cause chronic inflammation, which can lead to heart attacks, strokes, cancers, and other serious health conditions. Activated cells can also produce scarring (also called fibrosis) in lymph nodes, a critical part of the immune system. For most purposes, chronic immune activation equals chronic inflammation (that is, every state of chronic inflammation leads to chronic immune activation and vice versa).

**Latency Reversal**
Latency reversal is fundamental to activating the bound HIV proviral DNA in resting CD4+ T cells in latent reservoirs in the body to make it susceptible to destruction in the approach to cure known as shock and kill. This is considered by many HIV cure researchers to be fundamental to curing HIV. The Glossary entry with the same name lists 16 of the many types of substances and individual substances being tested as latency-reversal agents.

**Latency Silencing**
Latency silencing is a term used to describe an approach to completely stop reactivation of latently infected CD4+ T cells in latent reservoirs, thus making them incapable of producing further HIV virions. Latency silencing is essential to curing HIV in areas such as the central nervous system (CNS) where latency reversal is believed to have disastrous consequences. At least five distinct approaches are currently being explored, and NIH has a request for research-grant applications for another that is active as this is being written.

**Latent Reservoir**
Latent reservoir is used in HIV cure research in two closely related senses, as follows:

(1) A latent HIV reservoir is a tissue in a person’s body that is reachable by HIV. In the context of HIV infection, it is a part of the body that, it is generally believed, is not affected by antiretroviral therapy (ART) as effectively, if at all, as in the blood. Latent reservoirs provide long-lived homes for HIV to reemerge from if therapy is stopped. Examples of confirmed and likely latent reservoirs include a subset of CD4+ T cells named resting memory CD4+ T cells, macrophages and monocytes (white blood cells), and parts of the intestines.

(2) The latent HIV reservoir is the totality of the individual latent reservoirs of type (1). The size of the latent reservoir is estimated to be anywhere from 1 million to over 50 million HIV-infected resting memory CD4+ T cells by the methods listed in the Measuring the Latent Reservoir Glossary entry.

A recently reported study of HIV and macrophages performed in bone marrow-liver-thymus (BLT) mice showed that HIV persists in macrophages in vivo and thus they are very likely to be a component of the latent reservoir.

A 2011 freely available survey article (Richman D “Introduction: challenges to finding a cure for HIV infection” Current Opinion in HIV and AIDS 6, January 2011, p. 1; it can be downloaded from the webpage http://journals.lww.com/co-hivandaids/toc/2011/01000) noted what we know about the latent reservoir as follows (lightly edited):

a) Latently infected resting memory CD4+ T cells are the best characterized latent reservoir for HIV-1.
b) Less than 1 cell per million of resting CD4+ T cells from persons on potent antiretroviral therapy harbors replication-competent latent provirus.
c) Other drug-insensitive reservoirs, including brain, macrophages and hematopoietic stem cells, may also exist.
d) The genetic information in latent proviruses does not evolve—because it is produced by a clonal expansion of a single infected cell—which suggests there is no ongoing viral replication within the cells containing them. Discontinuation of antiretroviral therapy permits the rebound of viral replication originating from the latent reservoir.
e) Patients successfully treated with antiretroviral therapy for a decade or more exhibit no appreciable decrease in the size of the latent reservoir.
f) The persistence of the latent reservoir precludes its elimination by antiretroviral therapy for the lifetime of the patient.
g) Latency is likely established by numerous steps of HIV-1 replication, which potentially complicates eradication strategies.

It is generally accepted that the latent reservoir of at least HIV-infected resting memory CD4+ T cells containing proviral DNA and almost certainly other
types of HIV-infected cells is established within days after infection.

**Lymph Node**
A lymph node is a small organ containing immune-system cells named lymphocytes that filter lymph, which is a milky fluid similar in composition to blood plasma that contains fats (responsible for its color), B cells, and T cells; the latter include CD4+ T cells and CD8+ T cells. Prominent clusters of lymph nodes are found in the underarms, the groin, and the neck. See the Lymphatic System & Lymphoid Tissues Introduction and Glossary entries for more information about them.

**Lymph Node Collagen Deposition (Fibrosis)**
When cells die, they are sometimes replaced by scar tissue composed of collagen, which is a protein found in numerous tissues including bones. This is called fibrosis. When lymph nodes are inflamed by HIV viral replication they can lay down scar tissue. This can begin within days of HIV infection and may be largely complete within months after infection. Experts currently believe that when lymph nodes are scarred, it may be difficult to regain their ability to respond to HIV and other infections as effectively as before the deposition had occurred, causing lasting damage to the immune system that a cure may not be able to reverse.

**Lymphatic System & Lymphoid Tissues**
A lymphoid tissue is an individual component of the lymphatic system. The lymphatic system is made up of lymph nodes; local immune cells in many other lymphoid tissues, such as gut-associated lymphoid tissue (GALT), Peyer’s patches, the spleen, tonsils, and adenoids; and the lymphatic vessels that lead from lymphatic tissues toward the heart. The lymphatic system is essential to fighting infections. See Figure 7 in the Glossary for a diagram of the lymphatic system.

**Measuring the Latent Reservoir**
Measuring the latent HIV reservoir(s) is vital to determining the effectiveness of approaches to latency reversal. It can be used to determine the number of reactivated HIV-infected CD4+ T cells, in addition to its basic measurement role.

It is estimated that the latent reservoir typically contains anywhere from about 1 million to over 50 million HIV-infected CD4+ T cells. The ultimate goal of measuring the latent reservoir is to count all and only replication-competent provirus, which no measurement tool is yet capable of doing. There are several approaches to measuring the number of HIV-infected CD4+ T cells in the latent reservoir, and more are being designed continually.

The “gold standard” to which all other approaches are compared is the quantitative viral outgrowth assay (QVOA), which attempts to count replication-competent latent provirus. It is complex and expensive and has the added disadvantage of being very likely to underestimate the actual size of the latent reservoir. However, some studies show a significant correlation between the results of QVOA and total HIV DNA.

**Natural Killer (NK) Cells**
Natural killer (NK) cells are white blood cells responsible for killing infected cells and cancer cells. They are the most ancient component of the cellular immune system. They have long been thought to be purely “natural” in the sense that they are preprogrammed to respond to particular types of infected or disabled cells, unlike CD4+ T cells and CD8+ T cells, which must be trained to respond to their target pathogens and thus can have numerous distinct targets. However, recent evidence suggests that there are memory-like subsets of natural killer cells in mice and in nonhuman primate (NHP) models, such as rhesus macaques infected with SHIV. There is ongoing research into whether such memory-like natural killer cells may play a role in curing HIV infection.

**Post-Therapy Controllers**
Post-therapy controllers are a small group of HIV+ individuals, so far mostly the VISCONTI (Viro-Immunologic Sustained Control after Treatment Interruption) cohort in France, who started antiretroviral therapy (ART) within weeks of infection, stayed on therapy for an average of about four years, and then stopped therapy. Because there has been no large or lasting rebound of HIV, these individuals are able to stay off therapy for as long as 10 years. Unlike most elite controllers, these people mostly lack immune-system mutations that would make them less susceptible to ongoing virus replication. Natural killer (NK) cells are believed to be largely responsible for HIV control in this cohort.

**Receptor**
A receptor, in the context of HIV cure research, is a chemical (such as CD4 and CD8). For a CD4+ T cell, the corresponding CD4 receptor facilitates attachment and entry along with a co-receptor, namely CCR5 or CXCR4, of an HIV virion into a CD4+ T cell.

**Remission**
Remission is a term preferred by many researchers for HIV Cure (Functional). This is because functional cures, like cures for many types of cancers, may be short lived though they are likely to be repeatable at least for HIV.
Retrovirus
A retrovirus is a virus, such as HIV, whose genetic material is RNA rather than DNA. Retroviruses are special in that they are able to integrate their RNA into the host DNA as proviral DNA, which enables the creation of new virions.

Ribozyme
A ribozyme is a small RNA that acts as if it were an enzyme.

RNA
RNA stands for ribonucleic acid. Unlike DNA, which exists only in the well-known double helix structure found in all living things or as single strands in some viruses, there are more than 30 forms of RNA with distinct functions. One form serves as the two unconnected strands of genetic material in HIV.

Stakeholder Engagement
Stakeholder engagement refers to the involvement of essential people and organizations, including governments, foundations, research groups, companies, and especially individuals, in promoting understanding of HIV-related research, particularly clinical trials of both cure basic science and, potentially, curative processes; developing appropriate expectations; and sustaining involvement of persons in those trials. See also the Resource Guide entry with the same header.

Thymus Gland
The thymus gland is located in the chest just below the neck. It is the origin of all T cells (including specifically CD4+ T cells and CD8+ T cells) all of which migrate to the bone marrow. The thymus gland typically shrinks to almost nothing during adolescence.

Viral Load
HIV viral load measures the amount of HIV virions circulating in the blood. It is usually reported as copies of virus per milliliter of blood (abbreviated c/ml). It is important in HIV cure research because activating cells containing latent HIV from latent reservoirs increases viral load in a measurable way.

Virion
A virion is a single complete virus particle that consists of an RNA or DNA core with proteins, such as enzymes, and often with an external envelope. It is the extracellular infective form of a virus.

Women’s Involvement in Cure Research Studies
A recent open-access viewpoint article concerning women’s involvement in cure research suggests six ways to increase women’s involvement. Before summarizing the points in the article, we must point the reader to the Estradiol, Estrogen, Progesterone, and Estrogen Receptors Glossary entry, which makes clear several very important biological reasons for increasing women’s involvement. Current barriers and suggested ways to increase involvement are as follows:

1. The possibility of pregnancy and its unknown or not clearly understood impact on HIV-related research of all kinds is a very frequent barrier, especially for treatment studies. Most study designs can be modified to reduce the impact of this barrier, if not eliminate it.
2. Researcher and clinic coordinator perceptions may impact recruitment of women.
3. Engagement of women stakeholders and improving the perceptions of women held by male stakeholders can increase women’s recruitment and retention in clinical trials.
4. Overcoming structural barriers, such as the lack of child care at research sites, and including women-focused community organizations in recruitment can improve involvement of women in studies.
5. Policy interventions in research funding can promote sex and gender equity.
6. The Gender, Race, and Clinical Experience (GRACE) study (a description of which can be downloaded from http://online.liebertpub.com/doi/pdf/10.1089/apc.2013.0015) is an excellent example that specifically included recruitment of women and can serve as a model for other studies.

Perspectives on HIV/AIDS Cure Research
This section presents several of the most important trends, subject areas, and less than obvious reasons for HIV cure research, with references to items in the following two sections that are related to them.
**Chronic Inflammation**

Chronic inflammation is a process that involves body-wide inflammation, which is very deleterious to overall health, and begins very early in the course of HIV infection. While antiretroviral therapy (ART) is highly effective at reducing or nearly stopping HIV replication, it lessens but does not eliminate chronic inflammation, which is implicated in premature aging, heart and circulatory problems, cognitive decline, and numerous other serious medical problems. All this makes it one of the most urgent reasons for cure research.

**CRISPR**

CRISPR (clustered regularly interspaced short palindromic repeats) are segments of DNA in some bacteria and archaea that, combined with a protein such as Cas9 (CRISPR associate protein 9) or Cpf1 (centromere and promoter factor 1), constitutes a primitive immune system that is mostly effective against genetic sequences found in viruses, and plasmids (genetic structures in cells that reproduce independently of the DNA in the nucleus—see also the Organelle Glossary entry), two types of potentially injurious foreign material. The combination of CRISPR and either of the two proteins has been found to be the most effective and exact technique for editing DNA. It is particularly useful to HIV cure because it can be used to edit out the genes for the co-receptors CCR5 and CXCR4 and/or the entire HIV genome. In fact, CRISPR was recognized as the breakthrough of the year for 2015 by the journal *Science* and number one of the ten breakthroughs of 2015 by the journal *Nature*. It is fair to say that while there are researchers and companies still using several of the other techniques listed in the Gene Editing Glossary entry, CRISPR is very likely to eclipse them within the next few years—it already has a significant industry: as of February 2017 there were already at least three public companies and numerous others that were still private. Several research projects that used other gene-editing techniques have recently been repeated using CRISPR/Cas9, which has shown that some of them had incorrect conclusions.

**Diversity and Inclusiveness in Cure Research**

It is no secret that HIV/AIDS is a pandemic, yet HIV-related research and cure research in particular tend very strongly to be concentrated in the developed world (particularly the United States, Canada, Western Europe, and Australia) plus a few isolated outposts in Thailand and South Africa. There are issues of sex, gender, sexuality, age, race, economics, convenience, and researcher bias at the least that are responsible for this. The following are a few of the relevant facts and resources that make clear some of the issues and possible approaches to dealing with some of them:

- It is clear from numerous studies that the immune system’s effectiveness decreases with increasing age (see, for example, for a very readable exposition, Chapter 2 “Things Fall Apart” in the book A Gawande *Being Mortal* pp. 25 – 54 Henry Holt and Co. New York 2014). This has effects on how well the body can deal with HIV infection among many other types of assaults and it also probably impacts the effectiveness of approaches to HIV cure, though this is currently unknown, in large part because most HIV research studies along with other HIV research have upper limits on the age of participants.
- Similarly, the hormonal and other developmental changes that occur during adolescence and the legal issues involved in obtaining informed consent for research very often exclude adolescents from HIV research studies. A notable positive development in this area is in South Africa, the country with the highest prevalence of HIV youths and young adults. There, for example, the Centre for the AIDS Program of Research in South Africa (CAPRISA) is enrolling not just adolescents but also children in research. An article about CAPRISA is available online at http://www.unicef.org/infobycountry/southafrica_70973.html and CAPRISA’s website is http://www.caprisa.org/Default.
- There are barriers to including women in cure research, at the least because current approaches to cure have unknown interactions with pregnancy, both on the mother and the fetus.
- Initial research on the effects of female hormones on HIV cure research are described in the Estradiol, Estrogen, Progesterone, and Estrogen Receptors Glossary entry below and barriers to and some suggestions for increasing participation by women in cure research are discussed in the Women’s Involvement in Cure Research Studies Glossary entry.
- The AIDS Malignancy Consortium (website: https://web.emmes.com/study/amc/public/), a clinical-trials-sponsoring network of the National Cancer Institute that supports studies of cancers in HIV+ people and their treatment, has set up a laboratory in eastern Africa because of the expense and infeasibility of getting frozen samples to laboratories in the United States. This might conceivably be shared with cure research studies.
- Transgender health is a rapidly developing field, but so far almost nothing is known about the impact of combining hormonal treatment with cure approaches. A wonderful recent book that explores transgender health issues is the book L Erickson-Schroth *Trans Bodies, Trans Selves: A
Resource for the Transgender Community
Oxford Univ. Press New York 2014. While it devotes only about a dozen pages to HIV specifically, it also provides access to other relevant resources.

Microbiome and Microbiota
A microbiota is a collection of bacteria, archaea, fungi, and viruses that colonizes a particular part of a plant or animal’s body. The term microbiome was originally coined to refer to the genome of a microbiota, but it is now increasingly used interchangeably with and more commonly than microbiota.

Our concern is with the human microbiomes; it is estimated that the genomes of all microbiomes in one person have roughly 200 times the genetic material of the human genome. Various parts of our skin have individual microbiomes, as do parts of the digestive system, the respiratory system, and other parts of the body. Further, microbiomes vary from person to person. Particular changes in microbiomes are associated with diseases. HIV alters human microbiomes, and they are involved in all aspects of HIV disease from prevention through treatment and cure. For example, very early in infection, the gut-associated lymphoid tissue (GALT) is severely depleted, and this changes the intestinal microbiome. In HIV cure research microbiomes are just beginning to be a subject of significant study. This is definitely an area to watch.

Remission (Functional Cure)
While the term “cure research” continues to be used somewhat indiscriminately, it is recognized by most researchers that a generally applicable approach to a sterilizing cure (see the HIV Cure (Sterilizing) Glossary entry) is extremely difficult to develop and is very unlikely to be developed any time soon. Thus, almost all cure researchers use the term remission or functional cure (see the “HIV Cure (Functional)” Glossary entry) in a similar sense to how it is used in cancer treatment instead. Remission would involve being entirely symptom free for at least several years—and, one hopes, preferably much longer—before requiring treatment to re-achieve remission.

Shock and Kill
Shock and kill has been the subject of intensive research in many laboratories, but it is increasingly recognized as likely to be insufficient to achieve a cure on its own. There are several reasons this is the case, but the most important ones are as follows:

1. We lack the capacity to measure the latent reservoir accurately, so shock-and-kill studies may impact it, but we have no way to know to what degree they do; nevertheless it is clear that current shock agents affect only a small fraction of the latent reservoir;
2. The sites of integration of the virus are very likely to affect the potency of a shock agent (latency reversal agent), and they have off-target effects—we need more powerful and more specific agents and likely ones that also attack infected cells that have the same HIV integration site in their DNA (that is, cells that are the result of clonal expansion);
3. Any shock agent might induce infected cells to proliferate and expand, but they have not yet been paired with powerful enough kill drugs, such as, perhaps, immunotherapeutic agents, vaccines, or other types of drugs that induce cell death in response to HIV proteins.

Glossary of HIV Research Terms & Phrases

1-LTR and 2-LTR Circles
1-LTR and 2-LTR circles are dead-end byproducts of partial HIV viral replication: neither can make additional virions. A 1-LTR circle is distinguished from a 2-LTR circle by incorporating only a single long terminal repeat, while a 2-LTR circle has two adjacent ones. See the HIV Genome Glossary entry for a description of long terminals repeats (LTRs). In the shock and kill approach to purging latent reservoirs of HIV, the quantities of 1-LTR and 2-LTR circles resulting from the shock are measured because they are indications of the quantity of defective virions made by reactivation.

Adeno-Associated Virus (AAV)
An adeno-associated virus (AAV) is a type of virus that can be used as a vector to carry genetic material (typically DNA but occasionally RNA) or a protein into humans by injection. Adeno-associated viruses are not known to cause disease in humans, which makes them typically better candidates as vectors than adenoviruses. Adeno-associated viruses are expected to be used to deliver therapeutic vaccines in some approaches to the “kill” phase of some shock and kill strategies for reactivation and elimination of HIV-containing resting memory CD4+ T cells in latent reservoirs.

Adenovirus (AV)
An adenovirus (AV) is one of the many types of rhinoviruses, which cause the common cold. It can be
used as a vector to carry genetic material (DNA or RNA) or a protein into a cell or in a vaccine. There are 57 known types of adenoviruses that are known to infect humans.

**Adjuvant**

An adjuvant is a substance administered with a vaccine that increases the effectiveness of the vaccine.

**Adoptive Immunotherapy**

Adoptive immunotherapy is transfer of immunity from a donor to a recipient (the adopter) through inoculation of modified white blood cells or antibodies into the recipient’s blood or bone marrow. This term is frequently used in gene editing studies.

**Agonist**

An agonist is a drug or other substance that causes the action of another drug or substance. The opposite of an agonist is the much more familiar antagonist, which in biology prevents something from happening.

**AIDS (Acquired Immune Deficiency Syndrome)**

AIDS (Acquired Immune Deficiency Syndrome) is the final stage of HIV infection. While AIDS and death for most HIV-positive people before 1996, with the advent of highly active antiretroviral therapy (HAART) that year it slowly retreated into the background in the developed world, though it remains a serious problem in some areas.

**Allele**

An allele is a variant of a gene at a particular position on a chromosome. Humans and all other living organisms have two alleles for each gene, one each in a corresponding position on each of the two strands making up the double helix of DNA.

Retroviruses, such as HIV, have two strands of RNA, but the strands are not linked together unlike in the DNA double helix found in living organisms. They also have alleles, but they are single ones on each strand.

**Allogeneic Transplant**

An allogeneic transplant, in the context of curing HIV infection, involves transplanting hematopoietic stem cells from a donor other than the transplant recipient. This is being studied as a possible way of performing a sterilizing cure of HIV infection.

Allogeneic transplants, so far (and this is shared with autologous transplants), are very expensive making this simply technologically infeasible. What is needed has called “transplant in a box” technology, analogous to what has been achieved by home HIV testing, and, indeed, there are researchers working on this, though achieving the goal is still far in the future.

**Amino Acid**

An amino acid is one of twenty types of organic compounds that make up proteins. Each amino acid has an amino group (-NH₂) at one end and an organic acid group (-COOH) at the other—it’s what’s in between that distinguishes one from another. Biologists and other researchers use both three-letter and single-letter abbreviations to denote them. For example, the amino acid proline is denoted both by “Pro” and by “P”, cysteine by “Cys” and “C”, and tyrosine is denoted by “Tyr” and “Y”. Cysteine is special in that it’s one of the two amino acids that contain a sulfur atom. In the co-receptor CCR5 the two C’s refer to two cysteines that are linked together by their two sulfur atoms; similarly in the co-receptor CXCR4, the two C’s also refer to cysteines but there’s an amino acid between them denoted by the X (see the CC and CXC Chemokine Structure and Naming Glossary entry).

**Analytical Treatment Interruption (ATI)**

An analytical treatment interruption (ATI) is a medically monitored interruption of antiretroviral therapy (ART) as part of a research study. The monitoring is almost always done by the researchers performing the study or by clinicians working with them. The purpose of the interruption is to determine the effect of the intervention used in the study on one or more measures of, for example, latent reservoir reactivation or CD4+ T cell count. Analytical treatment interruptions pose important ethical issues, such as the possibility that the participant’s viral load becomes high enough that he or she infects one or more other persons or that his or her virus population becomes resistant to all available antiretrovirals (ARV); for a discussion of the ethical issues see the article that the Ethics of ART interruption after stem-cell transplantation Resource Guide entry concerns.

**Animal Models**

Animal models, such as macaque monkeys, are particularly useful in HIV cure research because

- They make it possible for the researcher to do what he or she wants;
- The ethical issues concerning them are simpler than those for people;
- They may be quite faithful models of what occurs in humans; and
- They may be “sacrificed” as the final step in the research and their tissues analyzed in ways that are obviously not possible in human clinical trials.

Numerous studies have been done in monkeys using simian immunodeficiency virus (SIV), a variety of which...
is the virus HIV developed from, or simian-human immunodeficiency virus (SHIV), a genetic combination of SIV and HIV created in the laboratory, before they were tried in human clinical trials. Unfortunately neither of these models is as faithful to HIV and humans as would be preferred.

**Antigen-Presenting Cell**
An antigen-presenting cell is a cell whose primary purpose is presenting antigens to B cells and CD4+ T cells.

**Antigens and Antibodies**
An antigen is a toxin or other foreign substance that induces an immune response in the body, particularly the production of an antibody. It is presented to a B cell (which produces antibodies) by an antigen-presenting cell, such as a dendritic cell. An antibody is a mechanism the body has for fighting infections and other foreign substances. It is a protein produced by a B cell in the blood that is produced in response to and to counteract a specific antigen. It forms a chemical combination with the foreign substance that neutralizes it.

**Antiretroviral Therapy (ART)**
Antiretroviral therapy (ART) involves the use of several (usually three) antiretroviral drugs to halt HIV viral replication. ART drugs may target any of several viral enzymes, such as reverse transcriptase, protease, or integrase, or entry of HIV into cells. Some drugs may instead target cellular structures, as the CCR5 blocker drugs do. Many experts believe that ART will be needed in cure strategies to halt HIV reproduction in cells that have been perturbed by latency reversal.

**Antiretroviral Therapy (ART) Intensification**
Antiretroviral therapy (ART) intensification involves adding drugs to an existing three-drug regimen to reduce inflammation caused by HIV and residual HIV viral replication and hence the size of HIV latent reservoirs. There is mixed data indicating whether intensifying ART will be necessary in cure strategies or not.

**Apoptosis**
Apoptosis is a form of cell death in which a programmed sequence of events leads to the elimination of the cell. It plays a crucial role in developing and maintaining the health of the body by eliminating old, unneeded, and unhealthy cells. Pronunciation hint: the second “p” is silent.

**Auranofin**
Auranofin (brand name Ridaura) is a gold-containing drug used to treat rheumatoid arthritis. It has a partially selective killing effect against central memory T cells (Tcm) and transitional memory T cells (Ttm). It has also been shown in the macaque nonhuman primate (NHP) models, when combined with antiretroviral therapy (ART), to produce a long-term reduction in simian immunodeficiency virus (SIV) viral set point after stopping ART.

**Australian Patients**
Prof. David Cooper of the University of New South Wales, Sydney, Australia, reported in 2014 that two men with cancer and HIV infection had received bone-marrow transplants that cured their cancers (one had non-Hodgkin’s lymphoma and the other leukemia—see the Cancer Glossary entry) and maybe have cured their HIV infections. They had no detectable HIV in their blood by very sensitive tests two and three years, respectively, after their transplants, but they were being kept on antiretroviral treatment (ART), so it is not clear whether they have been cured.

**Autologous Transplant**
An autologous transplant is, specifically for curing HIV, a transplant of hematopoietic stem cells that have been provided by the recipient and have been modified to remove the HIV proviral DNA, CCR5 gene, or something else that is relevant. This is being studied as a possible way of performing a sterilizing cure of HIV infection. It has been argued that autologous transplantation is significantly more likely to be scalable to larger patient populations than allogeneic transplants for at least two reasons, namely, (1) it avoids the issue of having to find a very well-matched donor, since the recipient is the donor; and (2) it greatly reduces the risk of graft-versus-host disease, again because the donor is the recipient.

However, autologous transplants have issues of their own, the most important of which are that

1. The cells to be transplanted (presumably hematopoietic stem cells) must be modified by some method to make them resistant to HIV infection (rather than being selected to be resistant, for example, by having the CCR5Δ32/Δ32 mutation—see the Zinc-Finger Nuclease (ZFN) item in the Gene Editing Glossary entry for an example of a clinical trial with this goal);
2. There is not yet a clearly safe and effective method for selecting the gene-modified cells, though several have been tried;
3. There must be sufficient numbers of transplanted cells to swamp the already infected stem cells in the recipient.

Finally, autologous transplants, so far (and this is
shared with allogeneic transplants), are very expensive making this simply technologically infeasible. What is needed has been called “transplant in a box” technology, analogous to what has been achieved by home HIV testing, and, indeed, there are researchers working on this, though the goal is still far in the future.

**Aviremia**

Aviremia in peripheral blood, as reported, for example, for the Ethiopian Patient, refers to having no detectable virus in circulating blood.

**Barcelona Patients**

The Barcelona patients are five of the 13 participants in a shock-and-kill clinical trial. All 13 received romidepsin (see the Latency Reversing Agents Glossary entry) and a therapeutic vaccine. Five of the 13 achieved the trial’s definition of remission, namely, maintaining a very low viral load for up to six months. Three of the five maintained viral loads below 20 c/ml of blood; the other two have had occasional blips up to about 2,000 copies.

**B Cell**

A B cell is a variety of immune-system cell that originates in the bone marrow (hence the “B”). It produces antibodies in response to an antigen presented by an antigen-presenting cell, such as a dendritic cell.

**B Cell Follicle**

A B cell follicle is a component of a lymphoid tissue (such as a lymph node or the spleen that contains B cells) that hosts HIV production in humans and SIV production in nonhuman primate (NHP) models.

**Berlin Patient (Timothy Ray Brown)**

The Berlin Patient (Timothy Ray Brown) is the only person to have achieved a sterilizing cure of his HIV infection so far. His cure occurred after he had been diagnosed with acute myeloid leukemia, which affects white blood cells named granulocytes that are essential for fighting infections. The leukemia would almost certainly have been fatal, so he had nothing to lose by trying a CCR5Δ32/Δ32 allogeneic transplant of hematopoietic stem cells in his bone marrow. He actually required two transplants (one each in 2006 and 2007) for the cure to be successful. A very serious infection after the second transplant nearly killed him, but he bounced back from it, and he remains HIV free. Replicating such a cure remains a very high priority of cure research, preferably without requiring the chemotherapy (called conditioning) that Timothy required to wipe out his leukemia and prepare his bone marrow for the transplants.

See the Essen/Berlin Patient Glossary entry for another, less successful German cure attempt and the Resource Guide entry for the book **CURED: How the Berlin Patients Defeated HIV and Forever Changed Medical Science**.

**Biomarker**

A biomarker is a measurable substance in an organism whose presence is indicative of some phenomenon, such as a cell type or disease. In HIV cure research biomarkers are almost always cell-surface markers, such as CD4 and CD8.

**Biomarker for the Latent Reservoir’s Size and Viral Rebound**

The SPARTAC (Short Pulsed Anti-Retroviral Therapy At seroConversion) clinical trial provided the first evidence (in 2013) of a biomarker for the size of the latent reservoir and viral rebound upon stopping therapy, namely, total HIV proviral DNA in CD4+ T cells as early as possible in the course of infection. Total HIV proviral DNA overestimates the size of the reservoir, as described in the Latent Reservoir Glossary entry, since it measures defective virions as well as replication-competent latent virus.

**Bone Marrow-Liver-Thymus (BLT) Mouse**

A bone marrow-liver-thymus (BLT) mouse, developed in the 1990s by Joseph M. McCune, MD (formerly one of the principal investigators of the Delaney AIDS Research Enterprise (DARE) to Find a Cure’s first iteration) is a severely immune-depleted mouse that has been “humanized” by having human bone marrow, liver, and thymus-gland tissues grafted into it. It develops robust human bone marrow and a thymus gland roughly 12 to 16 weeks after the grafting process. BLT mice serve as a very good model for HIV research, including cure research, in animals that are much less expensive and much more manageable than nonhuman primate (NHP) models, such as rhesus and pigtail macaques. However, they are quite susceptible to lymphoma (see the Cancer Glossary entry) of the thymus gland and tend not to live longer than about 8½ months after grafting, so they are not suitable for long-term research studies. One researcher has suggested they be called NPHs for “non-primate humans.”

Bone marrow-liver-thymus (BLT) mice are one that has very severe immunodeficiency, lacking all the varieties of white blood cells involved in the immune system, such as natural killer (NK) cells, macrophages, and T cells, making them good platforms for the creation of bone marrow-liver-thymus (BLT) mice. “γ” is the lower-case Greek letter gamma.
Boston Patients

The Boston patients were three men with lymphoma (see the Cancer Glossary entry) and HIV infection who underwent CCR5Δ32/Δ32 hematopoietic stem cell transplants after milder myeloablative conditioning than the Berlin Patient (Timothy Ray Brown). All three had been on long-term antiretroviral therapy (ART). One of the three died from recurrence of his lymphoma several months after the transplant. Both of the others were put back on ART, and had weekly leukapheresis to obtain samples of CD4+ T cells to apply very sensitive tests for the presence of HIV RNA and proviral DNA that were negative in both cases. In 2.6 years in one case and 4.3 years in the other, they were taken off therapy. Both had HIV viral rebound. The researchers concluded that "allogeneic hematopoietic stem cell transplantation can result in loss of detectable HIV-1 from blood and gut tissue and antiretroviral-free HIV-1 remission for variable duration," but "viral rebound occurred despite a reduction in reservoir size ... of at least a thousand-fold."

Broadly Neutralizing Antibodies (bNabs) for Reservoir Eradication

A neutralizing antibody (NAb) is an antibody that fully defends its target cell from an antigen. A broadly neutralizing antibody (bNAb) is a neutralizing antibody that has this effect against a wide range of antigens. In recent years about two dozen broadly neutralizing antibodies have been isolated from persons living with HIV. Some of them are being studied and, in a few cases, used in clinical trials, to defend humans against HIV infection, to treat HIV infection, and to kill HIV-infected CD4+ T cells in latent reservoirs.

![Figure 1. Structure of chemokines with cysteine ("C") crosslinks.](image)

CC and CXC Chemokine Structure and Naming

CC and CXC are two chemokine varieties that are characterized by having cysteine amino acids (abbreviated "C") in them. (The "X" abbreviates some amino acid other than cysteine, and the red lines represent chains of other amino acids.) Cysteine is one of two amino acids that contain sulfur and is special in that sulfur atoms in pairs of cysteines can form cross links that form loops in the structure of a CC or CXC chemokine, as shown in Figure 1 (adapted from a figure provided by Prof. Laszlo Kohidai, MD, PhD, Semmelweis University, Budapest, Hungary). Pairs of chemokines are named, for example, CCL2 and CCR2, to denote a ligand and its receptor (a ligand is a chemical that binds to a receptor to cause a biological action).

Cancer

Several types of cancers are either associated with HIV infection (usually in its last stages) or have been serious morbidities that have encouraged researchers to attempt cure or remission of HIV infection. The latter include the following discussed here:

- Leukemia is a cancer of the bone marrow and other blood-producing organs, such as the spleen, that results in the overproduction of abnormal white blood cells (the “leuk” part of the name is from Greek and translates as “white”). The overproduction reduces creation of normal blood cells, including red cells.
- Lymphoma is a cancer of immune-system blood cells, including natural killer (NK) cells, B cells, and T cells. There are numerous types of lymphomas, and the lack of detailed descriptions makes it impossible to know which ones are present in the several cure attempts (and one success, namely, the Berlin Patient (Timothy Ray Brown) discussed here.
- Melanoma is a cancer that results in the production of abnormal melanocytes (pigment-containing cells) that occur mostly in the skin, though they may occur in the digestive system. The first two syllables of the name come from Greek and translate as “black.”

CCR5

CCR5, which abbreviates CC chemokine receptor type 5, is a co-receptor on the surface of CD4+ T cells that, during early HIV infection, is essential to entry of HIV into these cells. HIV attaches to both CD4 and CCR5 to achieve entry. (Some variants of HIV use a co-receptor called CXCR4 rather than CCR5; those variants almost always occur only late in the course of untreated HIV
infection; HIV transmitted from one person to another almost always uses the CCR5 co-receptor. However, some rare strains of HIV use both the CCR5 and the CXCR4 co-receptors. Figure 2 (adapted from https://en.wikipedia.org/wiki/CCR5) shows the sequence HIV binding to CD4, then to CCR5, and finally having released its genetic material into a CD4+ T cell. CCR5-tropic HIV is also called M-tropic because it can infect macrophages and monocytes. See the CC and CXC Chemokine Structure and Naming entry for a description and illustration of the CC in the name.

Figure 2. This sequence shows HIV binding to CD4, then to CCR5, and finally having released its genetic material into a CD4+ T cell in four steps: (1) the CD4 receptor and CCR5 co-receptor; (2) HIV glycoprotein gp120 binds to CD4; (3) gp120 binds to CCR5 and releases gp41, which pierces the cell surface opening a pore in the cell’s surface; (4) the capsid (see HIV Structure & Function) enters the CD4+ T cell through the pore in the cell wall created in (3).

CD3
CD3 is a receptor found on the surface of all T cells, including natural-killer (NK) cells, CD4+ T cells, and CD8+ T cells, among others. CD3 is one of hundreds of receptors known as clusters of differentiation that are found on the surfaces of various cell types and facilitate attachment of virions, chemicals, and other cells. CD4 and CD8 are two others.

CD32a
CD32a may be a cell-surface marker for as many as 50% of the CD4+ T cells in the latent reservoir, but this is not yet certain. In an in vitro study of a model of latency, the most common relevant gene was one the coded for CD32a, making it a very likely marker of latency. In a small clinical study (12 participants), done by the researchers who discovered the connection, CD32a+CD4+ T cells had a thousand times the HIV proviral DNA of cells without CD32a. In a viral culture, CD32a+CD4+ T cells had 3,000 times the replication-competent HIV proviral DNA in other CD4+ T cells.

The researchers responsible for this discovery suggest several important implications of their findings, as follows:

1. Sorting CD4+ T cells based on CD32a expression should provide an easier way to study the latent reservoir than methods currently available.
2. CD32a’s primary function is to recognize antigen-
antibody combinations and cause activation of numerous types of immune responses.

3. CD32a might have a role in controlling responses to broadly neutralizing anti-HIV antibodies (see the Broadly Neutralizing Antibodies (bNAb) for Reservoir Eradication Glossary entry) and might possibly contribute to clearance of the latent reservoir by the bNAb.

4. CD32a may contribute to targeting a large fraction of the CD4+ T cells in the latent reservoir for elimination.

The next steps in this research include the following:

1. to determine what maintains latency in resting cells,
2. to analyze the effect of the resting state on the establishment of latency,
3. to determine the function of CD32a+CD4+ T cells, and
4. to understand how this can drive an effective killing method.

**CD32a as a Biomarker for CD4+ T Cells in the Latent Reservoir**

CD32a may be a cell-surface marker for as many as 50% of the CD4+ T cells in the latent reservoir, but this is not yet certain. In an in vitro study of a model of latency, the most common relevant gene was one the coded for CD32a, making it a very likely marker of latency. In a small clinical study (12 participants), done by the researchers who discovered the connection, CD32a+CD4+ T cells had a thousand times the HIV proviral DNA of cells without CD32a. In a viral culture, CD32a+CD4+ T cells had 3,000 times the replication-competent HIV proviral DNA in other CD4+ T cells.

The researchers responsible for this discovery suggest several important implications of their findings, as follows:

1. Sorting CD4+ T cells based on CD32a expression should provide an easier way to study the latent reservoir than methods currently available.
2. CD32a’s primary function is to recognize antigen-antibody combinations and cause activation of numerous types of immune responses.
3. CD32a might have a role in controlling responses to broadly neutralizing anti-HIV antibodies (see the Broadly Neutralizing Antibodies (bNAb) for Reservoir Eradication Glossary entry) and might possibly contribute to clearance of the latent reservoir by the bNAb.
4. CD32a may contribute to targeting a large fraction of the CD4+ T cells in the latent reservoir for elimination.

The next steps in this research include the following:

1. to determine what maintains latency in resting cells,
2. to analyze the effect of the resting state on the establishment of latency,
3. to determine the function of CD32a+CD4+ T cells, and
4. to understand how this can drive an effective killing method.

**CD34**

CD34 is a receptor that is found on the surface of all and only hematopoietic stem cells.

**CD4**

CD4 is a receptor that is necessary, along with a co-receptor such as CCR5 or CXCR4, to the attachment of HIV virions to CD4+ T cells. CD4 is one of hundreds of receptors known as clusters of differentiation that are found on the surfaces of various cell types and facilitate attachment of virions, chemicals, and other cells. CD3 and CD8 are two others. Note that, in addition to HIV-specific CD4+ T cells, CD4 is also found on other types of T cells, macrophages, monocytes, and dendritic cells.

**CD4+ T Cells**

CD4+ T cells are primary white blood cells of the adaptive immune system; they are also known as helper T cells. These cells act, in part, as the “directors” of the immune system that signal to other immune-system cells how and when to fight infections. CD4+ T cells are preferentially infected by HIV, which reverse transcribes its own genes and integrates them into the cells’ DNA. HIV-infected CD4+ T cells, when activated, produce copies of HIV instead of reproducing or conducting other immune functions.

CD4+ T cells can develop that specifically target parts of an infectious agent and those T cells are activated in response to infection by that pathogen. After the infection is cleared or controlled, they can then become resting memory CD4+ T cells that lie in wait for future occurrences of the pathogen to which they then respond. These resting memory CD4+ T cells are thought to constitute most of the latent reservoir of HIV. CD4+ T cells all have the CD4 receptor on their surfaces.

**CD8**

CD8 is a receptor that is necessary to the attachment of virions, chemicals, and other cells to CD8+ T cells. CD8 is one of hundreds of receptors known as clusters of differentiation that are found on the surfaces of various cell types and facilitate attachment of virions, chemicals, and other cells. CD3 and CD4 are two others. Note that, in addition to responding to HIV-specific
CD4+ T cells. CD8+ T cells also respond to other CD4+ T cells and CD8 is found on natural killer (NK) cells and dendritic cells.

**CD8+ T Cells**
CD8+ T cells are primary white blood cells of the adaptive immune system that are responsible for recognizing infected CD4+ T cells and macrophages, among other duties, the most important of which is killing infected or disabled cells as directed by CD4+ T cells. CD8+ T cells can be created that are specific to HIV. CD8+ T cells all have the CD8 receptor on their surfaces. These cells are also known as cytotoxic T lymphocytes (CTLs). Recent research strongly suggests that harnessing the killing power of CD8+ T cells may be essential to both functional and sterilizing HIV cures (see the “HIV Cure (Functional)” and “HIV Cure (Sterilizing)” Glossary entries).

**Cell-Associated RNA (caRNA)**
Cell-associated RNA (caRNA) is HIV RNA found in peripheral blood CD4+ T cells, which may be complete HIV genomes or any of nearly 40 other types of HIV-derived RNAs that are found in infected CD4+ T cells. Early in HIV infection, they are typically RNA sequences that transcribe, resulting in the production of the HIV proteins Tat, Rev, and Nef; later in untreated infection they are more likely to be sequences that result in producing the HIV proteins Gag, Pol, Env, Vif, Vpr, and Vpu. For descriptions of both types of proteins, see the HIV Structure & Function Glossary entry.

**Cell-to-Cell HIV Infection**
Cell-to-cell HIV infection refers to HIV infection of cells by coming in contact with already infected cells, rather than by free-floating HIV. It is believed that this type of infection is a significant factor in the overall rate of propagation of HIV, perhaps accounting for more than 50% of newly infected cells.

**Central Memory CD4+ T Cell (T_{CM})**
Once a CD4+ T cell responds to a pathogen, it can go into a resting state, which allows it to lie in wait for further instances of infection by that pathogen, to then replicate, producing many copies of itself, and to mount a quick immune response. Such memory cells can live for many years. In HIV infection, central memory CD4+ T cells (T_{CM}) may be infected with the virus, but are invisible to the immune system, which allows HIV to reemerge in individuals whose immune systems can’t control the virus over long periods of time or who have been on successful antiretroviral therapy and then stop that therapy.

**Central Nervous System (CNS)**
The central nervous system (CNS) consists of the brain and spinal cord. It is important for curing HIV for at least four reasons:

1. It is a latent reservoir for HIV that is affected by chronic inflammation established very early in HIV infection;
2. It can only be reached by a small minority of HIV antiretroviral medications;
3. HIV gp120 glycoprotein impacts the function of neurons; and
4. Since the brain is so very essential, there is concern among cure researchers that approaches other than shock and kill, such as latency silencing of reactivation entirely, will be necessary to achieve a cure in the CNS because of the seriously toxic effect reactivation is likely to have on CNS functioning.

At least two types of cells in the CNS are latent reservoirs for HIV as follows:

- Microglia are macrophages that maintain homeostasis (stability of internal conditions, such as pH balance) and are both the most important immune-system component and the largest latent reservoir of HIV-infected cells in the CNS; and
- Astrocytes (“star-shaped cells”) are a smaller population of HIV-infected cells in the CNS than microglia that perform numerous functions, such as physically supporting the cells that constitute the blood-brain barrier (a filter composed of capillaries that carry blood to the CNS that blocks certain substances, such as nerve poisons, while allowing the passage of water, some gasses, glucose, and amino acids), providing nutrients to nerve cells, repairing the CNS after trauma, and maintaining electrolyte balance in the fluid surrounding neurons.

In addition to the cellular latent reservoirs of HIV in the CNS, several free-floating HIV proteins, including Tat, gp120, and Vpr, have been shown to enter neurons and have pathogenic functions. For descriptions of these proteins, see the HIV Structure & Function Glossary entry.

A recent development for quantifying a protein named neurofilament light-chain protein (NFL) that may be a significant biomarker for the effect of HIV on nerve cells is the Single Molecule Array (Simoa) immunoassay.

A substudy of a latency reversal clinical trial using the histone deacetylase inhibitor (HDACi) panobinostat (see the Latency Reversal Glossary entry) probed the effect of the drug on the central nervous system. It found no panobinostat or HIV RNA in cerebrospinal fluid and no...

Chemokine
A chemokine is a signaling protein secreted by a cell to produce a reaction in a nearby cell; the reaction is frequently chemotaxis, which is movement of the target cell in response to the chemokine. See also the Cytokine and CC and CXC Chemokine Structure and Naming Glossary entries.

Chimeric Antigen Receptor (CAR)
A chimeric antigen receptor (CAR) is an artificial T-cell receptor that usually consists of a monoclonal antibody that is recognized by the desired target cell combined with part of the typical cellular receptor to facilitate entry into the cell. Chimeric antigen receptors are mostly used to fight cancers, but they can also be designed to be HIV specific.

Chimerism
Chimerism, in the context of chimeric antigen receptors, refers to a molecule that is made in a laboratory from two unrelated biological substances. Chimerism is also used to refer to entire (usually mythical) organisms made up of parts of two distinct organisms, such as a centaur with horse and human parts; such organisms are called chimeras.

Chromatin
Chromatin is the material of which the chromosomes of organisms other than bacteria are composed. It consists of DNA and proteins called histones. Chromatin is a very efficient packaging mechanism that holds DNA in a cell. Once HIV integrates into a cell's DNA, whether the HIV genes are bound in chromatin or not determines whether they are kept packaged in a latent form or are able to make more virions, respectively.

Clade
A clade is, in the context of a virus, a subgroup of viruses that consists of a common ancestor and all its descendants. There are four major subtypes or groups of HIV called M, N, O, and P. “M” stands for major; “O” for outlier; and “N” for non-M, non-O. In 2009, a new subtype was reported in Cameroon that is very similar to the wild type of simian immunodeficiency virus (SIV) found in gorillas; it is now identified as subtype “P”. In turn, subtype M is divided into 11 clades identified by the letters “A” through “K”, as follows:

- Clade A is common in West Africa;
- Clade B is the dominant form in Europe, the Americas, Japan, Thailand, and Australia;
- Clade C is the dominant form in southern and eastern Africa, India, Nepal, and parts of China;
- Clade D is seen in eastern and central Africa;
- Clade E is found only in a genetic recombinant called CRF01_AE;
- Clade F is found in central Africa, South America, and Eastern Europe;
- Clade G and the genetic recombinant CRF02_AG are found in Africa and central Europe;
- Clade H is found only in central Africa;
- Clade I was formerly used as the name of what is now termed the genetic recombinant CRF04_cpx, which is understood to be a genetic recombinant of several clades (thus “cpx” for complex);
- Clade J is found primarily in northern, central, and western Africa and the Caribbean; and
- Clade K, including the recombinant CRF03_AB, is found only in the Democratic Republic of Congo and Cameroon.

Some research has shown that clade variation contributes to the magnitude of replication capacity via variations in part of the gp41 glycoprotein and other aspects of the HIV subtype.

Clinical Trials
Clinical trials are the standard process for testing new medications, medical devices, and medical procedures in humans. They are typically preceded by studies done in nonhuman animals (sometimes called “Phase 0”) to weed out those that are not worth the effort and expense of clinical trials. Here we focus on medical procedures, such as the shock and kill approach to eliminating latent HIV from latent reservoirs. There are three phases of clinical trials, as follows:

- Phase I: A phase I clinical trial involves a small number (usually not more than about 20) of healthy volunteers to test the safety of the medical procedure and any side effects it may have. If the procedure is determined to be safe and to have only acceptable side effects, it may proceed to phase II.
- Phase II: A phase II clinical trial usually involves several hundred volunteers. Its goal depends on what is being tested. For a medical procedure, it continues to test for safety and side effects and adds on determination of whether it is effective.
- Phase III: A phase III clinical trial involves several thousand volunteers and is intended to confirm the effectiveness of the medical procedure, monitor its
side effects, compare it to commonly used procedures if there are any yet, and continue to collect information to determine whether the procedure is safe. Only after a successful Phase III study does a medication go before a panel of the U.S. Food and Drug Administration (FDA) or similar agency elsewhere in the world for approval for distribution.

There is also what is sometimes called “Phase IV”: a post-marketing phase, in which the medication or procedure is used in diverse populations and continues to be monitored for side effects.

In some case, clinical trials have phases that are numbered with a Roman numeral followed by the letter “A” or “B” to indicate whether it is an early or late part of the phase, respectively. These letters are usually used in combinations of phase numbers to indicate that the clinical trial straddles two consecutive phases.

Every clinical trial done in the United States is required to have a written trial protocol that describes at the least:

- a detailed plan of what is to be done,
- why it is being done,
- justification for it based on prior research,
- known and hypothetical risks and benefits,
- criteria for inclusion and exclusion of potential participants, and
- a schedule of what will be done (for example, physical exams, blood draws, and checking for side effects).

It also must have an informed consent form (ICF) that explains the trial to the volunteers, informs them of the above facts in lay language, tells them they may withdraw from participation at any point without giving a reason for doing so, and requires their signed and witnessed consent to participation before they begin the trial’s procedures. Every clinical trial protocol and ICF are reviewed and approved by an independent Institutional Review Board and one or more of several government agencies (which one(s) depend on the nature of the trial) before it can begin recruiting volunteers. For a glossary of terms commonly used in descriptions of clinical trials, see https://clinicaltrials.gov/ct2/about-studies/glossary. Additional resources for understanding clinical trials and the clinical-trial process can be found on the web at https://clinicaltrials.gov/ct2/resources.

Clinical trials done outside the United States are required to follow the same or a very similar rigorous plan and process.

**Clonal Expansion**
Clonal expansion is the production of numerous daughter cells with identical genomes resulting from a parent cell. Clonal expansion of HIV-infected CD4+ T cells in circulating blood is thought by some researchers to be a significant contributor to the latent reservoir and so a barrier to HIV remission.

**Co-Receptor**
A co-receptor, in the context of HIV medicine (including cure research), is a chemical, such as CCR5 or CXCR4, attached to the surface of a cell such as a CD4+ T cell that facilitates attachment and entry along with a receptor, such as CD4, of an HIV virion into the cell.

**CXCR4**
CXCR4, which abbreviates CXC chemokine receptor type 4, is a co-receptor on the surface of CD4+ T cells that, late in HIV infection’s course, is essential to entry of HIV into these cells. Some HIV variants attach to CCR5 and CXCR4 to achieve entry. (Some variants of HIV use a co-receptor named CCR5 rather than CXCR4; these variants almost always occur early in the course of untreated HIV infection; HIV transmitted from one person to another almost always uses the CCR5 co-receptor, though rare cases with the CXCR4 co-receptor do occur.) Further, some rare strains of HIV use both the CCR5 and the CXCR4 co-receptors. Also, unlike CCR5, CXCR4 is not a good candidate for gene editing because it occurs on several cell types other than CD4+ T cells and is essential to their function. CXCR4-tropic HIV is also called T-tropic because unlike CCR5-tropic virus it can infect CD4+ T cells but not macrophages. See the CC and CXC Chemokine Structure and Naming Glossary entry for a description and illustration of the CXC in the name.

**Cytokine**
A cytokine is a signaling protein secreted by a cell to produce a reaction in a nearby cell. See also the Chemokine Glossary entry.

**Cytomegalovirus (CMV)**
Cytomegalovirus (CMV) is a common virus that infects people of all ages. In the United States, more than half of adults have been infected with it by age 40. Once one is infected, cytomegalovirus stays in the body for life and can reactivate. Most people infected with CMV show no symptoms because a healthy person’s immune system usually keeps it from causing illness. However, CMV infection can cause serious health problems for people with compromised immune systems.

**Defective Virion**
A defective HIV virion is one containing an RNA
genome that makes it incapable of viral replication. This results from the single-stranded nature of HIV's RNA. All living organisms have linked double-stranded DNA making up the well-known double helix that provides an inherent self-checking mechanism to prevent frequent mutations; of course, mutations do occur in living organisms, and they are one of the mechanisms that cause cancers. However, the unlinked single strands of HIV's RNA have no such self-checking mechanism and mutations occur in them very, very frequently.

Let’s calculate how often a typical nucleic acid base is mutated each day in a person who is not on antiretroviral therapy (ART). Note that, despite the extremely high frequency of mutations, this has no chance at all of eliminating HIV from the body in a human lifetime because resting memory CD4+ T cells are the largest component of the latent reservoir and not undergoing HIV mutation because they are resting!

1. The current best estimate for the overall mutation rate is one per 34 viral replication cycles.
2. Given that about 10 billion new virions are created (that is, that many viral replication cycles occur) each day, roughly 300 million of the new virions will have at least one mutation.
3. With roughly 9,750 nucleic acid bases in each strand or 19,500 across both strands, that’s one mutation in each base position, on average, about 16,000 times each day!

Compared to a living organism's mutation rate, this is absolutely staggering! It’s especially so with no mechanism to detect defective virions. In addition to the lack of a built-in checking mechanism for defects in viral replication, new research reported in late 2015 shows that there is a family of cellular enzymes called A3 that contributes very heavily to the creation of defective virions; in particular, the A3 enzymes are believed to be at least partially responsible for about 98% of the mutations that occur.

It doesn’t require very many mutations in genes encoding critical proteins, such as reverse transcriptase or integrase (see the HIV Structure & Function Glossary entry), to make a virion incapable of infectivity, that is, make it defective.

Even in persons on suppressive antiretroviral therapy (ART), the accumulation of mutations that render new virions defective is very common.

Furthermore, there is an extreme form of being defective named hypermutation that is defined as the accumulation of an immense number of mutations per genome. Hypermutation invariably leads to defective virions. In particular, it frequently results in mutations in the HIV proviral DNA that stop transcription in its tracks, that is, creation of a new virion is simply not even completed.

Dendritic Cell
A dendritic cell is one variety of antigen-presenting cell whose main function is presenting antigens found on external surfaces in the body to B cells or CD4+ T cells. They are found in the skin and other areas that are on the outside of the body, such as the nose, lungs, mouth, stomach, and intestines, and so in contact with the environment.

Droplet Digital Polymerase Chain Reaction (ddPCR)
Droplet digital polymerase chain reaction (ddPCR) is a type of polymerase chain reaction that is characterized by the creation under digital control of tiny droplets of highly amplified DNA resulting from an initial single molecule that are digitally measured. This technique has greatly automated the PCR technology and markedly decreased its expense.

Dual Antibody Use to Reduce the Latent Reservoir
Three studies published in late 2015 examine the use of so-called dual antibodies to achieve various aspects of reduction of the latent reservoir of HIV-infected CD4+ T cells, as follows:

1. One study discusses the use of dual-affinity re-targeting (DART) molecules to bind to both the HIV Env protein and the CD3 receptor on infected cells and “recruit” CD8+ T cells to kill the bound cells.
2. Another study used DARTs to bind to the same protein and receptor as in item 1 above to direct CD8+ T cells to kill infected CD4+ T cells.
3. The third study used what it calls bispecific antibodies that bind to the Env epitope recognized by the broadly neutralizing antibody VRC07 and the CD3 receptor to reduce HIV DNA in most of the laboratory isolates of infected cells tested. A broadly neutralizing antibody is one that is effective against a large class of antigens. “VRC” abbreviates the Vaccine Research Center at NIH that was responsible for discovering and characterizing the antibody.

One potential concern about all three of these studies is the possibility that their targeting CD3 might cause general activation of T cells, since it is the receptor that occurs on all of them, which could be disastrous. Apparently the dual nature of the targeting caused only
minor, transient effects of this sort.

**Düsseldorf Patient**
The Düsseldorf patient is a 41-year-old man who was diagnosed with CCR5-tropic HIV infection in 2010 and acute myeloid leukemia (see the Cancer Glossary entry) in 2011. Like the Berlin patient (Timothy Ray Brown), he required two allogeneic CCR5Δ32/Δ32 hematopoietic stem cell transplants to possibly cure his HIV infection because his leukemia recurred. He has remained on antiretroviral therapy (ART), but shows no signs of viral rebound. He may be the second person to have received a sterilizing cure of his HIV infection.

**Early Initiation of Antiretroviral Therapy (ART) and Remission**
At least one recent study has shown that initiation of antiretroviral therapy (ART) during primary infection (Fiebig stages I and II) and continuing it for two years will, in some cases, lead to remission. In particular, it can lead to reduction of HIV DNA in central memory CD4+ T cells (Tcm) to levels typically found in naïve T cells (Tn), transitional memory CD4+ T cells (Ttm) being the major reservoir of HIV, and significant restriction of HIV mutation. Further, continuing ART for a total of six years can drive reservoir size and distribution down to levels close to those seen in post-therapy controllers, such as the VISCONTI cohort.

**Effector Memory CD4+ T Cell (Tem)**
An effector memory CD4+ T cell (Tem) is a CD4+ T cell that is replicating in response to a pathogen and quick mounting an immune response to the pathogen.

**Elite Controllers**
Elite controllers are rare individuals living with HIV who maintain undetectable viral loads in the absence of—in most cases—any antiretroviral therapy (ART). In about 2/3 of known cases, they possess immune-system mutations, such as one or both of HLA-B*5701 and HLA-B*2701, which appear to enhance recognition of HIV. In some elite controllers, undetectable viral loads are found in the absence of protective genes, indicating that specific HLA-B genes are neither necessary nor sufficient for elite control of HIV. However there is evidence that some elite controllers suffer from inflammation like other people living with HIV, so they are likely to suffer from its long-term effects. A study published in 2014 identified ten very divergent definitions of elite controller in previous studies, as follows—all required that an individual not have AIDS and never have used antiretroviral therapy (ART):

1. HIV-positive at least 6 months with at least 2 consecutive viral loads < 75 c/ml,
2. HIV-positive at least 1 year with at least 1 viral load < 50 c/ml,
3. HIV-positive at least 1 year with at least 1 viral load < 75 c/ml,
4. HIV-positive at least 1 year with at least 3 viral loads < 2,000 c/ml,
5. HIV-positive at least 1 year with at least 3 viral loads < 75 c/ml spanning at least one year
6. HIV-positive at least 1 year with at least 3 viral loads < 75 c/ml spanning at least one year and no viral blips >= 1,000 c/ml; a blip is defined as an isolated significant increase in viral load,
7. HIV-positive at least 2 years and at least 2 viral loads < 75 c/ml,
8. HIV-positive at least 5 years and at least 5 consecutive viral loads < 500 c/ml,
9. HIV-positive at least 10 years and all measured viral loads < 50 c/ml, or
10. HIV-positive at least 10 years and at least 90% of viral loads < 400 c/ml with at least 2 viral loads measured.

The 2014 study mentioned above examined how these definitions applied to a cohort of over 25,000 HIV-positive people known as CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) that, despite its name, includes participants in Australia, Canada, and Africa in addition to Europe. All the definitions determined that elite controllers were rare, in almost no case accounting for more than about 1% of the participants.

**Engraftment**
Engraftment is the successful incorporation of grafted tissue into the host’s body.

**Enzyme**
An enzyme is an organic molecule, in most cases a protein or peptide but in a few cases an RNA (such as a ribozyme described in the Gene Editing Glossary entry), that acts as a catalyst: It facilitates a biochemical process without itself being modified, so it can be used again. Almost all proteins that are enzymes have names ending in “ase”.

**Epitope**
An epitope (also known as an antigenic determinant) is a part of an antigen that is recognized by the immune system, specifically by an antibody, a B cell, or a T cell.

**Escape Mutation**
An escape mutation, in the context of HIV, is a genetic change (a mutation, also called antigenic drift) in a daughter HIV virion that makes the resulting virion unable to be treated by antiretroviral therapy (ART) and impervious to clearance of latent cells infected with daughters of the resulting HIV virion that has the
escape mutation.

**Essen/Berlin Patient**
The Essen/Berlin patient is a man who goes by the pseudonym Christian Hahn (see the Resource Guide entry for the book *CURED: How the Berlin Patients Defeated HIV and Forever Changed Medical Science*) with Non-Hodgkin’s lymphoma (see the Cancer Glossary entry), CCR5-tropic HIV infection, and the HLA-B*5701 protective mutation (see the HLA-B*5701 and HLA-B*2701 Glossary entry). Because of the poor prognosis for his lymphoma, he underwent a CCR5Δ32/Δ32 bone-marrow transplant. However, following the transplant, he was found to have either CXCR4-tropic or dual CCR5- plus CXCR4-tropic HIV infection and subsequently died from a recurrence of his lymphoma. It is not well understood why the CXCR4- or dual-tropic HIV infection was not detected; it may have been simply because there were very, very few such virions. Alternately, the detection failure may have been because the patient’s particular lymphoma is an AIDS-defining condition, and progress to AIDS and some biological changes that occur in parts of CD4+ T cells’ gp120 spikes are the clinical factors most likely to predispose a transition from CCR5 tropism to CXCR4 tropism.

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>T cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increases expression of CCR5 and CCR1;</td>
</tr>
<tr>
<td></td>
<td>• Lower doses enhance T\textsubscript{\text{H1}} cell response;</td>
</tr>
<tr>
<td></td>
<td>• Higher doses enhance T\textsubscript{\text{H2}} cell response; and</td>
</tr>
<tr>
<td></td>
<td>• Expands Treg cells</td>
</tr>
<tr>
<td>B cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increases survival;</td>
</tr>
<tr>
<td></td>
<td>• Decreases apoptosis; and</td>
</tr>
<tr>
<td></td>
<td>• Increases certain immunoglobulins</td>
</tr>
<tr>
<td>NK cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lower doses increase cytotoxic activity; and</td>
</tr>
<tr>
<td></td>
<td>• Higher doses decrease cytotoxic activity</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increases production of several cytokines; and</td>
</tr>
<tr>
<td></td>
<td>• Promotes cell differentiation</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>Enhances anti-inflammatory activity</td>
</tr>
<tr>
<td>Macrophages &amp; Monocytes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lower doses promote cell differentiation and stimulate cytokine production; and</td>
</tr>
<tr>
<td></td>
<td>• Higher doses reduce expression of CD16 and decrease cytokine production</td>
</tr>
</tbody>
</table>

Table 1. Estrogen’s impact on immune system cells.
For explanation of terms see the notes immediately below.

Notes: (1) T\textsubscript{H1} and T\textsubscript{H2} cells are varieties of CD4+ T cells; T\textsubscript{H1} cells act against bacteria inside cells; T\textsubscript{H2} cells act against parasites outside cells. (2) Monocytes are the largest white blood cells; they have multiple roles in immune function including replenishing macrophages, and responding to inflammation. (3) Dendritic cells are antigen-presenting cells of the immune system. In most cases, the antigens are acquired from outside the body. (4) Neutrophils are a component of the innate immune system; they are the first responders to infection by bacteria. Recent data has suggested they may be a significant agent to be used in the kill phase of shock-and-kill strategies. (5) CCR1 (also called CD191) is a co-receptor that affects differentiation of hematopoietic stem cells; it is also critical for the recruitment of immune-system cells to sites of inflammation. (6) CD16 is found on the surface of natural killer cells, neutrophils, monocytes, and macrophages.

**Estradiol, Estrogen, Progesterone, and Estrogen Receptors**
Estradiol, estrogen, and progesterone are female sex hormones. The influences of these hormones that are relevant to HIV, and particularly cure research, are as follows:

- Estradiol at peak menstrual levels is a powerful inhibitor of HIV viral replication which may explain in part the observation that women have smaller latent HIV reservoirs than men (though a more recent study suggests that this is not true), but not smaller activatable latent reservoirs than men;
- Estrogen (one of the two primary female sex hormones along with progesterone) can both increase and decrease inflammation: at low concentrations it promotes inflammation, thus increasing the chance of HIV infection, while at
high concentrations it inhibits it; it has other impacts on the specific cells of the immune system as shown in Table 1 (based on Figure 1 in the article Gianella S Tsibiris A Barr L Godfrey C “Barriers to a cure for HIV in women” Journal of the International AIDS Society 18 February 2016; available at http://www.jiassociety.org/index.php/jias/article/view/20706; Creative Commons Attribution 3.0 License; courtesy of first author);

- Progesterone is a component of the injectable birth-control drug medroxyprogesterone (brand name Depo-Provera) that, when administered as a drug, enhances HIV infection;
- Agonists of the estrogen receptor ESR-1 on resting memory CD4+ T cells, such as the breast cancer drug Tamoxifen, weakly enhance latency reversal of HIV-infected cells. In contrast, ESR-1 inhibitors, such as diethylstilbestrol (brand name Stilbetin or Stilbestrol), reduce reactivation of resting memory CD4+ T cells; and
- Selective estrogen receptor modulators (SERMs) combined with histone deacetylase inhibitors (HDACi) are promising candidates for potent latency reversal (see the Latency Reversal by Combinations of Drugs Glossary entry).

**Ethiopian Patient**

The Ethiopian patient is a woman with clade C HIV infection who began antiretroviral therapy (ART) during acute infection, stopped treatment after six years, and maintained peripheral blood HIV aviremia and had a normal CD4+/CD8+ T-cell ratio, so far, for ten years, despite having a low-level persistent viral latent reservoir.

**Fiebig Stages**

Fiebig stages are used to classify the progress of HIV infection, particularly in its early stages, which is relevant to cure because numerous studies strongly suggest that eradication is easier the earlier it is undertaken. The stages are shown in Table 2 (derived from Figure 1 in “The immune response during acute HIV-1 infection: clues for vaccine development” McMichael AJ Borrow P Tomaras GD Goonetilleke N Haynes BF Nature Reviews Immunology 10 11-23 January 2010 and Figure 1 and Table 1 in “The Detection of Acute HIV Infection” MS Cohen CL Gray MP Busch FM Hecht Journal of Infectious Diseases 202 2010 Suppl 2: S271 & S272).

<table>
<thead>
<tr>
<th>Fiebig Stage</th>
<th>Characterization (beginning of test)</th>
<th>Duration in days (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eclipse</td>
<td>undetectable</td>
<td>10 (7 - 21)</td>
</tr>
<tr>
<td>I</td>
<td>Viral RNA+</td>
<td>7 (5 - 10)</td>
</tr>
<tr>
<td>II</td>
<td>p24 antigen+</td>
<td>5 (4 - 8)</td>
</tr>
<tr>
<td>III</td>
<td>Antibody ELISA+</td>
<td>3 (2 - 5)</td>
</tr>
<tr>
<td>IV</td>
<td>Western blot+ or -</td>
<td>6 (4 - 8)</td>
</tr>
<tr>
<td>V</td>
<td>Western blot+ &amp; integrase-</td>
<td>70 (40 - 122)</td>
</tr>
<tr>
<td>VI</td>
<td>Western blot &amp; integrase+</td>
<td>Open ended</td>
</tr>
</tbody>
</table>

Table 2. Fiebig stages, characterizations, and durations.

Note: Western blot is typically used as a confirmatory test for HIV infection; it uses electrophoresis to separate a purified antigen mixture into bands that correspond to the gp160, gp120, p66, p55, p51, gp41, p31, p24, p17, and p15 proteins (see the HIV Genome Glossary entry for descriptions of the proteins). See the Seroconversion Glossary entry for a description of the ELISA test. Integrase is the HIV protein responsible for integrating HIV’s genome converted to DNA to be integrated into host DNA.

**Follicular Dendritic Cell (FDC)**

A follicular dendritic cell (FDC) is an immune-system cell found in lymphoid tissue and is a type of reservoir of latent HIV infection. This type of cell has several functions, including antigen presentation to CD4+ T cells; assisting in apoptosis; organizing the structure of lymphoid tissues, such as lymph nodes and gut-associated lymphoid tissue (GALT); and attracting B cells.

**Gene Editing**

Gene editing is a cure strategy for modifying the genetic information in cells, such as removing HIV proviral DNA from the cells’ DNA or altering the CD4 receptor, CCR5 co-receptor, or anti-HIV restriction factors to make CD4+ T cells resistant to HIV infection. There are numerous experimental gene editing techniques being investigated (many targeting the gene that encodes CCR5—the ones listed are designed to do so unless specified as having other or more general targets). Though we list 11 approaches, CRISPR is by far the most important, and zinc-finger
nucleases and TALENs are the only ones that have so far been used in significant clinical trials of gene editing intended as a step toward a functional cure of HIV infection. A recent mathematical modeling study of gene editing strategies for HIV cure has shown that achieving positive results is possible only under a narrow range of conditions and that further improvement of engraftment is likely to be necessary to improve outcomes.

1. CRISPR: What’s known as CRISPR is actually a combination of two drugs: CRISPR (clustered regularly interspaced short palindromic repeats) and either, most frequently, a Cas protein (CRISPR associated protein—most often Cas9) or another protein, such as Cpf1 (centromere and promoter factor 1). It is currently the most efficient, effective, and easy-to-use method for gene editing. Science, the most prominent U.S. scientific journal, declared CRISPR to be the “Breakthrough of the Year” for 2015 because of its very wide applicability and ease of use, and Nature, the most prominent British scientific journal, chose it as No. 1 among its ten most important breakthroughs of 2015. CRISPR is actually a primitive immune-like system found in bacteria. Further, in early 2016, it was reported by two research teams that CRISPR technology, one using Cas9 and another using a different protein, had been used to remove entire HIV proviral DNA from latently infected CD4+ T cells in vitro and this has more recently been reported in vivo. See also the CRISPR Perspectives entry.

2. Homing Endonuclease: A homing endonuclease is an enzyme (either a protein or a small RNA) that homes in on a specific segment of DNA or RNA and either cuts out or replaces that part of it. If a DNA segment is cut, it is then reconnected by the enzyme DNA ligase, a DNA repair mechanism found in all human cells. It is a goal of cure research to design homing endonucleases such that the repair will make the cells unable to make new HIV virions. Meganucleases, megaTALs, transcription-activator-like effector nucleases (TALENs) and zinc-finger nucleases (ZFNs) discussed below are four types of homing endonucleases.

3. Intrabody: An intrabody is a variety of antibody that can bind to a protein and make it dysfunctional. CCR5 intrabodies have been found to be more effective than the intrakines described immediately below.

4. Intrakine: An intrakine is a chemokine found inside a cell that can target newly formed CCR5 blocking its transport to the cell surface. Unfortunately this approach resulted in incomplete inhibition of CCR5, that is, only some CCR5 co-receptors were blocked from reaching the cell surface.

5. Meganuclease: A meganuclease is a relatively long engineered peptide that has been used to edit DNA in genes to remove HIV proviral DNA.

6. Mega-Transcription-Activator-Like (MegaTAL): A mega-transcription-activator-like (megaTAL) is a long peptide useful for removing HIV proviral DNA from CD4+ T cells. It consists of a meganuclease bound to part of a transcription-activator-like endonuclease (TALEN). A megaTAL has greater specificity and is more effective than either of its component parts. MegaTALS also have more general application than just CCR5 gene editing.

7. Ribozyme: A ribozyme is a small strand of RNA that acts as if it were an enzyme. Ribozymes have been used in several clinical trials to target HIV genes with some success. In combination with other approaches, one type of ribozyme targeted to the CCR5 co-receptor has been effective to curtail the effectiveness of CCR5 for as long as 24 months.

8. Short Hairpin RNA (shRNA): A short hairpin RNA (shRNA) is an artificially produced RNA molecule that has a quite small hairpin-shaped segment and that can be used to silence expression of a gene via a mechanism called RNA interference; it requires delivery by a viral vector.

9. Short Interfering RNA (siRNA): A short interfering RNA (siRNA) is a very short synthetic strand of RNA that can be used to edit out the gene for CCR5; however they are somewhat problematic because they tend to have off-target effects also.

10. Transcription-Activator-Like Effector Nuclease (TALEN): A transcription-activator-like effector nuclease (TALEN) is a peptide useful for gene editing to remove HIV proviral DNA from CD4+ T cells.

11. Zinc-Finger Nuclease (ZFN): A zinc-finger nuclease (ZFN) is a variety of homing endonuclease that cuts strands of cellular DNA into segments that must be repaired by the immune system. When a zinc-finger nuclease that cuts the gene for the cellular co-receptor CCR5 is introduced into cells, those cells’ ability to produce the co-receptor is inhibited, at least to a degree. This can potentially make those cells resistant to HIV infection by virus that requires CCR5. Sangamo Biosciences has a Phase 2 clinical trial named SB-728-T using a zinc-finger nuclease to modify CCR5 genes to make the CD4+ T cells they appear on the surfaces of incapable of being infected by HIV (see
Genetic Recombinant
A genetic recombinant is a virus or other organism whose genetic material (DNA or RNA) is a mosaic of two (or more) others’ genetic material.

Genome
A genome is the collection of all the genes in a living organism or virion.

Glycoprotein
A glycoprotein is a complex of sugars (the “glyco” part of the word) and a protein. In particular, HIV’s gp120 and gp41 are glycoproteins, though there are many others found in viruses and cells.

gp41
gp41 is a component of the HIV glycoprotein gp160 that pierces the outer membrane of the HIV virion; note that it occurs as a trimer, that is, three copies of it are bound together; see also the HIV Structure & Function Glossary entry.

gp120
gp120 is a component of the HIV glycoprotein gp160 that sticks out of the HIV virion; note that it occurs as a trimer, that is, three copies of it are bound together; see also the HIV Structure & Function Glossary entry.

Graft-versus-Host Disease (GVHD)
Graft-versus-host disease (GVHD), also called rejection, is a natural reaction by the body’s immune system to a graft or transplant that typically results in elimination of the graft or transplant unless immunosuppressing drugs, such as cyclosporine, are administered. The reaction is predominantly carried out by CD8+ T cells. Nevertheless, in the case of the Berlin Patient (Timothy Ray Brown), graft-versus-host disease may have played a significant positive role in destroying his original HIV-infected CD4+ T cells.

Histone
A histone is a protein that combines with DNA to form chromatin, the very compact structure in which DNA is stored in cells and stops it temporarily from being replicated.

Histone Deacetylase (HDAC)
A histone deacetylase (HDAC) is an enzyme that causes chromatin to bind its DNA, stop being replicated, and become inactive in resting memory CD4+ T cells. Because of this, HIV-infected cells can have bound DNA that keeps the virus in latent form, does not lead to production of any virus proteins or RNA, and therefore leaves the cell unexposed to both CD8+ T cells and antiretroviral therapy (ART).

HIV Cure (Functional)
This type of cure allows some infected cells to persist in the body of a person living with HIV but means that antiretroviral therapy is no longer necessary, at least for a long time. With this approach, the immune system should be able to handle the virus that is still in the body. Because such people would typically have...
very low levels of HIV, they would be less likely to transmit HIV to others than most infected people but might be vulnerable to reinfection with other strains of HIV than the one with which they are already infected. This type of cure is also called HIV remission.

**HIV Cure (Sterilizing)**

This type of cure completely eliminates HIV from an infected person’s body, which would likely require activation and killing of all infected CD4+ T cells (and probably infected macrophages and other cells contained in latent reservoirs). Depending on the strategy used, such people might or might not be resistant to reinfection with HIV. This approach results in there being no HIV capable of viral replication left in the body, so the person would not be able to transmit HIV to others. However, proving that all HIV has been eliminated from a person’s body is impossible with current approaches, including in the case of the Berlin Patient (Timothy Ray Brown), though he has been HIV-negative for ten years.

**HIV Genome**

The nucleus of HIV (see the HIV Structure & Function Glossary entry) contains the two separate single strands of RNA that comprise its genetic material or genome. The structure of each strand of RNA is shown in Figure 3 (produced by Janie Vinson Productions, San Francisco, CA, 2016). It comprises nine genes and the two long terminal repeats (LTR), the right-hand one of which in the figure is crucial for beginning the production of proteins from the resulting proviral DNA. The overlapping of segments in the diagram corresponds to what are known as open reading frames. (Note that the open reading frames in the HIV genome are *never* directly transcribed and translated to proteins: The HIV genome must first be integrated into a host cell’s DNA as proviral DNA that is, in turn, transcribed and translated to proteins.) In all, each strand has roughly 9,750 bases (nucleic acids), though this varies somewhat with the faulty replication of HIV RNA (see the Defective Virion Glossary entry).

**~9,750 bases (nucleic acids)**

![Diagram of HIV genome](image)

The components of the HIV RNA genome and their functions are described below; the *gag*, *pol*, and *env* genes shown in gray in Figure 3 are found in all retroviruses.

- **env** encodes the protein Env, which creates the glycoproteins gp120 and gp41 that make up the spikes shown in the HIV Structure & Function Glossary entry and that are critical for entry of virions into cells;
- **gag** (group antigen) encodes the Gag precursor protein (also called p55), whose components “orchestrate” the assembly of almost all of the resulting virion. Gag is cleaved to produce six regulatory proteins and one probably nonfunctional spacer, as follows:
  - matrix polypeptide (MA), also called p17, which becomes part of the virion’s enclosing membrane,
  - capsid protein (CA), also called p24, which forms the virion’s capsid,
  - spacer peptide 1 (SP1), also called p2, whose function is to cause the capsid protein CA to become part of the virion’s capsid,
  - nucleocapsid protein (NC), which forms the virion’s nucleocapsids, which are the membranes containing the RNA genome,
  - spacer peptide 2 (SP2), also called p1, which serves as a separator between NC and p6 (described next) and may have an as-yet unknown additional function, and
  - p6, a peptide that recruits cellular proteins essential to the budding of mature virions from the cell in which they are assembled;
- **pol** (polymerase) is reverse transcribed into proviral DNA named Pol that, in turn, encodes a polypeptide that is cleaved into four enzymes, the first three of which are targets for HIV
antiretroviral therapy (ART), namely,

- protease (PR),
- reverse transcriptase (RT, also called p51),
- integrase (IN, also called p31), and
- RNase (also called p15);

- tat encodes the transactivator of transcription protein Tat that strongly increases the transcription of integrated proviral HIV DNA to messenger RNA (mRNA) that, in turn, is used by the cell to produce proteins; note that tat is composed of two separated pieces that must be spliced together to become functional;

- rev encodes a protein named Rev that is essential to regulating HIV protein production by causing the transition from the first to the second phase of HIV proviral DNA transcription and translation; note that rev is composed of two separated pieces that must be spliced together to become functional;

- vpu encodes the protein Vpu (viral protein unique) that induces destruction of the CD4 receptor and may facilitate creation of Env (described above);

- vif, vpr, and nef encode the proteins Vif, Vpr, and Nef, respectively, which are discussed in the HIV Structure & Function Glossary entry; and

- finally, LTR is a long terminal repeat; it is a sequence of ~640 bases that are identical across the two LTRs; HIV's right-end long terminal repeat is reverse transcribed to produce five double-stranded DNA sequences, as follows:

  - TAR, the transactivation response element, interacts with Tat and other HIV proteins in an unknown manner,

  - Poly A, which is involved in creating mature virions,

  - PBS, the primer binding site, is an 18-base sequence that encodes a peptide involved in initiation of retrotranscription of HIV RNA,

  - Ψ, the Psi packaging element, is involved in packing the viral genome into the capsid; it varies from ~80 to ~150 bases, depending on the strain of HIV, and

  - DIS, the dimer initiation site, takes part in preparing the viral RNA for packaging by Ψ.

Note that the genome in Figure 3 is a simplification: It shows only the genes in the RNA that is the actual genome. Figure 8 shows the actual structure, which comprises a backbone to which the nucleic acids are connected.

**HIV Latency**

Although effective antiretroviral therapy (ART) can keep a very large fraction of activated infected CD4+ T cells from reproducing HIV, it is not effective against CD4+ T cells and other types of cells that are in a resting state and not actively reproducing or producing chemical messages to cause an immune response against a pathogen. These resting memory CD4+ T cells provide a latent reservoir of virus that can be reawakened to begin producing HIV virions if antiretroviral therapy is stopped.

**HIV Remission**

HIV remission is an alternate term for HIV cure (functional) that is preferred by many researchers.

**HIV Structure & Function**

The cutaway diagram in Figure 4 (from https://commons.wikimedia.org/wiki/File:HIV_Virion-en.png) shows schematically the structure of an HIV virion. The components are as follows:

- The lipid membrane (light yellow) is a fat bi-layer that is recruited from the cell membrane of a cell when a new virion “buds” from it; it accounts for about 30% of the total weight of the virion (Gag, described in the HIV Genome Glossary entry, accounts for about another 50%) and contains all of the virion except the glycoprotein spikes named gp160 (comprising the HIV protein Env, which forms a trimer coated with about 90 glycans (chains of sugars) containing the sugar lactose found in milk). Each gp160 spike splits to form two glycoproteins, the docking protein gp120 (purple elongated ovals) on the outside of the virion’s membrane and the transmembrane protein gp41 (elongated green ovals) that actually pierces the viral membrane; gp160 is the part of an HIV virion that attaches it to a target cell, most often a CD4+ T cell; each of gp120 and gp41 is a trimer, that is, there are three copies of each bound together; when a virion attaches to a target CD4+ T cell, the trimers open to create a mechanism that, accomplishes entry into the cell;

- Inside the membrane is a protein layer called the matrix (light blue) made up of matrix protein or p17, which contains essential proteins and the nucleus;

- Protease (black squares with light blue inside) is an enzyme that cleaves newly formed HIV polyproteins during viral replication into their constituent protein components;

- The capsid (dark blue) is the outer membrane of the virion’s nucleus and is composed of molecules of a protein known as p24; the capsid’s contents are as follows:

  - The genome (black lines sticking out of the nucleocapsids) consists of two separate strands of RNA, as described in the HIV
Genome Glossary entry partially encased in the nucleocapsids (grayish green);

- The capsid also contains several proteins,
  - Reverse transcriptase (RT) (black circles with red insides) is the enzyme responsible for reverse transcribing HIV RNA to HIV proviral DNA;
  - Integrase (IN) (light blue open circles) is the enzyme responsible for integrating the reverse-transcribed DNA into the host cell’s DNA;
  - Nef (negative regulatory factor) (one of the circles in the black bracket) is a small protein that causes numerous changes in an infected cell to adapt it to reproducing HIV;
  - Vpr (viral protein R) (another of the circles in the black bracket) is a small protein that is essential to HIV viral replication in non-dividing cells, such as macrophages;
  - Vif (viral infectivity factor) (another of the circles in the black bracket) is a small protein that is essential to HIV viral replication; and
  - p7 (another of the circles in the black bracket) is a peptide that facilitates reverse transcription.

The virion also includes a transfer RNA (tRNA) from the cell that produced the virion that serves to prime insertion of the resulting proviral DNA into a newly infected cell.

---

**HIV Therapeutic Vaccine**

An HIV therapeutic vaccine is an immune-system-stimulating vaccine that prompts or boosts immune responses to HIV in infected individuals.

**HIV’s Uniqueness**

HIV is unique among human pathogens in several respects, as follows (adapted in part from a slide created and provided for use by Nobel Prize winner David Baltimore, PhD):

- It preferentially attacks CD4+ T cells, the “directors” of the adaptive immune system.
- It eludes control by antibodies.
- Sugars cover almost its entire accessible surface. The only notable exception is the CD4 binding site, but that site is deep inside the protein coat, where it can’t be reached by most antibodies.
- It employs a remarkable two-part entry mechanism,
using CCR5 or CXCR4 in addition to CD4 that only takes place after viral gp120 has bound to the CD4 site (see the CCR5 Glossary entry). As a result, very few antiviral antibodies can neutralize it, and fewer still are both broadly neutralizing and potent.

- It destroys the gut-associated lymphoid tissue (GALT) very early in infection altering the gut’s microbiome.
- It also attacks the central nervous system (CNS) very early,
  - can have anywhere from minor to profound consequences there,
  - can be very hard to reach by therapies there, and,
  - because of the absolutely essential maintenance of functioning of the CNS, very likely requires much more delicate approaches to cure (such as latency silencing) rather than shock and kill.

All of these aspects of HIV’s uniqueness make it a much more difficult target for cure research than for almost all other pathogens.

**HIV-2**

HIV-2 is a virus distinct from but quite similar to HIV-1, which is what is referred to as simply HIV throughout this document. The reasons for paying so little attention to HIV-2 here are as follows:

- While HIV-1 is pandemic (that is, found around the world), HIV-2 is concentrated in West Africa and a few other places, most notably in parts of Europe, particularly France and Portugal, with large numbers of immigrants from West Africa.
- HIV-2’s zoonotic (that is, animal) origin is distinct from HIV-1’s. It resulted from consumption of “bush meat,” like HIV-1, but from monkeys named sooty mangabeys, rather than chimpanzees.
- HIV-2 is much less pathogenic than HIV-1; while it causes AIDS, it progresses to AIDS much more slowly. In fact, it has been suggested that a large fraction of HIV-2-infected persons can reasonably be described as elite controllers because the asymptomatic stage of HIV-2 infection between the very early acute stage and AIDS often lasts several decades in untreated persons and the viral load is frequently undetectable except during AIDS.
- Several more varieties of HIV-2 than HIV-1 have been shown to infect cells that lack the CD4 receptor.
- Finally, but most important, approaches to curing HIV-1 disease are almost certain to be applicable to HIV-2 disease.

Recent research suggests that the typically slower progression of HIV-2 infection may be the result of a significantly higher fraction of HIV-2-infected persons naturally being elite controllers because of some unknown difference in the virus compared to HIV-1.

**HLA-B*5701 and HLA-B*2701**

HLA stands for Human Leukocyte Antigen and is the cellular mechanism that enables the human body to recognize non-self antigens, such as pathogens and cancer cells, and reject them. See the description of HLA in the Immune System Glossary entry. HLA-B*5701 and HLA-B*2701, in particular, are specific parts of the human leukocyte antigen that are advantageously mutated in a majority of elite controllers of HIV infection, and they are one of the mechanisms that contribute to their control of HIV infection without antiretroviral therapy (ART).

**Humanized Mouse**

A humanized mouse, such as the bone marrow-liver-thymus (BLT) mouse, is a laboratory mouse that has some human genes and tissues. It serves as a very useful model for testing strategies for latency reversal and other strategies for HIV remission, such as allogeneic transplants.

**Immune Checkpoint**

An immune checkpoint is a molecule in the immune system that either up-regulates a signal (co-stimulatory molecules) or down-regulates a signal. Many cancers protect themselves from the immune system by inhibiting T cell signals. Immune checkpoint inhibitors, such as PD-1, block the action of an immune checkpoint as described in the Latency Reversal Glossary entry.

**Immune Correlate of Persistence**

An immune correlate of persistence of HIV infection is a measurable sign that statistically correlates well with the degree to which one’s HIV infection remains latent in the body.

**Immune System**

The immune system is the bodily system that protects against disease. It consists of two major parts, the innate immune system and the adaptive immune system.

The innate immune system comprises three parts: biological barriers, natural killer (NK) cells, and killer-cell immunoglobulin-like receptors on the surfaces of NK cells, which are generally known by their abbreviation “KIR”. Biological barriers at the surface of the body may be effective in keeping out pathogens, such as foreign substances, bacteria, and viruses that they recognize as different from the body. Pathogens
that make it through the biological barriers may be recognized by KIR components that they are specific to. If a KIR component recognizes a pathogen, it activates natural killer cells (NK cells)—see their Glossary entry for a description of their function.

The adaptive immune system comprises B cells, T cells, antibodies produced by B cells, and the human leukocyte antigen (HLA) complex, which consists of genes that code for body-surface proteins that distinguish between self and non-self and cell-surface proteins that regulate the adaptive immune system in humans; it is the human instance of a system named the major histocompatibility complex (MHC) found in all vertebrates. T cells, in turn, are a large family of varieties, including at least CD4+ T cells (and their latent varieties the central memory (Tcm) T cells, effector memory (Tem) T cells, and stem-cell-like memory (Tscm) T cells), CD8+ T cells, T follicular helper (Thp) cells, T helper 17 (T17) cells, and at least a half dozen other types; see the entries for the underlined cell types for descriptions of their roles in immunity.

**Immune-System Stimulation**

Immune-system stimulation is an alternative term for latency reversal. Most HIV cure researchers believe that some form of immune-system stimulation to activate latently infected CD4+ T cells and kill them are essential to curing HIV infection.

**In Vitro & In Vivo**

In vitro (from Latin, literally “in glass”) is used in biological research to mean “in the laboratory”, while “in vivo” (also from Latin, literally “in life”) means in a human or animal. Both phrases are used to refer to experimental procedures.

**Infant CD4+ T Cells**

Recent research has shown that the CD4+ T cell populations in infants are quite different from those in adults. In particular, naïve (that is, undifferentiated) CD4+ T cells (TN cells) constitute a significantly larger fraction than in adults. Understanding the implications of this distinction may provide insight into how best to cure HIV infection in infants differently from how it might be done in adults.

**Inflammation**

Inflamed immune-system cells can signal other immune-system cells to reproduce or respond to a pathogen. The key white blood cell in inflammation is the macrophage. Macrophages can assemble within themselves platforms named inflammasomes that produce the substances that promote inflammation. These platforms are assembled when needed and destroyed when they are no longer needed. This is usually helpful.

However, HIV infection, even in those whose virus is either suppressed naturally (elite controllers) or by antiretroviral therapy (ART), is known to cause chronic inflammation, which can lead to cardiovascular disease, cancers, and other serious health conditions. Activated cells can also produce scarring (also called fibrosis) in lymph nodes, a critical part of the immune system. For most purposes chronic immune activation equals chronic inflammation (that is, every chronic inflammation leads to chronic immune activation and vice versa). In most cases, short-term inflammation is a good thing because it controls many types of infections, though not HIV infection.

The New Yorker article “INFLAMED” Groopman J 30 November 2015, issue available at http://www.newyorker.com/magazine/2015/11/30/inflamed provides an excellent layperson’s introduction to inflammation in its first few paragraphs.

**Integrin**

An integrin is a receptor that has a part outside a cell, extends through the cell wall, and has a part inside the cell. The integrin of greatest current interest in HIV cure research is a receptor named α4β7 (alpha 4 beta 7). α4β7 forms a complex with the CD4 receptor to produce a subset of T cells that is very susceptible to HIV infection. Such cells are found, most notably, in gut-associated lymphoid tissue (GALT).

**Kick and Kill**

Kick and kill is a synonym preferred by some researchers for shock and kill.

**Latency Reversal**

Latency reversal, also called reactivation, is fundamental to activating the bound HIV proviral DNA in resting memory CD4+ T cells in latent reservoirs in the body to make it susceptible to destruction in the approach to cure known as shock and kill. This is considered by many HIV cure researchers to be fundamental to curing HIV. The following are 16 of the many types of substances and individual substances being tested as latency-reversal agents; most (though not all) are either experimental cancer drugs or ones already in use and are as follows:

1. **Bromodomain Inhibitors**: A bromodomain inhibitor attaches to proteins called histones in chromatin, causing the chromatin to release its bound DNA. The name has no connection with the element bromine; instead it is derived from its discovery in fruit flies in association with a gene named brahma.
2. Bryostatin or Prostratin Analogue: A bryostatin or prostratin analogue is a drug that has been shown to potentiate induction of latency reversal of HIV in CD4+ T cells in laboratory experiments. An analogue, in this context, is an organic compound created in a laboratory that is similar to the naturally occurring chemical it is analogous to. Bryostatin is named from its discovery in undersea animals named bryozoa. Prostratin is found in the bark of a tree from Samoa. Given the difficulty of obtaining both drugs, it has become essential to develop methods to synthesize analogous chemicals with the same properties. Because bryostatin analogues can be quite toxic, some cure researchers have investigated delivering them inside lipid (fatty) nanoparticles.

3. Checkpoint Inhibitors: Immune checkpoints, such as Programmed Cell Death 1 (PD-1) (described in item 11 below), mark TCM and TEM cells. Checkpoint inhibitors, in turn, block the activity of immune checkpoints. This makes checkpoint inhibitors useful for latency reversal.

4. Disulfiram (DSM): Disulfiram (DSM) is a drug that was used for several decades to treat alcohol dependence because drinking alcohol while taking it causes a severe generalized physical reaction. It is rarely used for that purpose now because, in a few cases, the reaction caused the person taking it to die.

5. DNA Methyltransferase Inhibitors: A DNA methyltransferase is an enzyme that attaches methyl groups to locations in DNA. A DNA methyltransferase inhibitor blocks the activity of that enzyme. One DNA methyltransferase inhibitor that has been tested for latency reversal is the cancer drug decitabine (brand name Dacogen).

6. Farnesyl Transferase Inhibitor (FTI): A farnesyl transferase inhibitor (FTI) inhibits the action of an enzyme named farnesyl transferase that replaces a hydrogen atom in the amino acid cysteine with a molecule named farnesyl.

7. Histone Deacetylase Inhibitor (HDACi): A histone deacetylase inhibitor (HDACi) causes chromatin to release HIV proviral DNA to reproduce and become exposed to the immune system and potentially to HIV antiretroviral therapy (ART). Numerous examples that have been used in latency reversal studies are belinostat product name Beleodaq), droxistatin, givinostat, oxamflatin (brand name Metacept 3), panobinostat (product name Farydak), romidepsin (brand name Istodax), Scriptaid, trichostatin A, and vorinostat (formerly and still occasionally called SAHA and brand named Zolinza). As of late 2015, romidepsin appeared to be the most effective HDACi drug for reversing latency.

8. Histone Methyltransferase Inhibitor (HMTi): Histone methyl transferases (HMTs) are enzymes that facilitate the transfer of methyl groups to two types of amino acids in histones. A histone methyltransferase inhibitor (HMTi) keeps this transfer from happening. Two HMTis are currently in testing as latency reversal agents, namely, one as yet unnamed one called BIX 01294 and the other named chaetocin, which was isolated from a fungus. Both are supplied by several drug companies.

9. Interleukin-7 and -15 (IL7 and IL15): Interleukin-7 and -15 (IL7 and IL15) are essential to the maturation of all types of T cells.

10. Ingenols: Ingenols are drugs used primarily for treating certain skin cancers but that have also been used experimentally in latency reversal of DNA in resting memory CD4+ T cells.

11. Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: Programmed cell death 1 (PD-1), also known as CD279, is a receptor found on the surface of some T cells. It both promotes and inhibits apoptosis, depending on the type and location of the T cells it is found on. Recently developed drugs inhibit its effect, thereby activating the immune system to fight certain types of tumors. Programmed cell death ligand 1 (PD-L1), also known as CD274, is a receptor found on the surface of some T cells. It suppresses the immune system during pregnancy so as to avoid abortion of the fetus as non-self, among other functions. Both for PD-1 and PD-L1, drugs have been developed recently that inhibit their effects, thereby reactivating HIV-infected CD4+ T cells. Because of PD-1 and its ligands' involvement in apoptosis, inhibiting them is potentially dangerous. In fact, a recent trial of a PD-L1 inhibitor resulted in one participant's developing a serious autoimmune disease (a disease in which the immune system acts against the body), with the result that the drug will not be used in future clinical trials.

12. Proteasome Inhibitors: A proteasome is an organelle that destroys proteins by breaking them up into their constituent amino acids. A proteasome inhibitor acts against a proteasome by blocking this action and can, as a result, inhibit latency.

13. Protein Kinase C (PKC) Agonists: Protein kinase C (PKC) is a family of proteins that add phosphate groups to amino acids in other proteins. Protein kinase C agonists have been used experimentally to induce latency reversal.

14. Rottlerin: Rottlerin is an inhibitor of a protein named kinase Cδ, which is essential to HIV viral replication. Laboratory experiments are ongoing to
determine its effectiveness as a latency-reversal agent. “θ” is the lower-case Greek letter theta.

15. Sirolimus: Sirolimus (brand name Rapamune) is a drug that is frequently used to suppress immune reactions to transplanted organs. It originated from a bacterium found on Easter Island.

16. Toll-Like Receptors 4, 7, and 9 (TLR4, TLR7, and TLR9) Agonists: Toll-like receptors 4, 7, and 9 (TLR4, TLR7, and TLR9) are proteins that are important to recognition of pathogens and activation of natural killer (NK) cells. A toll-like receptor agonist binds to a toll-like receptor and activates it. They may be the most promising latency-reversal agents so far. In particular, Gilead Sciences’ drug candidate GS-9620 is a very potent TLR7 agonist, which, it is believed, is why Gilead Sciences is a partner in the amfAR Institute for HIV Cure Research. A trial of GS-9620 in rhesus macaques resulted in two of the nine macaques maintaining undetectable viral loads for three to four months. A more recently reported study showed that repeated administration of GS-9620 can lead to remission in SIV-infected rhesus macaques. Gilead Sciences has developed another TLR7 agonist named GS-986.

Latency Reversal by Combinations of Drugs
Several articles published in 2015 discuss combinations of latency reversal agents tested in cell lines (that is, human cells grown in a laboratory) outside the body and found them to be more effective than single agents. The determination of effectiveness was made by the observation of biological signaling pathways associated with latency reversal. The combinations are as follows:

- Ingenol-3-angelate (brand name Picato) and JQ1 (a potent bromodomain inhibitor),
- Vorinostat and chaetocin,
- Vorinostat and prostratin,
- Histone deacetylase inhibitor (HDACi) and anti-PD-1,
- Anti-PD-1 and the antiretroviral therapy (ART) drug raltegravir,
- Bryostatin-1 and JQ1,
- Ingenol-B and JQ1, and
- A selective estrogen receptor modulator (SERM)—see the item in the Estradiol, Estrogen, Progesterone, and Estrogen Receptors Glossary entry—and a histone deacetylase inhibitor (HDACi).

It is not known whether any of these combinations will be safe when used in humans.

A triple combination that was tried in humanized mice is vorinostat, a bromodomain inhibitor named I-BET 151, and an antibody.

Latency Silencing
Latency silencing is a term used to describe an approach to completely stopping reactivation of latently infected CD4+ T cells in latent reservoirs, thus making them incapable of producing further HIV virions. It is of interest because of the potentially serious problems latency reversal would create if it were applied to the central nervous system (CNS). Several approaches are being explored, as follows:

- Using gene editing to modify the HIV tat gene so that the HIV is no longer infective,
- Inhibiting the Tat protein with didehydro-cortistatin A, an analogue of the steroid cortistatin isolated from an ocean sponge,
- Using short hairpin RNAs (shRNAs) to perform HIV gene editing,
- Using mammalian target of rapamycin (mTOR) pathway inhibitors to suppress HIV retrotranscription: rapamycin is an alternate name for sirolimus, a latency reversal agent, and
- Using a protein named lens epithelium-derived growth factor (LEDGF/p75) that plays a critical role in integrating HIV into cellular DNA.

NIH has a request for research-grant applications active for another approach as this is being written.

Latent Reservoir
Latent reservoir is used in HIV cure research in two closely related senses:

1. A latent HIV reservoir is a part of a person’s body that may be cells or a tissue that is reachable by HIV. Further, it is a part of the body that, it is generally believed, is not affected by antiretroviral therapy (ART) as effectively, if at all, as in the blood. Latent reservoirs provide long-lived homes for HIV to reemerge from if therapy is stopped. Examples of confirmed and likely latent reservoirs include:
   - resting memory CD4+ T cells,
   - macrophages and monocytes (white blood cells),
   - lymph nodes,
   - the brain,
   - the innermost layer of fat (technically called the stromal vascular layer), whose cells display the CD4 receptor and both the CCR5 and CXCR4 co-receptors,
   - the female and male genital tracts,
   - Peyer’s patches and other parts of the
A type of T cell named Vγ9Vδ2 that does not have the CD4 receptor but is a latent reservoir for HIV was discovered in 2015; these cells contain replication-competent latent proviral DNA. There are other types of cells that may be latent reservoirs, including natural killer cells (NK cells), renal (kidney) epithelial cells, mucosal epithelial cells, skin fibroblasts (cells that produce collagen—see the Lymph Node Collagen Deposition (Fibrosis) Glossary entry), and pluripotent stem cells (stem cells that can differentiate into any other type of cells). Epithelial cells form the outer surface of the skin and other parts of the body that are effectively outside it, such as the alimentary canal. “γ” and “δ” are the lower-case Greek letters gamma and delta, respectively.

In 2012 two researchers proposed an alternate “practical definition” of a latent reservoir as an “Infected cell population that allows persistence of replication-competent HIV-1 in patients on optimal HAART regimens on the order of years.” HAART abbreviates highly active antiretroviral therapy (ART).

A recently reported study of HIV and macrophages performed in bone marrow-liver-thymus (BLT) mice showed that HIV persists in macrophages in vivo and thus they are very likely to be a component of the latent reservoir.

The latent HIV reservoir is the totality of all the individual latent reservoirs of type (1) above. The size of the latent reservoir is estimated to be anywhere from 1 million to over 50 million HIV-infected resting memory CD4+ T cells by the methods listed in the Measuring the Latent Reservoir Glossary entry. Richman D “Introduction: challenges to finding a cure for HIV infection” Current Opinion in HIV and AIDS 6, January 2011, p. 1 noted what we know about the latent reservoir as follows (lightly edited):

a) Latently infected resting memory CD4+ T cells are the best characterized latent reservoir for HIV-1.

b) Less than 1 cell per million of resting CD4+ T cells from persons on potent antiretroviral therapy harbor replication-competent latent provirus.

c) Other drug-insensitive reservoirs, including the brain, macrophages, and hematopoietic stem cells, may also exist.

d) The nucleotide sequences of latent proviruses do not incur mutations, so there is no ongoing viral replication within them. Discontinuation of antiretroviral therapy permits the rebound of viral replication originating from the latent reservoir.

e) Persons successfully treated with antiretroviral therapy for a decade or more exhibit no appreciable decrease in the size of the latent reservoir.

f) The persistence of the latently infected reservoir precludes its elimination by antiretroviral therapy for the lifetime of the person.

g) Latency is likely established by numerous steps of HIV replication, which potentially complicates eradication strategies.

h) It is generally accepted that the latent reservoir of at least HIV-infected resting memory CD4+ T cells containing proviral DNA and almost certainly other types of HIV-infected cells is established within days after infection, and the existence of the latent reservoir has been known since 1995. The establishment of the latent reservoir and its reactivation are shown in Figure 5 (used with permission from “An Integrated Overview of HIV-1 Latency” Ruelas DS Greene WC Cell 155, 24 October 2013, p. 522). Recent research has shown that some subpopulations of replication-competent HIV-infected resting memory CD4+ T cells continue to undergo expansion in latent reservoirs.

i) Latency is initiated by the transactivation of transcription (Tat) protein (see the Tat item in the HIV Structure & Function Glossary entry) level in susceptible cells decreasing below a threshold. Resting CD4+ T cells maintain proviruses by sequestering three transcription-related proteins.

The perspective “Redefining the Viral Reservoirs that Prevent HIV-1 Eradication” Eisele E Siliciano RF is freely available from the 21 September 2012 issue of the journal Immunity. It can be downloaded from the webpage http://www.cell.com/immunity/abstract/S1074-7613(12)00376-7. While the article is rather technical, as a perspective it should be accessible to a significant fraction of readers.

**Latent Reservoir Maintenance**

The latent reservoir is maintained by two mechanisms,
homeostatic proliferation and clonal expansion, described below:

- Homeostatic proliferation occurs in the bone marrow when there is a low level of white blood cells, including CD4+ T cells, and it has the goal of maintaining a constant number of T cells. When the body has fewer white blood cells than needed to maintain a normal number, they proliferate in response to HLA direction. It is the major source of T cells following the withering of the thymus gland in adolescence.
- Clonal expansion is a process that generates daughter memory cells (a clone) of a single cell. If the original cell is a T or B cell, all the cells in the clone are specific to the same antigen, namely, that of the parent cell.

![Figure 5. Establishment of the latent reservoir and its reactivation.](image)

**Latent Reservoir Reduction to Achieve HIV Cure (Functional) or Remission**

Estimating latent reservoir reduction to achieve a functional HIV cure or remission is a major goal of cure research, since remission is believed to be much more easily achievable than a sterilizing cure—see the HIV Cure (Sterilizing) Glossary entry. However, the standard estimates of the reduction necessary to achieve a 30-year (essentially lifetime for many people) remission is a factor in the range of 100,000 to 1 million of the overall latent reservoir and roughly 1,000 to achieve a one-year remission.

A more recent and clearly more optimistic model suggests that only roughly a factor of 60 could achieve a one-year remission; nevertheless, while such a reduction has been realized in a few cases, it has not shown a yearlong remission yet.

Finally, note that this type of remission is distinct from the virologic remission found in the VISCONTI cohort (see the Post-Therapy Controllers Glossary entry): a remission of this type requires that all latently infected resting memory CD4+ T cells remain inactive for the period of the remission. This type of remission, further, is more like being fully healthy in that it implies no ongoing inflammation, unlike what happens in virologic remission.

**Lentivirus**

A lentivirus, such as HIV or simian immunodeficiency virus (SIV), is a type of retrovirus that causes a very slowly progressing infection. The prefix “lenti” comes from the Latin word meaning slow. Lentiviruses are further distinct from other retroviruses in that only they can infect cells that are latent, i.e., not dividing.

**Leukapheresis**

Leukapheresis is a medical procedure used in cure research to collect large numbers of white blood cells. It requires insertion of a catheter into a vein in each arm; blood is drawn out via one of them, a fraction of the white blood cells is collected by the process known as apheresis (from the Greek for “taking away”), and the remaining blood is reinserted into the body via the other catheter. The quantity of white cells collected is never enough to affect immune function. Leukapheresis is used in several areas of cure research, most prominently in some of the methods for determining the results of latency reversal.
**Los Angeles Baby**
The child known as the Los Angeles baby was actually born in Long Beach, CA, (in Los Angeles County) in April 2013 and was HIV+ at birth. She was treated aggressively within hours of her birth and six days later was found to have no detectable HIV in her body. She was kept on antiretroviral therapy (ART), so it is not possible to determine whether she has actually been cured.

**Lymph Node**
A lymph node is a small organ containing immune-system cells named lymphocytes that filter lymph, which is a fluid similar to blood plasma that contains fats that are responsible for its white milky color, B cells, and T cells; the latter include CD4+ T cells and CD8+ T cells. Prominent clusters of lymph nodes are found in the underarms, the groin, and the neck. See the Lymphatic System & Lymphoid Tissues Glossary entry for related information.
Lymph Node Collagen Deposition (Fibrosis)
When cells die in the body, they are sometimes replaced by scar tissue composed of collagen, a protein found in numerous tissues including bones—in fact it is the most common protein in a person's body. This is called fibrosis. When lymph nodes are inflamed by HIV replication they can lay down scar tissue. This can begin within days of HIV infection and may be largely complete within months. Experts believe that when lymph nodes are scarred, it may be difficult to regain their ability to respond to HIV and other infections as effectively, causing lasting damage to the immune system that a cure may not be able to reversible.

Lymphatic System & Lymphoid Tissues
A lymphoid tissue is an individual component of the
lymphatic system. The lymphatic system is made up of lymph nodes and immune-system cells in many other lymphoid tissues, and is responsible for producing lymphocytes and antibodies, and are found in lymph nodes, the thymus gland, gut-associated lymphoid tissue (GALT), Peyer's patches, the spleen, tonsils, and adenoids; and the lymphatic vessels that lead from lymphatic tissues to the heart. The lymphatic system is essential to fighting infections. Figure 6 shows the human lymphatic system in green (from http://lymphatictherapy.co.za/manual-lymph-drainage/the-lymphatic-system/ , used courtesy of C Hoffman, B.Sc., T.M.T., Vincent Pallotti Hospital, Pinelands, South Africa).

**Macrophage**

A macrophage is a type of white blood cell that may be infected with HIV and, hence, may serve as a latent reservoir component. Macrophages are found in almost all organs, in addition to circulating in the blood. Macrophage translates from Greek as “large eater.” Macrophages perform what is known as phagocytosis—literally (from Greek) “cell-eating process”—which well describes what they do, namely, engulf cellular debris, bacteria, viruses, cancer cells, and other foreign substances—essentially anything that doesn't have the proteins found on the surfaces of healthy native cells. In particular, macrophages devour HIV-infected CD4+ T cells. A subset of HIV virions use any of at least nine co-receptors other than CCR5 and CXCR4, some which virions attack macrophages directly. Thus, it is very likely that macrophages provide additional latent reservoirs beyond those containing resting memory CD4+ T cells.

Measuring the Latent Reservoir

Measuring the latent HIV reservoir(s) is a vital step in determining the effectiveness of approaches to both latency reversal and latency silencing. For latency reversal, it can be used to determine the number of reactivated HIV-infected CD4+ T cells, in addition to its obvious basic measurement role.

It is estimated that the latent reservoir typically contains anywhere from about 1 million to over 50 million HIV-infected CD4+ T cells. The ultimate goal of measuring the latent reservoir is to count all and only replication-competent provirus, which no measurement tool is yet capable of doing (see Figure 7 from Barton KM Palmer SE “How to Define the Latent Reservoir: Tools of the Trade” Current HIV/AIDS Reports 11 February 2016, under the terms of the Creative Commons Attribution 4.0 International License http://creativecommons.org/licenses/by/4.0/ ). There are several approaches to measuring the number of HIV-infected CD4+ T cells in the latent reservoir, some of which are as follows:
1. The quantitative viral outgrowth assay (QVOA) attempts to count replication-competent latent provirus. It begins by collecting very pure latent resting memory CD4+ T cells by leukapheresis. It then dilutes the cells in several steps and reactivates them. Then activated CD4+ T cells also collected by leukapheresis from an uninfected person or persons are added to the diluted cells and mixed with the infected CD4+ T cells to infect them and thus propagate the virus. The quantitative viral outgrowth assay is complex and expensive and has the added disadvantage of being very likely to underestimate the actual size of the latent reservoir. However, some recent studies show a significant correlation between the results of QVOA and total HIV DNA, suggesting that it may be a reasonable measure of the latent reservoir. Approaches to improving the effectiveness of QVOA are a subject of research—see, for example, item 4.

2. The quantitative polymerase chain reaction (qPCR) assay measures total HIV DNA or cell-associated HIV RNA (caRNA) in a latent reservoir. This assay is most frequently used to measure persistent HIV infection, but it can be used to measure the latent reservoir. It has the disadvantage of massively overestimating the magnitude of the latent reservoir—by as much as 300 times—because it does not discriminate between functional (that is, replication competent) and defective (that is, not capable of replicating HIV—see the Defective Virion Glossary entry for an explanation of this) HIV RNA. It is relatively inexpensive compared to QVOA.

3. The single-copy assay of latent HIV RNA is an extremely sensitive method that counts as few as one HIV+ CD4+ T cell at a time. It is most often used to detect low-level viremia in people on antiretroviral therapy (ART), but it may be useful for measuring the latent reservoir. A variant named droplet digital polymerase chain reaction (ddPCR) can be used to precisely measure very low levels of HIV RNA or cell-associated RNA (caRNA). This approach (obviously) detects single copies of latent HIV RNA, and efficient counting techniques are under development to enable it to measure the magnitude of the latent reservoir. This may turn out to be the most effective way to perform such measurements if it can be refined to distinguish replication-competent HIV-infected resting cells from defective ones.

Monoclonal Antibody
A monoclonal antibody is a clone or cluster of identical antibody molecules made by identical immune-system cells that are all clones (identical copies) of a specific parent cell. Monoclonal antibodies that serve as medications are also produced industrially by engineered bacteria that are altered to be specific to those antibodies.

Monocyte
A monocyte is a type of blood cell that accounts for 2 – 10% of the population of white cells. Like natural killer (NK) cells, monocytes are part of the innate immune system. In response to infections, they differentiate into macrophages and dendritic cells to produce inflammation. They are also believed to be a component of the HIV latent reservoir.

Myeloablative Conditioning
Myeloablative conditioning is the medical procedure that typically precedes a hematopoietic stem cell transplant. It consists of either chemotherapy or radiation sufficient to destroy the myeloid cells other than red blood cells and platelets—that is, the hematopoietic stem white blood cells in the bone marrow and usually white blood cells elsewhere in the body because it is relatively “scattershot.”

Natural Killer (NK) Cells
Natural killer (NK) cells are white blood cells responsible for killing infected cells and cancer cells. They are the most ancient component of the cellular innate immune system. They have long been thought to be purely “natural” in the sense that they are preprogrammed to respond to particular types of infected or disabled cells, unlike CD4+ T cells and CD8+ T cells, which must be trained to respond to their target pathogens; however, recent evidence suggests that there are memory-like subsets of natural killer cells in mice; the clearest evidence for such memory-like properties in people is in response to cytomegalovirus (CMV) infection, which is very common in HIV+ persons. They have also been found
in some nonhuman primate (NHP) models, such as rhesus macaques infected with SHIV. There is ongoing research into whether such memory-like natural killer cells may play a role in curing HIV infection. Also, some ongoing research is directed to “supercharging” natural killer cells to make them more effective at killing HIV-infected latent memory CD4+ T cells.

Nonhuman Primate (NHP) Models

Nonhuman primates (most commonly rhesus or pigtail macaques) are used in HIV research because they can be readily infected with SIV or SHIV and provide a reasonably faithful model for prevention, treatment, and cure research. The variety of SIV that infects chimpanzees has been shown to be the zoonotic source of HIV-1 (the most common form of HIV and usually referred to as just HIV), probably as a result of humans eating so-called bush meat; “zoonotic” is the scientific term for a human disease that results from an animal disease. See also Bone Marrow-Liver-Thymus (BLT) Mouse for a description of another mammal model used in cure research.

Nucleic Acid (Base)

A nucleic acid or base is a component of DNA or RNA. Each of them has four types of nucleic acids, three of which are common to both. Triplets of consecutive bases in DNA (called codons) code for specific amino acids; there is significant redundancy among the triplets, since there are 64 distinct triplets but only 20 different amino acids.

Organelle

An organelle is, effectively, a tiny organ within a non-bacterial cell. It has its own genetic material. Two examples of organelles are chloroplasts, which conduct photosynthesis; and ribosomes, which synthesize proteins.

p and gp Numbers

p and gp numbers indicate the atomic weight in thousands of the amino acids strung together to make a protein (“p/n”) or glycoprotein (“gp/n”), where n is a numeral. For example, p24 (see the relevant item in the HIV Structure & Function entry) is a protein with roughly 24 x 1,000 = 24,000 atomic mass units (protons or neutrons).

Paris Patient

The Paris patient was the first reported HIV+ person with acute myeloid leukemia (see the Cancer Glossary entry) to have undergone conditioning with chemotherapy followed by a hematopoietic stem cell transplant (HSCT) in the hope of curing both of his diseases. He had serious graft-versus-host disease (GVHD) and died of multi-organ failure six months after the transplant.

Pathogen

A pathogen is a virus (such as HIV), a bacterium, a chemical foreign to the body, a fungus, a parasite, or anything else that may cause disease.

Pegylated and Pegylation

Pegylation is an organic chemical process that attaches PolyEthylene Glycol (hence the “peg” in the two terms) polymers to a drug to mask the drug from the host’s immune system and increase its time in the body. Pegylated preceding a drug name refers to the result of pegylation of the drug.

Peyer’s Patch

A Peyer’s patch is a small mass of lymphatic tissue found throughout the ileum region of the small intestine. Peyer’s patches are latent reservoirs for HIV-infected CD4+ T cells.

Polymerase Chain Reaction (PCR)

Polymerase chain reaction (PCR) is a molecular biology technology that revolutionized the field. It enables as little as a single molecule or part of a molecule of DNA to be magnified to millions or more copies that can be analyzed, measured, etc. In essence, it uses an enzyme name DNA polymerase that, beginning with as few as a single molecule or fragment of DNA, repeatedly doubles the number of copies of the DNA, growing them literarily exponentially. It has become an indispensable tool in biological research and medicine. Applications range from disease diagnosis to quantification of DNA, which is, of course, the reason for HIV cure researchers’ interest in it.

Positron Emission Tomography (PET)

Positron emission tomography (PET) is a nuclear medicine imaging technique used to observe metabolic processes in the body. It detects pairs of gamma rays emitted indirectly by a positron-emitting tracer compound. Three-dimensional images of tracer concentration within the body are then constructed by computer analysis in a PET scanning machine.

Post-Therapy Controllers

Post-therapy controllers are a small group of individuals living with HIV, so far mostly the VISCONTI (Viro-I mmunologic Sustained CON trol after T reatment I nterruption) cohort in France, who started antiretroviral therapy (ART) within weeks of infection, stayed on therapy for an average of about four years, and then, for various reasons, stopped therapy. Because there has been no large or lasting rebound of HIV, these individuals are able to stay off therapy for long periods, so far as long as 10 years. Unlike the
Majority of elite controllers, these post-therapy controllers mostly lack advantageous immune-system mutations (for example, HLA-B*5701 and HLA-B*2701). Natural killer (NK) cells are believed to be largely responsible for HIV control in this cohort.

Another cohort of post-therapy controllers with so far much shorter follow-up is the subgroup of participants in the RV254/SEARCH010 (a collaboration of the U.S. Military HIV Research Program and the Southeast Asian Research Collaboration with Hawaii) who started antiretroviral therapy (ART) within two weeks of infection, all of whom later had undetectable HIV proviral DNA in central memory CD4+ T cells.

**Practical Considerations in Gene Therapy for Curing HIV**

A 2014 article discusses practical considerations in gene therapy for curing HIV infection using autologous transplants. The main points discussed are as follows:

1. Autologous transplants are significantly easier, though definitely still very challenging, than allogeneic transplants because there is no need to find a well-matched donor. Note by author of this document: However, it is very likely that autologous transplants need gene editing to at least make them CCR5Δ32Δ32 and to delete proviral DNA.

2. There are several gene therapy strategies that might be used, including adoptive immunotherapy of modified messenger RNA (mRNA), RNA interference (RNAi), molecules that compete with HIV RNA, ribozymes, and several others.

3. There are several major barriers to the use of gene therapy including
   - the very large number of infected persons who would need to be treated,
   - the lack of safety of the conditioning necessary before therapy can be applied, as exemplified by the Berlin Patient (Timothy Ray Brown)’s case—though his transplants were allogeneic,
   - risk-benefit analysis for clinical trials,
   - the lack of a completely safe and effective method for identifying the cells to be modified, and
   - the very high cost so far of the therapy.

**Preclinical Model**

A preclinical model is an organism (usually an animal) that has sufficient similarity to humans to be useful in testing a medication or medical procedure before it enters human clinical trials. For HIV, Bone Marrow-Liver-Thymus (BLT) mice and nonhuman primate (NHP) models are common preclinical models.

**Pre-Integration Complex**

A pre-integration complex is a combination of genetic material and protein that can insert a viral genome into a cell’s genome. With regard to HIV, it is formed after retrotranscription of HIV RNA to DNA and consists of the DNA and at least the viral proteins integrase, matrix, and Vpr (see the HIV Structure & Function entry). The complex’s DNA may be integrated into the host cell’s DNA as proviral DNA. HIV pre-integration complexes are important because they may lead to the creation of latent unintegrated HIV DNA. It is known that the resulting DNA can replicate HIV virions, but relatively inefficiently.

**Proviral DNA**

Proviral (HIV) DNA is the DNA resulting from retrotranscription of HIV RNA that is integrated into cellular DNA. It results from HIV infection and is the sine qua non of making new virions—put simply, without it there would be no transmission of HIV infection from one person to another.

**Quantitative Polymerase Chain Reaction (qPCR)**

Quantitative polymerase chain reaction (qPCR) is a variety of polymerase chain reaction (PCR) that is intended to count the initial number of DNA sequences that have been amplified. This is, of course, why the technology is of interest to HIV cure researchers, specifically to measure the latent reservoir of HIV-infected CD4+ T cells. Droplet digital polymerase chain reaction (ddPCR) is the most widely used version of it.

**Receptor**

A receptor, in the context of HIV medicine (including cure research), is a chemical (such as CD3, CD4, CD8, CD34, CD274, and CD279) attached to the surface of a cell that indicates its function and what will attach to it. For a CD4+ T cell, the corresponding CD4 receptor facilitates attachment and entry along with a co-receptor, namely CCR5 or CXCR4, of an HIV virion into the cell.

**Regulatory T Cells (Treg Cells)**

Regulatory T cells (Treg cells) are a population of T cells that participate in distinguishing between self and non-self. In particular, they suppress the activity of the immune system to prevent auto-immune disease. They may be capable of infection by HIV.

**Remission**

Remission is a term preferred by many researchers for HIV Cure (Functional) because functional cures, like cures for many types of cancers, are much more likely to be relatively short lived than permanent, though they are also likely to be repeatable for HIV. Table 3 summarizes 32 cases of remission.
Remission in Macaques Using an Antibody to the Integrin α₄β₇
It has recently been shown in a study of SIV-infected macaques that an antibody to the integrin α₄β₇ can result in remission for at least 50 weeks. However this is unlikely to be a practical approach to remission from HIV infection in humans because α₄β₇ has multiple uses making suppressing it potentially dangerous. See also “Anthony Fauci Explains Alpha-4 Beta-7 and HIV” in the Resource Guide.

Replication-Competent Latent Proviral DNA
Replication-competent latent proviral DNA is HIV proviral DNA in cells (mostly CD4+ T cells) that can produce new HIV virions.

<table>
<thead>
<tr>
<th>Name</th>
<th>No.</th>
<th>Sex</th>
<th>Length of Remission</th>
<th>On ART?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian patients</td>
<td>2</td>
<td>M</td>
<td>2 yrs./3 yrs.</td>
<td>Yes</td>
</tr>
<tr>
<td>Barcelona patients</td>
<td>5</td>
<td>?</td>
<td>≤ 6 mos.</td>
<td>Yes</td>
</tr>
<tr>
<td>Boston patients</td>
<td>3/2</td>
<td>M</td>
<td>1 died/2.6 yrs./4.3 yrs.</td>
<td>Yes</td>
</tr>
<tr>
<td>Esser/Berlin patient</td>
<td>1</td>
<td>M</td>
<td>Died</td>
<td>?</td>
</tr>
<tr>
<td>Ethiopian patient</td>
<td>1</td>
<td>F</td>
<td>10 yrs.</td>
<td>?</td>
</tr>
<tr>
<td>Los Angeles baby</td>
<td>1</td>
<td>F</td>
<td>?</td>
<td>Yes</td>
</tr>
<tr>
<td>Mississippi baby</td>
<td>1</td>
<td>F</td>
<td>4 yrs.</td>
<td>No</td>
</tr>
<tr>
<td>Paris patient</td>
<td>1</td>
<td>M</td>
<td>Died</td>
<td>?</td>
</tr>
<tr>
<td>Rochester patient</td>
<td>1</td>
<td>?</td>
<td>288 days</td>
<td>No</td>
</tr>
<tr>
<td>Utrecht/EPISTEM patients</td>
<td>2</td>
<td>M</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>VISCONTI cohort</td>
<td>14</td>
<td>?</td>
<td>≤ 10 yrs.</td>
<td>No</td>
</tr>
</tbody>
</table>

Table 3. Summary of 32 cases of remission.

There were originally three Boston patients, but one died after a car accident and a relapse of his leukemia (see the Cancer Glossary entry) thought to have resulted from the stress of the accident.

This is an indication of whether the patients were on antiretroviral therapy (ART) after beginning their remissions.

Resting Memory CD4+ T Cells
There are at least five types of resting memory CD4+ T cells found in latent reservoirs in the body, namely, T naïve (naive CD4+ T cells), TCM (central memory CD4+ T cells), T TM (transitional memory CD4+ T cells), TEM (effector memory CD4+ T cells), and T SCM (stem-cell-like central memory CD4+ T cells). Memory CD4+ T cells recognize pathogens that they have been previously exposed to and target them for elimination by CD8+ T cells. Each of the types may be latently infected with HIV; the T SCM cells are the smallest component, but they are thought to be very important because they serve as a source for the other types (except naive CD4+ T cells) and are very long lived. Thus, targeting HIV-infected T SCM cells for activation and elimination is believed to be essential to latency reversal of HIV latent reservoirs.

Restrictiveness Factor
An HIV restriction factor is a protein that significantly decreases HIV replication. Several examples are the APOBEC3 family, Tetherin, and SAMHD1, all of which have Wikipedia entries, in case you want to follow up on them. HIV has evolved mechanisms to counter all known restriction factors. Also, all restriction factors are strongly related to innate immunity (see the Immune System Glossary entry for a description of innate immunity).

Retrotranscription
Retrotranscription of RNA is the process of transcribing RNA, typically from a retrovirus’s nucleus, to proviral DNA that can be integrated into a host cell’s DNA to make it available to produce new virions. Retrotranscription is also called reverse transcription.

Retrovirus
A retrovirus is a virus, such as HIV, whose genetic material is RNA rather than DNA. Retroviruses are special in that they are able to integrate their genetic
material into a host cell's DNA (using the enzyme RNA polymerase) as proviral DNA that enables the creation of new virions.

**Ribozyme**
See the Gene Editing Glossary entry.

**RNA**
RNA stands for ribonucleic acid. Unlike DNA, which exists only as single strands in some viruses or in the well-known double helix structure found in all living things, there are more than 40 forms of RNA with distinct functions. Several of them are described in entries in this Glossary, namely, cell-associated RNA (caRNA), messenger RNA (mRNA), multiply spliced (MS) RNA, ribozyme, short hairpin RNA (shRNA), short interfering RNA (siRNA), transfer RNA (tRNA), and unspliced (US) RNA. For descriptions of multiply spliced (MS) RNA and unspliced (US) RNA, see the Splicing of HIV RNA & Measurement of Unspliced and Multiply Spliced RNA in Cure Research Glossary entry. The structure of RNA is shown in Figure 8 and described below it.

![Figure 8](https://en.wikipedia.org/wiki/RNA)

RNA interference (RNAi)
RNA interference (RNAi), also (more descriptively) previously known as post-transcriptional silencing, is a process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific messenger RNA molecules.

**Rochester Patient**
The Rochester patient is an individual (sex not disclosed) with acute lymphoblastic leukemia (see the Cancer Glossary entry) who had a hematopoietic stem cell transplant (HSCT) lacking the CCR5Δ32/Δ32 mutation. By the 56th day after the transplant, HIV proviral DNA was undetectable in the person's blood. A leukapheresis performed at some time following day 56 showed that typical measures of the latent reservoir had significantly decreased. The person had graft-versus-host disease (GVHD) that seemed to be affecting most of his or her CD4+ T cells: They were about 1/10th of white cells on day 142 and about 13/1,000,000 on day 265. Like the third Boston patient,
viral load rebound, but while the resulting systemic inflammation may have been at least a partial cause of rebound, that is not yet clear. Research is ongoing to obtain a better understanding of the course of remission and rebound.

**Seroconversion**

HIV seroconversion is the period of time during which a person goes from being HIV antibody negative to having HIV antibodies circulating in her or his blood. After seroconversion an HIV antibody test, such as the ELISA (Enzyme-Linked ImmunoSorbent Antibody) tests positive.

**Shock and Kill**

The shock and kill strategy combines “shocking” latent HIV proviral-DNA in CD4+ T cells in latent reservoirs out of latency and killing them by apoptosis or a monoclonal antibody. Shock and kill is called kick and kill by some researchers.

**Shock and Kill Clinical Trials**

Several small shock and kill clinical trials have been undertaken using various latency reversal agents and various approaches to killing. An example of a small (20-participant) completed shock and kill trial is the REDUC Phase IB/IIA clinical trial that administered a series of immunizations using the Vacc-4-x therapeutic vaccine and, as an adjuvant, a protein named GM-CSF that induces the creation of macrophages and another type of white blood cells named granulocytes followed by three infusions of romidepsin and killed by an HIV-specific CD8+ T cell response. REDUC is listed in the EU Clinical Trials Register as number 2013-004747-23. The company responsible for the REDUC trial announced in November 2015 a follow-on trial named BIOSKILL that is enrolling participants in several countries. It is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to confirm and expand on the results of REDUC.

**Short Hairpin RNA (shRNA)**

**Splicing of HIV RNA & Measurement of Unspliced and Multiply Spliced RNA in Cure Research**

Two concepts that are mentioned frequently by researchers studying the sizes of latent reservoirs of HIV-infected CD4+ T cells and the creation of new HIV virions are multiply spliced messenger RNA (mRNA) and unspliced RNA (see Figure 9) (Figure 3, Furtado MS Calloway DS et al. New England Journal of Medicine 340: 27 May 1999; used by permission of the Massachusetts Medical Society).

See the Gene Editing Glossary entry.

**Short Interfering RNA (siRNA)**

See the Gene Editing Glossary entry.

**Simian Human Immunodeficiency Virus (SHIV)**

Simian/human immunodeficiency virus (SHIV) is a series of chimeric retroviruses created in laboratories whose genetic material is a combination of simian immunodeficiency virus (SIV) genes and HIV genes. It is capable of infecting almost every type of nonhuman primate that can be infected with SIV. It serves as a model of human infection with HIV.

**Simian Immunodeficiency Virus (SIV)**

Simian immunodeficiency virus (SIV) is a series of retroviruses that infect nonhuman primates. The type of SIV that infects chimpanzees is the source of human infection with HIV by a species-to-species transfer that probably resulted from humans eating chimpanzee “bush meat.” It serves as a model of human infection with HIV.

**Single Molecule Array (Simoa) Immunoassay**

The Single Molecule Array (Simoa) immunoassay is a commercially available ultrasensitive technology that uses arrays of femtoliter-sized chambers to analyze and identify proteins. Its relevance to HIV cure research is that it has been used to detect neurofilament light-chain protein (NFL) in central nervous system (CNS) samples. Neurofilament light-chain protein is a biomarker of the progress of neurodegenerative diseases, including HIV, in the central nervous system.

**Single-Copy Assay**

A single-copy assay is a quantitative polymerase-chain-reaction-based tool designed to exponentially amplify a single copy of DNA or RNA that can be used to measure the HIV latent reservoir. An RNA sample must first be retrotranscribed to DNA.

The first step in the creation of new virions is transcription of the proviral HIV DNA to make short completely spliced messenger RNAs called multiply spliced mRNAs that are exported from the nucleus to the cytoplasm (that is, outside the nucleus) of an infected cell. The multiply spliced mRNAs make proteins that are essential for next making unspliced RNA. The proteins made by multiply spliced mRNAs include Tat, Rev, and Nef encoded by the tat, rev, and nef HIV genes, respectively (see the HIV Genome Glossary entry).
The viral protein Tat is needed to boost synthesis of unspliced RNA. The viral protein Rev is needed to chaperone the unspliced RNA out of the nucleus. The unspliced RNA, in turn, makes the proteins Gag, Pol, Env, Vif, Vpu, and Vpr encoded by the HIV gag, pol, env, vif, vpu, and vpr genes, respectively, that are essential to the creation of new HIV virions. Unspliced (full-length) RNA is essential to making new virions and is also incorporated into them as the viral genome. Unspliced and multiply spliced RNA are also collectively called cell-associated RNA (caRNA) by HIV cure (and other) researchers.

Unspliced and multiply spliced mRNA are measured by cure (and other) researchers because both are markers related to whether host CD4+ T cells are actively making HIV RNA, and consequently making new virions, and, if so, how effectively they are doing that. The detection of unspliced RNA in latently infected cells indicates that latency is not fully silent, that is, there is some (probably very inefficient) creation of new pieces of RNA going on in latent reservoirs. These cells have recently begun to be called “active” reservoirs, which some researchers consider (and probably rightly so) to be a confusing concept at best.

**Stakeholder Engagement**

Stakeholder engagement refers to the involvement of essential people and organizations, including governments, foundations, research groups, companies, and especially individuals, in promoting understanding of cure research, particularly clinical trials of both basic science and, potentially, curative processes; developing appropriate expectations; and sustaining involvement of persons in those trials. See also the Resource Guide entry with the same header.
**Stem-Cell-Like Memory CD4+ T Cell (TSCM)**

Stem-cell-like memory CD4+ T cells (TSCM) are resting memory CD4+ T cells that are a very important target for elimination from the latent reservoirs they are found in because they are progenitor cells that can differentiate to produce central memory CD4+ T cells (TCM), transitional memory CD4+ T cells (TTM), effector memory CD4+ T cells (TEM), and circulating CD4+ T cells.

**Sterilizing Cure**
See HIV Cure (Sterilizing).

**Transitional Memory CD4+ T Cell (TTM)**

A transitional memory CD4+ T cell (TTM) is a type of memory CD4+ T cell that is in the process of transitioning from being a central memory CD4+ T cell (TCM) to an effector memory CD4+ T cell (TEM).

**Tropic and Tropism**

Tropism (adjective and combining form “tropic”; from Greek) means "turning toward" in general and, in the specific context of HIV co-receptors, it refers to the type of HIV (CCR5-tropic, CXCR4-tropic, or dual-tropic) that binds to a CD4+ T cell.

**Utrecht/ EPI STEM Patients**

The two Utrecht/EPI STEM have HIV infection and two different forms of leukemia (see the Cancer Glossary entry). Both received allogeneic CCR5Δ32/Δ32 hematopoietic stem cell transplants after myeloablative conditioning. Both had significant reductions in viral load, but neither was cured. Of the two, one experienced significant graft-versus-host disease (GVHD), and that seems to have contributed to his lower viral load post-transplant than the other one had. EPI STEM abbreviates “European Project to guide and Investigate the potential for HIV cure by STEM cell transplantation.”

**Vector**

A vector is typically a virus (such as an adenovirus, adeno-associated virus, or lentivirus) that can be used to carry genetic material (DNA or RNA) or protein into human cells. Vectors are used in both HIV prevention research to deliver vaccine candidates and in cure research.

**Viral Load**

HIV viral load measures the amount of HIV virions circulating in the blood. It is usually reported as copies of virus per milliliter of blood (abbreviated c/ml). It is important in HIV cure research because activating cells containing latent HIV from latent reservoirs increases viral load in a measurable way.

**Viral Rebound and Remission**

Viral rebound refers to the level of virus found in the blood after an analytical treatment interruption, possibly because it is believed one has achieved remission.

**Viral Replication**

Viral replication is the process by which HIV reproduces, making more HIV virions. To do so, it must first reverse transcribe its genetic material from ribonucleic acid (RNA) to the infected cell’s deoxyribonucleic acid (DNA). The HIV DNA is then integrated into the cell’s DNA. When HIV-infected CD4+ T cells are activated, they produce HIV virions, damaging the normal function of the cells and, usually, leading to cell death by apoptosis.

**Viral Set Point**

HIV viral set point is the viral load which stabilizes after the acute infection phase. It also applies to SIV and SHIV infection in the nonhuman primate (NHP) models.

**Virion**

A virion is a single complete virus particle that consists of an RNA or DNA core with proteins, such as enzymes, and often with an external envelope. It is the extracellular infective form of a virus.

**Women’s Involvement in Cure Research Studies**

A recent open-access viewpoint article that can be downloaded as a PDF is ME Grewe Y Ma A Gilbertson et al. Women in HIV cure research: multilevel interventions to improve sex equity in recruitment from the URL http://viruseradication.com/past_articles/issue_text_search/women%20in%20HIV%20cure%20research/. It suggests six ways to increase women’s involvement in cure research studies. Before summarizing the points in the article, we must point the reader to the Estradiol, Estrogen, Progesterone, and Estrogen Receptors...
Glossary entry, which makes clear several very important biological reasons for increasing women’s involvement in cure research. The existing barriers and suggested ways to increase involvement are as follows:

1. The possibility of pregnancy and its unknown or not clearly understood impact on HIV-related research of all kinds is a very frequent barrier, especially for treatment studies. Most study designs can be modified to ease this barrier, if not eliminate it.
2. Researcher and clinic coordinator perceptions may impact recruitment of women.
3. Engagement of women stakeholders and improving the perceptions of women held by male stakeholders can increase women’s recruitment.
4. Overcoming structural barriers, such as the lack of child care at research sites, and including women-focused community organizations in recruitment can improve involvement of women in studies.
5. Policy interventions in research funding can promote sex and gender equity.
6. The Gender, Race, and Clinical Experience (GRACE) study (a description of which can be downloaded from http://online.liebertpub.com/doi/pdf/10.1089/apc.2013.0015) is an excellent example that specifically included recruitment of women and that can serve as a model for other studies.

Resource Guide

AIDS Clinical Trials Group (ACTG) HIV Reservoirs and Viral Eradication Translational Science Group (Cure TSG)

The AIDS Clinical Trials Group (ACTG) HIV Reservoirs and Viral Eradication Translational Science Group (Cure TSG) organizes and directs clinical trials intended to test drugs that may be useful in curing HIV infection. The ACTG is funded by the U.S. National Institutes of Health. Its active trials are listed on the https://ClinicalTrials.gov website.

amfAR Institute for HIV Cure Research

The amfAR Institute for Cure Research, announced on 30 November 2015 and funded initially with a five-year $20M grant, is headquartered at the University of California, San Francisco’s AIDS Research Institute (website: https://ari.ucsf.edu/) and is a “virtual institute” composed of researchers from UCSF’s Medical School, the co-located Gladstone Institute of Virology and Immunology, the University of California, Berkeley, Blood Systems Research Institute (BSRI) (San Francisco, CA), Oregon Health and Science University (Portland, OR), Gilead Sciences (Foster City, CA), GeoVax (Atlanta, GA), the Infectious Disease Research Institute (IDRI) (Seattle, WA), Monogram Biosciences (South San Francisco, CA), and RainDance Technologies (Lexington, MA). The institute’s “dream team” of researchers initially included UCSF’s Steven Deeks, MD, and Joseph M. “Mike” McCune, MD, the Gladstone Institute’s Warner Greene, MD, PhD, associate investigator, Blood Systems Research Institute; Steven Deeks, MD, professor of medicine, UCSF; Teri Liegler, PhD, director of the Virology Core Laboratory at UCSF; and Peter Hunt, MD, associate professor of medicine in the UCSF HIV/AIDS Division. The institute’s home page is http://ari.ucsf.edu/research/amfar-institute-hiv-cure-research. The Gladstone Institute of Virology and Immunology’s website is http://gladstone.org/institutes/virology-immunology; the Blood Systems Research Institute’s website is http://www.brsrf.org/; Oregon Health and Science University’s website is http://www.ohsu.edu/xrl/; Gilead Sciences, Inc.’s website is http://www.gilead.com/; GeoVax’s website is http://www.geovax.com/; and the Infectious Disease Research Institute’s website is http://www.idri.org/; Monogram Biosciences’ website is http://www.monogrambio.com/; and Raindance Technologies’ website is http://raindancetech.com/.

Anthony Fauci Explains Alpha-4 Beta-7 and HIV

Anthony Fauci Explains Alpha-4 Beta-7 and HIV is a YouTube video in which Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases, discusses the role of the $α4β7$ integrin in HIV treatment and cure in the YouTube video at
Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication (BELIEVE)

Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication (BELIEVE) is one of the six collaboratories making up the Martin Delaney Collaboratories for HIV Cure Research. Its principal investigator is Douglas Nixon, MD, PhD, of George Washington University in Washington, DC. Its primary purposes are

- enhancing the killing ability of HIV-specific killer T-cells;
- augmenting natural killer cell functions; and
- harnessing T-cell, natural-killer-cell, and antibody-mediated effectors in both adult and pediatric HIV infections.

BELIEVE is partnering with two companies: ALTOR Bioscience Corp. (website: http://www.altorbioscience.com/), whose cancer drug candidate ALT-803, a proprietary interleukin-15 superagonist, has been found to not only reverse HIV latency, but also to enhance the immune system's ability to kill the resulting cells; and Torque (website: http://www.torquebx.com/), a biomedical engineering company with the technology to deliver drugs to CD8+ T-cells that they plan to use to clear the reservoir. It also has a Community Advisory Board (CAB). BELIEVE does not have a website at the time of this writing.

Numerous other U.S. institutions involved in BELIEVE are

- Children's National Health System (website: http://childrensnational.org/);
- NIH (website: https://www.nih.gov/);
- Howard University (website: https://www2.howard.edu/);
- the University of Arizona (website: http://www.arizona.edu/);
- the University of Pittsburgh (website: http://www.pitt.edu/);
- Brigham Young University (website: https://home.byu.edu/home);
- the University of Minnesota (website: http://twin-cities.umn.edu/);
- Johns Hopkins University (website: https://www.jhu.edu/);
- Seattle Children's Hospital (website: http://www.seattlechildrens.org/);
- Beth Israel Deaconess Medical Center, Harvard University (website: http://www.hms.harvard.edu/hfpsg/bidmc.aspx);
- the University of Pennsylvania (website: http://www.upenn.edu/);
- Georgetown University (website: https://www.georgetown.edu/);
- and Albert Einstein College of Medicine (website: http://www.einstein.yu.edu/).

Several international institutions are also involved, namely,

- the University of Toronto, Canada (website: https://www.utoronto.ca/);
- Simon Fraser University, British Columbia, Canada (website: https://www.sfu.ca/);
- Centro de Investigación en Enfermedades Infecciosas, Mexico City, Mexico (website: http://www.cieni.org.mx/);
- and the University of São Paulo, Brazil (website: http://www5.usp.br/english/?lang=en).

Studies will be conducted in concert with communities at local clinics and agencies associated with these institutions in Canada, Brazil, and Mexico plus the U.S.

California Institute of Regenerative Medicine (CIRM) HIV Cure Research Grants

The California Institute of Regenerative Medicine (CIRM/"California's Stem Cell Agency") has given out, as of this writing, 16 grants for HIV cure research. They can be found listed at https://www.cirm.ca.gov/grants?field_public_web_disease_focus_tid[]=826.

CAN GENE THERAPY CURE HIV? With DAVID BALTIMORE & PAULA CANNON

"Can Gene Therapy Cure HIV? with David Baltimore & Paula Cannon" is a YouTube video of a community event with Nobel laureate David Baltimore, PhD, and Paula Cannon, PhD, sponsored by the Delaney Cell and Genome Engineering Initiative (defeatHIV) that was recorded on 12 August 2015 as a community addition to the August 2015 Cell & Gene Therapy for HIV Cure conference that took place at the Fred Hutchinson Cancer Research Center (the “Fred Hutch”) in Seattle, WA. The video can be found at https://www.youtube.com/watch?v=LVR_-rUQHa0&feature=youtu.be.

CAN GENE THERAPY CURE HIV/AIDS?

"Can Gene Therapy Cure HIV/AIDS?" is a YouTube video of a community event with Paula Cannon, PhD, sponsored by the Delaney Cell and Genome Engineering Initiative (defeatHIV) that was recorded in August 2014 as a community addition to the August 2014 Cell & Gene Therapy for HIV Cure conference that took place at the Fred Hutchinson Cancer Research Center (the “Fred Hutch”) in Seattle, WA. The
video can be found at https://www.youtube.com/watch?v=plv07vd5iI.

CanCURE
CanCure is “The Canadian HIV Cure Enterprise.” It has a research program with four themes, as follows:

- **THEME 1** is defining the molecular, genetic, and functional characteristics of HIV/SIV persistence in human as well as in animal models, with a particular focus on myeloid cells.
- **THEME 2** studies the mechanisms underlying HIV latency and persistence in myeloid cells.
- **THEME 3** is seeking to identify new drug candidates and therapeutic approaches capable of eliminating persistent HIV infection and to test these in preclinical models.
- **THEME 4** is establishing appropriate infrastructure to conduct HIV Cure clinical trials, through testing of immune-based therapies aimed at depleting viral reservoirs in patients undergoing antiretroviral therapy.

It lists over 40 publications as of early 2016, and a website whose URL is http://www.cancurehiv.org.

Cell and Gene Therapy for HIV Cure (defeatHIV)
Cell and Gene Therapy for HIV Cure (defeatHIV) is one of the six collaboratories making up the Martin Delaney Collaboratories for HIV Cure Research. It is a consortium of academic and industrial investigators working together to eradicate HIV by gene editing. Its principal investigators are Keith Jerome, MD, PhD, and Hans-Peter Kiem, MD, both from the Fred Hutchinson Cancer Research Center (known as the Fred Hutch) in Seattle, WA. In addition it includes investigators at Beckman Research Institute of the City of Hope, Duarte, CA (website: https://www.cityofhope.org/research/beckman-research-institute), Sangamo Biosciences, Richmond, CA (website: http://www.sangamo.com), Seattle Children’s Research Institute, Seattle, WA (website: seattlechildrens.org/research/), and the University of Washington, Seattle, WA (website: washington.edu ).

Its projects are

- **hematopoietic stem cell transplant**: platform for purging the latent reservoir;
- **ZFN-modified stem cells for HIV eradication**;
- **CCR5 targeting to control HIV/SHIV in the pigtail macaque nonhuman primate model**;
- targeted disruption of integrated SHIV by engineering homing endonucleases; and
- delivery of zinc finger nuclease and homing mRNA and cDNA.

It also has a Community Advisory Board (CAB). Its website is http://defeathiv.org.

Center for International Blood & Marrow Transplant Research (CIBMTR)
The Center for International Blood & Marrow Transplant Research (CIBMTR) does HIV-related clinical trials of bone marrow transplants, among many other kinds. Its list of clinical trials is at https://www.cibmtr.org/Studies/ClinicalTrials/BMT_CTN/Pages/ProtocolsNew.aspx.

City of Hope Clinical Studies
City of Hope in Duarte, CA, is doing clinical studies to alter hematopoietic stem cells to fight HIV/AIDS. As of early 2016, its Alpha Clinic (a project of the California Institute for Regenerative Medicine) is doing two clinical trials, as follows: (1) with the goal of “resetting” the immune system to produce T cells resistant to HIV infection (COH Protocol #13282) and (2) in cooperation with Sangamo Biosciences and the Keck School of Medicine at the University of Southern California, using a zinc-finger nuclease (see the Gene Editing Glossary entry) to edit a gene in the hematopoietic stem cells that is needed for HIV infection; the resulting T cells will then lack a key protein (CCR5) required to infect cells (COH Protocol #14017). The clinical trial has been completed and is listed on the U.S. government list of clinical trials athttp://www.clinicaltrials.gov/; Sangamo Biosciences’ website is http://www.sangamo.com.

Clinical Trials List
A list of both currently active and completed clinical trials related to curing HIV infection is maintained by the Treatment Action Group and can be found online at http://www.treatmentactiongroup.org/cure/trials. It can be downloaded as a PDF from that page in addition to being viewed there. Also, clicking on the trial number there will take you to the https://clinicaltrials.gov entry for a full description of the trial. See also the EU Clinical Trials Register Resource Guide entry.

Clinical Trials Registries
In addition to the list of HIV cure clinical trials listed by the Treatment Action Group (see Clinical Trials List) and the EU Clinical Trials Register, there are clinical trial registries maintained by Canada, Germany, the Netherlands, Switzerland, the United Kingdom, Australia, China, India, Iran, Japan, Korea, New Zealand, the Philippines, Sri Lanka, Thailand, Brazil, Cuba, Peru, Pan Africa, South Africa, and Tanzania. See http://www.hhs.gov/ohrp/international/clinicaltrialregistriesweb.htm for descriptions of these lists and access information for them.
Collaboratory of AIDS Researchers for Eradication (CARE)
The Collaboratory of AIDS Researchers for Eradication (CARE) is one of the six collaboratories making up the Martin Delaney Collaboratories for HIV Cure Research. Its principal investigator is David Margolis, MD, of the University of North Carolina. Its aim is to pursue a comprehensive collaborative search for approaches to eradicate HIV. Its primary purposes are to characterize HIV latency and develop methods for determining the size of HIV’s latent reservoirs. Its website is http://www.delaneycare.org. Its partners include U.C. San Diego (website: https://ucsd.edu), Emory University (website: http://www.emory.edu) and its Yerkes National Primate Research Center (website: http://www.yerkes.emory.edu), the University of Southampton (website: http://www.southampton.ac.uk), Oregon Health & Science University (website: http://www.ohsu.edu), the University of Oxford (website: http://www.ox.ac.uk), the University of Pennsylvania (website: http://www.upenn.edu), Harvard University (website: http://www.harvard.edu), the Los Alamos National Laboratory (website: http://www.lanl.gov), MacroGenics (website: https://www.macrogenics.com/), and Merck (website: http://www.merck.com). It also has a Community Advisory Board (CAB).

Combined Immunologic Approaches to Cure HIV-1 (I4C)
Combined Immunologic Approaches to Cure HIV-1 (I4C) is one of the six collaboratories making up the Martin Delaney Collaboratories for HIV Cure Research. Its headquarters is at Beth Israel Deaconess Medical Center, Boston (website: http://www.bidmc.org/). Its two main focuses are to determine the “efficacy of combination immunologic approaches to target the viral reservoir” and “mechanisms and next generation strategies to target the viral reservoir.”

Countdown to a Cure for AIDS
Countdown to a Cure for AIDS is an amfAR-sponsored website that describes in lay language “Pathways to an HIV cure, namely, pharmacologic approaches, immunologic approaches, and cell therapy approaches.” Its website is http://www.curecountdown.org/pathways-to-an-hiv-cure/.

Coursera
Coursera is a free online learning center that provides college-level courses on numerous topics. There is no course specifically devoted to HIV, but there is one titled “How Viruses Cause Disease” that provides an “introductory virology course” including several relevant topics. The Coursera website is https://www.coursera.org/.

A Crack in Creation
A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution
Doudna JA Sternberg SH Houghton Mifflin Harcourt 2017 is a lay introduction to CRISPR and more specifically CRISPR/Cas9, whose broad and profound power was discovered in the first author’s lab among others. It traces the discovery of CRISPR, explains its mechanism of action, describes its applicability, explicates the scientific and public policy implications of its power, and calls for a moratorium on its use in humans until these issues have been, at the least, very carefully thought out. The book has copious endnotes, most of which are references to journal articles related to its subject. Even the title on the dust jacket refers to CRISPR’s use: occurrences of the letters A, C, G, and T, which abbreviate the names of the four nucleic acids making up DNA, are a different color from the others.

Critical Challenges in HIV Discovery: Cure and Vaccine
Critical Challenges in HIV Discovery: Cure and Vaccine by Anthony Fauci, MD, the Director of the National Institute of Allergy and Infectious Diseases, is a YouTube video of a plenary presentation to the 2014 International AIDS Conference. It focuses on the most important issues in the development of both a preventive vaccine for HIV and its cure. It should be accessible to any reader of this document. It can be found at https://www.youtube.com/watch?v=DS-6oSDt3gA.

Cure-Related Research Resources
Cure-Related Research Resources is a Treatment Action Group webpage that provides a list of web links related to curing HIV infection, as follows:

1. Trials and Research Studies,
2. TAG Publications,
3. TAG Cure Research Monitor,
4. Community-Based Articles and Reports
5. Mainstream Media Articles,
6. Scientific Publications (Open Access),
7. Research Projects and Funding,
8. Advocacy,
9. CUREiculum,
10. Conferences, Meetings, and Events,
11. General Resources, and

The last item is currently a reference to the 2016 English edition of this document. Most of the resources
are accessible to the nonscientific reader. The resources range from very accessible to the general reader (for example, nos. 4, 5, and 8) to intermediate (for example, no. 2) and very scientific (for example, 6). The list may be found on the webpage http://www.treatmentactiongroup.org/cure .

**CURED: How the Berlin Patients Defeated HIV and Forever Changed Medical Science**

CURED: How the Berlin Patients Defeated HIV and Forever Changed Medical Science N Holt Dutton 2014 is a book about the Berlin patient (Timothy Ray Brown) and a German man named Christian Hahn (see the Essery/Berlin Patient Glossary entry). Christian Hahn (a pseudonym—he remains anonymous), a German, in fact, was another man who was treated by Heiko Jessen, MD, for HIV infection in Berlin. It’s not clear in his case that he was actually cured, which is why Timothy Ray Brown is known as the Berlin Patient. It may be that, in Mr. Hahn’s case, we have an instance of postexposure prophylaxis: a combination of factors that resulted in HIV infection never truly becoming established or post-treatment control.

**CURED OF HIV: A COMMUNITY Q&A with TIMOTHY RAY BROWN & GERO HÜTTER, M.D.**

CURED OF HIV: A COMMUNITY Q&A with TIMOTHY RAY BROWN & GERO HÜTTER, M.D. is a video of the Berlin Patient (Timothy Ray Brown) and Gero Hütter, M.D., the doctor who cured him, at the Seattle Public Library, Seattle, WA, February 7, 2015. The video is on YouTube at https://www.youtube.com/watch?v=a1s7DKvHNrE .

**CURED/NOTCURED on Seattle Channel’s Town Square**

CURED/NOTCURED on Seattle Channel’s Town Square is a YouTube video of one of the two Boston Patients, Gary Steinkohl, and his doctor Timothy Henrich, MD, discussing his case. The video was published in August 2016 and can be found at https://www.youtube.com/watch?v=--Jg_bqCGDo .

**CUREiculum**

The CUREiculum is a suite of modules that provides simple, accessible information on HIV cure research, organizing it into a systematic format for ongoing and/or issue-specific learning that complements this Glossary and Resource Guide. The CUREiculum was developed in a multi-collaboratory process by leading scientists, community educators, and advocates who recognized the need for increasing literacy in this area. The modules are designed for community educators, funders, the media, and other stakeholders. Sixteen key areas of HIV cure research have been developed into freestanding modules. The CUREiculum’s website is http://www.avac.org/cureiculum . Please get in touch if there’s a cure-related question or issue you’d like to have addressed. Videos of the webinars, audio recordings of them, and their PowerPoint decks are also available on the website. The modules in the CUREiculum are as follows:

1. HIV/AIDS and Cure Basics
2. Stakeholder Engagement in HIV Cure Research
3. Gene Therapy/Stem Cell Transplant
4. Shock and Kill and Latency-Reversal Agents
5. Measuring the Latent HIV Reservoir
6. Regulatory Issues in HIV Cure Research
7. Early Antiretroviral Treatment
8. Pediatric HIV “Cure”
9. Concepts in Basic Science and Translational Research
10. Therapeutic Vaccines and Immune-Based Therapies
11. Informed Consent in HIV Cure Research
12. Ethics of HIV Cure Research
13. Participation in HIV Cure Research
15. History of Cures: Putting HIV Cure Research in Context
16. Combination Approaches and Conclusion - The Science Looking Forward

**David Baltimore (Caltech) Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV**

“David Baltimore (Caltech) Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV” is a YouTube video with Nobel Prize winning Prof. David Baltimore of CalTech about the subject of its title (there are also Parts 1 and 3, but they are about aspects of HIV other than cure). The video can be found at https://www.youtube.com/watch?v=6-1JFWodmQ&t=19s .

**Delaney AIDS Research Enterprise (DARE) to Find a Cure**

The Delaney AIDS Research Enterprise (DARE) to Find a Cure is one of the six collaboratories making up the Martin Delaney Collaboratories for HIV Cure Research. Its principal investigators are Steven G. Deeks, MD, from the University of California, San Francisco (website: https://www.ucsf.edu/); Louis J. Picker, MD, from the Vaccine & Gene Therapy Institute, Oregon Health & Science University (website: https://www.ohsu.edu/xd/research-centers-institutes/vaccine-and-gene-therapy/index.cfm) , Portland, OR; and Sharon Lewin, FRACP, PhD, from Monash University (website: https://www.monash.edu/), Melbourne, Australia. It also has a Community Advisory Board (CAB). Its
website is http://daretofindacure.org/.

DARE will initially

- define the role of reservoirs that enable SIV or HIV to persist during antiretroviral therapy (ART) and use the monkey model to develop therapies to breach them;
- characterize the distribution of replication-competent latent provirus in lymphoid tissues in ART-suppressed adults and develop positron emission tomography (PET) imaging techniques to quantify the reservoir;
- define the role of immune checkpoints, such as PD-1, and their blockade on T cell function in monkeys and people; and
- define the safety, immunogenicity, and anti-HIV effectiveness of a human cytomegalovirus (HCMV) vectored HIV vaccine in HIV-infected adults on ART.

Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV)
The Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV) is one of the six collaboratories making up the Martin Delaney Collaboratories for HIV Cure Research. It is a consortium of academic and industrial investigators with principal investigators Luis J. Montaner, DVM, DPhil, and James L. Riley, PhD, of the Wistar Institute (website: https://www.wistar.org/). It has partners at

- the University of Pennsylvania (website: http://www.med.upenn.edu);
- Philadelphia FIGHT (website: https://fight.org);
- Rockefeller University (website: http://www.rockefeller.edu/);
- VA San Diego Healthcare System (website: http://www.sandiego.va.gov/);
- Johns Hopkins University (website: https://www.jhu.edu);
- the University of Nebraska-Lincoln (website: http://www.unl.edu/); and
- the University of Utah (website: http://www.utah.edu/).

BEAT-HIV has three objectives, namely,

- to identify the locations of latent reservoirs;
- to stimulate the innate immune system with a combination of highly potent antibodies and pegylated interferon α2b; and
- a gene therapy strategy using CCR5Δ32/Δ32 CD8+ T cells.


As of this writing BEAT-HIV has no website.

Differences between Women and Men in HIV Cure Research
Several groups funded by amfAR's Research Consortium on HIV Eradication (ARCHE) are studying differences in inflammation and antiretroviral therapy (ART) of HIV infection between women and men that may lead to differences in cure research between the sexes.

Ethics of ART interruption after stem-cell transplantation
"Ethics of ART interruption after stem-cell transplantation" is an article in the January 2016 issue of The Lancet HIV that describes five cases of HIV+ people (the Berlin patient, the two Boston patients, the Essen/Berlin patient, and the Paris patient) with cancer who received hematopoietic stem-cell transplants (HSCT) followed by interruption of antiretroviral treatment (ART). Four of the five had rebound of detectable HIV and three of the four died within several years. To quote the article, “Analytical treatment interruptions after HSCT will impose an array of burdens on patients including the need for careful assessments before the interruption, frequent blood monitoring, invasive procedures to assess the viral reservoir, and psychosocial issues.” and “Finally, it is important to emphasise that analytical treatment interruptions after HSCT are experimental and subject to careful and competent ethics review.” Note that the article is not freely available.

EU Clinical Trials Register
The EU (European Union) Clinical Trials Register is a searchable database of all clinical trials that include EU sites or that are run by companies and research institutions located in EU countries. It also includes a "Glossary of Terms used in the EU Clinical Trials Register." Its website is https://www.clinicaltrialsregister.eu.

European AIDS Clinical Society (EACS)
The European AIDS Clinical Society (EACS) sponsors the European AIDS Conferences, among other activities. The 15th such conference includes six webcasts concerning "Prospects for HIV Cure and Post Treatment Remission" that are available on the society’s website at http://eacs.multilearning.com/eacs/ under its subject header.

Genome Engineering HIV and its Host
Genome Engineering HIV and its Host is a YouTube video by Paula Cannon, PhD, about what gene engineering is, how it applies to HIV and its human host, and its potential use to cure HIV. While it was designed as a presentation to a meeting of the American Society for Microbiology, much of it will be accessible to users of this document. It can be found online at https://www.youtube.com/watch?v=dsQzEEAI3CU.

Global Investment in HIV Cure Research and Development
AVAC, which describes its mission as “Global Advocacy for HIV Prevention” also has issued, so far, three documents titled “Global Investment in HIV Cure Research and Development” for 2012, 13, and 14. The most recent one can be downloaded from the AVAC website at http://www.avac.org by searching for “Global Investment in HIV Cure”.

Good Manufacturing Practices (GMP)
Good manufacturing practices (GMP) refers to the practices required to conform to the guidelines recommended by agencies that control licensing for manufacture and sale of food, drug products, and other medical products and devices. The agencies include the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA). The International Society for Pharmaceutical Engineering (ISPE) provides access to Australian, Canadian, European Union, Japanese, U.S. FDA, and World Health Organization GMP guidelines on the web at http://www.ispe.org/gmp-resources/gmp-guidelines.

Good Participatory Practice (GPP)
Good Participatory Practice (GPP) refers to the practices recommended by the United Nations AIDS Agency (UNAIDS) and AVAC, a U.S.-based organization engaged in “Global Advocacy for HIV Prevention,” for stakeholder engagement in biomedical HIV prevention trials. GPP has been generalized to apply to all HIV/AIDS-related biomedical clinical trials, including cure-related trials. AVAC provides access to the GPP guidelines on the web at http://www.avac.org/good-participatory-practice.

HIV Cure Research Fact Sheet
The HIV Cure Research Fact Sheet is published by the Treatment Action Group and provides a brief introduction to the issues involved in HIV cure research. The most recent edition was published in November 2015. It can be found online as a webpage and a downloadable PDF at http://www.treatmentactiongroup.org/cure/fact-sheet.

HIV: The Quest for a Cure
HIV: The Quest for a Cure by John Mellors, MD, is a YouTube video of a plenary presentation that was designed for the 2015 Conference on Retroviruses and Opportunistic Infections. Much of it is quite high level, but at slightly less than 22 minutes in length it is well worth the time for the reasonably accessible overview it presents of its topic. It can be found at https://www.youtube.com/watch?v=QDupxh3T2ZA.

i-base
i-base is a United Kingdom organization that provides information about curing HIV, in addition to its more basic aim of providing information about HIV treatment. Its website is http://i-base.info.

IrsiCaixa (Institut de Recerca de la Sida)
IrsiCaixa (Institut de Recerca de la Sida) is a research center located in Barcelona, Spain, that focuses on many of the issues involved in HIV/AIDS research. Its specific cure-related foci include achieving remission or eradication of HIV by combinations of therapeutic vaccines, antibodies, and latency reactivation.

Is the Cure for HIV Possible in Our Lifetime?
Is the Cure for HIV Possible in Our Lifetime? is a YouTube video composed by HIV treatment and cure activist Nelson Vergel that includes presentations by Steven Deeks, MD, about the Berlin Patient’s (Timothy Ray Brown) cure and the suffering involved in it that makes it so very impractical for general application, and with Timothy himself. It can be found at https://www.youtube.com/watch?v=Sj-dFQ6yi7k.

Journal of Medical Ethics, vol. 43, no. 2, February 2017
The Journal of Medical Ethics is the official journal of the (British) Institute of Medical Ethics and one of the BMJ journals published by the BMJ Group, a wholly owned subsidiary of the British Medical Association. The particular issue cited here is devoted entirely to issues in curing HIV infection, and most of the articles are freely available to download from the table of contents webpage at http://jme.bmj.com/content/43/2 and are quite accessible to lay readers. They provide an introduction to the subject, background information, articles concerning risks, benefits to clinical trial participants and nonparticipants, and an afterword.

Journal of Virus Eradication
The Journal of Virus Eradication is an open-access online and print journal devoted to cure research online at http://www.viruseradication.com. While much of its content is quite technical, it also includes quite accessible articles, such as “HCV cure for everyone or which challenges remain?”
Martin Delaney Collaboratories for HIV Cure Research

The Martin Delaney Collaboratories for HIV Cure Research is a group of six collaboratories (expanded from three in the initial grant cycle) that are organizations consisting of researchers devoted to studying cures for HIV infection and promoting them via clinical trials. The six collaboratories are

1. Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV),
2. Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication (BELIEVE),
3. the Collaboratory of AIDS Researchers for Eradication (CARE),
4. the Delaney AIDS Research Enterprise to Cure HIV (DARE),
5. the Delaney Cell and Gene Therapy for HIV Cure (defeatHIV), and
6. Combined Immunologic Approaches to Cure HIV-1 (I4C).

Each of the six consists of scientists and a Community Advisory Board (CAB). The overall Collaboratory is funded by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases. The Collaboratory also has a National Community Advisory Board (NCAB) made up of two members from each of the six CABs, plus a management member from each collaboratory (total: 18 members). Martin Delaney (1945 – 2009) was the founding director of Project Inform, one of the nation's oldest and best-known non-profit foundations working to combat HIV and AIDS by providing information and advocating for treatment.

Note that while the current NIH grant gives DARE the name above, it continues to use the name it chose for itself in the initial grant cycle: the Delaney AIDS Research Enterprise (DARE) to Find a Cure.

NATAP/ National AIDS Treatment Advocacy Project

Despite its name, NATAP does include information about curing HIV. The easiest way to find that information on its website is to go to http://natap.org/ and search for “cure”.

Progress towards an HIV Cure

Progress towards an HIV Cure is a YouTube video of a presentation of a panel at the 2014 International AIDS Conference chaired by Sharon Lewin, PhD, FRACP, that focuses on issues involved in understanding where we were at that time in the search for a cure for HIV infection. It can be found at https://www.youtube.com/watch?v=LltP2pVti-9g .

Project Inform HIV Cure Advocacy

Project Inform's HIV cure advocacy page provides up-to-date information about a variety of cure topics. Its website is https://www.projectinform.org/ .

Qura Therapeutics

Qura Therapeutics is a partnership between the University of North Carolina-Chapel Hill (UNC) (website: http://www.unc.edu/ ) and GlaxoSmithKline (website: https://www.gsk.com/ ) announced in May 2015 that “will focus exclusively on finding a cure for HIV/AIDS … including a leading research approach toward an HIV cure, sometimes called “shock and kill.” The announcement is available at http://uncnews.unc.edu/2015/05/10/unc-chapel-hill-and-gsk-announce-novel-partnership-to-accelerate-search-for-hiv-cure/ . Qura’s leadership is composed of David Margolis, MD, of the UNC School of Medicine, Zhi Hong of GlaxoSmithKline, and Matt Fajack, Vice Chancellor for Finance and Administration at UNC. Given that it has been more than two years since Qura Therapeutics was announced and nothing more has been heard about it, the author wonders what, if anything, is happening!

Recruitment and ethical considerations in HIV cure trials requiring treatment interruption

The Journal of Virus Eradication vol. 1 no. 1 includes the freely available article “Recruitment and ethical considerations in HIV cure trials requiring treatment interruption,” which (obviously) discusses the subject of its title; specifically it reports the results of a late 2011 – early 2012 online survey completed by 2,094 HIV+ individuals recruited via the web. The primary goal was to measure willingness to participate in cure research clinical trials that required interruption of antiretroviral treatment (ART). The primary result was based on a four point scale that ranged from “very willing” through “not at all willing”. Additional questions asked about the effects on willingness of

1. societal benefit,
2. scientific benefit,
3. perceived influence on personal health, and
4. compensation.

The sampled group was predominantly older white men with at least some college attendance and low to moderate income. More than half of the participants were motivated to take part for personal or societal benefits, compensation, or health benefits, while fewer than half were motivated by scientific benefit.

Research Toward a Cure Trials

Research Toward a Cure Trials is a collection prepared by Richard Jefferys of the Treatment Action Group and
updated roughly every three months of three lists, namely, “Current Clinical Trials,” “Observational Studies,” and “Completed Studies,” including for each one a short title, trial registry identifier(s), manufacturer/sponsor(s), phase, and either estimated completion date or published/presented data. The most recent list is dated 1 May 2017, lists about 125 studies, and can be downloaded as a PDF at http://www.treatmentactiongroup.org/cure/trials.

Role of Residual Viral Replication
Role of Residual Viral Replication is a YouTube video by Javier Martinez-Picado, PhD, that presents the issue of persistent low-level HIV replication in persons with very low viral loads and its implications for curing HIV. Although it was constructed to be a presentation to the American Society for Microbiology, much of it should be accessible to most readers of this document. It can be found at https://www.youtube.com/watch?v=qjAQ5WClTGQt.

Scared — and brave
Scared — and brave is an article about defeatHIV Community Advisory Board member Laurie Sylla presenting at Seattle’s Gay City LGBTQ (lesbian, gay, bisexual, transgender, queer) Center about the results of survey research done by a group of community members. The research was designed to ascertain what issues community members have about HIV cure research clinical trial participation. The article can be found online at http://www.fredhutch.org/en/news/center-news/2017/06/why-volunteer-for-an-hiv-cure-study.html. As time goes on it will be archived at http://www.fredhutch.org/en/news.html in the Story Archive under June 2017.

Stakeholder Engagement

Strategies for an HIV Cure: 2012
The meeting Strategies for an HIV Cure: 2012 was convened by the NIH in Washington, DC. The purpose of this meeting was to bring together researchers associated with each of the three NIH-funded Martin Delaney Collaboratories, other researchers engaged in HIV cure research, investigators in complementary disciplines, and community members to share scientific results and engage in active discussion about the merits of various approaches under investigation. It was hoped that these discussions would stimulate new ideas for research projects and lead to new scientific collaborations. Its agenda can be downloaded by searching for Strategies for an HIV Cure, November 28 – 30, 2012, and downloading it from the resulting page.

Strategies for an HIV Cure: 2014
The meeting Strategies for an HIV Cure: 2014 was convened by the NIH on its campus in Bethesda, MD, to give the Martin Delaney Collaboratories an opportunity to present their progress and to discuss future prospects for and approaches to curing HIV infection. Its agenda can be downloaded from https://www.blsmeetings.net/hivcuremeeting2014/.

Strategies for an HIV Cure: 2016
The meeting Strategies for an HIV Cure: 2016 will be convened by the NIH on its campus in Bethesda, MD, to give the Martin Delaney Collaboratories an opportunity to present their progress and to discuss future prospects for and approaches to curing HIV infection. The agenda can be downloaded as a PDF from the webpage https://respond.niaid.nih.gov/conferences/hivcuremeeting2016/Pages/Agenda.aspx; the poster abstracts can be downloaded as a PDF from the page https://respond.niaid.nih.gov/conferences/hivcuremeeting2016/Pages/Abstract-Submission.aspx.

A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies
The article “A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies” is freely available for download from the 1 February 2016 issue of the Journal of Acquired Immune Deficiency Syndrome (also known as JAIDS and on the web at http://www.jaids.com) and includes a section on cure research.

TAG HIV Basic Science, Vaccines, and Cure Project Blog
The TAG HIV Basic Science, Vaccines, and Cure Project blog, written by Richard Jefferys of the Treatment Action Group in New York City includes, among other topics—as its title says—updates and thoughts about HIV cure. It is moderated by Richard, and its website’s main web page is http://tagbasicscienceproject.typepad.com/. To subscribe, enter your email address in the box on the right of that page, click “Subscribe”, enter the displayed text in the resulting popup. You will then receive an email with a link to click on that will open a web page indicating that your subscription has been accepted.
confirmed. Note that the content may be too technical for some readers.

THE BODY
The BODY (http://www.thebody.com/) is “The Complete HIV/AIDS Resource” for people who are living with HIV.

THE BODY PRO
The Body Pro (http://www.thebodypro.com/) is designed for health professionals, but some of its HIV cure-related topics are quite accessible for the lay reader.

Why cure, why now?
"Why cure, why now?" is a freely available article by Daniel Kuritzkes, MD, published online in the Journal of Medical Ethics on 7 June 2016. It includes two sections titled “RISKS OF HIV CURE RESEARCH” and “ETHICAL CHALLENGES IN HIV CURE RESEARCH.” The website of the article is http://jme.bmj.com/content/43/2/67.

Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US
The article “Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US” in the freely available Journal of Virus Eradication issue 3.1 at http://viruseradication.com/ reports on a study concerning its title research. The research was performed by enrolling 400 HIV+ individuals online with diverse characteristics including women, men, and transgenders; whites, blacks, Hispanics, and a few members of other ethnic groups; a range of ages, education levels, incomes etc. Over half of the respondents were willing to take part in 14 types of cure studies ranging from surveys through allogeneic hematopoietic stem cell transplants. There are also questions regarding personal benefits (both general and clinical) and social benefits; and personal clinical risks, burdens, and societal risks.

Women and HIV Cure: A Three-Part Webinar Series
Women and HIV Cure: A Three Part Webinar Series is a project of the Women’s HIV Research Collaborative (WHRC), which is a working group of the Legacy Project. The first webinar is available at https://www.hanc.info/cp/resources/Documents/Women%20and%20HIV%20Cure%20Part%201.mp4; the second is at https://www.hanc.info/cp/resources/Documents/Women%20and%20Cure%20Part%202.mp4; and the third is at https://www.hanc.info/cp/resources/Documents/Women%20and%20Cure%20Part%203.mp4. The three webinars are titled “Where are We? Women in the HIV Cure Landscape,” “What Cure Means to Women, What Women Mean to Cure,” and “Barriers and Facilitators to Women’s Participation in HIV Cure.”

The Legacy Project’s mission is to build trust and collaboration between historically underrepresented communities most impacted by the domestic HIV epidemic, researchers, and research institutions; enhance cultural competence; and initiate scientific investigation to increase clinical research participation. The Legacy Project is a part of the HIV/AIDS Network Coordination (hanc), and information about may be found on the web at https://www.hanc.info/legacy/Pages/default.aspx.